0001013606-17-000121.txt : 20170804 0001013606-17-000121.hdr.sgml : 20170804 20170804171916 ACCESSION NUMBER: 0001013606-17-000121 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 66 CONFORMED PERIOD OF REPORT: 20170630 FILED AS OF DATE: 20170804 DATE AS OF CHANGE: 20170804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENDOLOGIX INC /DE/ CENTRAL INDEX KEY: 0001013606 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 680328265 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-28440 FILM NUMBER: 171009504 BUSINESS ADDRESS: STREET 1: 2 MUSICK CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 9495957200 MAIL ADDRESS: STREET 1: 2 MUSICK CITY: IRVINE STATE: CA ZIP: 92618 FORMER COMPANY: FORMER CONFORMED NAME: RADIANCE MEDICAL SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19990122 FORMER COMPANY: FORMER CONFORMED NAME: CARDIOVASCULAR DYNAMICS INC DATE OF NAME CHANGE: 19960506 10-Q 1 elgx_6302017-10q.htm 10-Q Document

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
__________________________________________________ 
FORM 10-Q
 __________________________________________________ 
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2017
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________to ________
Commission file number 000-28440 
 __________________________________________________
elgxnewlogoa04.jpg
ENDOLOGIX, INC.
(Exact name of registrant as specified in its charter) 
 __________________________________________________  
Delaware
68-0328265
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
2 Musick, Irvine, California 92618
(Address of principal executive offices)
(949) 595-7200
(Registrant’s telephone number, including area code)
   ________________________________________________
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x     No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
 
x
Accelerated filer
 
o
Non-accelerated filer
 
o  (Do not check if a smaller reporting company)
Smaller reporting company
 
o
 
 
 
Emerging growth company
 
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x
On August 1, 2017, there were 83,434,656 shares outstanding of the registrant’s only class of common stock.
 
 
 
 
 


ENDOLOGIX, INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2017

TABLE OF CONTENTS
 



Part I. Financial Information
 
ENDOLOGIX, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and par value amounts)
(Unaudited)

June 30,
 
December 31,

2017
 
2016
ASSETS

 

Current assets:

 


Cash and cash equivalents
$
81,641

 
$
26,120

Restricted cash
2,877

 
2,001

Marketable securities
10,000

 
20,988

Accounts receivable, net allowance for doubtful accounts of $994 and $1,037, respectively.
33,118

 
34,430

Other receivables
390

 
1,787

Inventories
43,555

 
41,160

Prepaid expenses and other current assets
4,235

 
3,359

Total current assets
$
175,816

 
$
129,845

Property and equipment, net
21,300

 
23,265

Goodwill
120,845

 
120,711

Intangibles, net
82,570

 
84,511

Deposits and other assets
1,536

 
1,352

Total assets
$
402,067

 
$
359,684



 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

Current liabilities:

 

Accounts payable
$
11,030

 
$
13,237

Accrued payroll
16,933

 
19,997

Accrued expenses and other current liabilities
10,001

 
11,668

Revolving line of credit
24,297


—

Total current liabilities
$
62,261

 
$
44,902

Deferred income taxes
879

 
879

Deferred rent
7,859

 
7,949

Other liabilities
4,194

 
3,783

Contingently issuable common stock
9,600

 
12,200

Debt
220,520

 
177,178

Total liabilities
$
305,313

 
$
246,891

Commitments and contingencies

 

Stockholders’ equity:

 

Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding.
—

 
—

Common stock, $0.001 par value; 135,000,000 shares authorized. 83,638,895 and 82,986,244 shares issued, respectively. 83,426,656 and 82,774,005 shares outstanding, respectively.
84

 
83

Treasury stock, at cost, 212,239 shares.
(2,942
)
 
(2,942
)
Additional paid-in capital
588,194

 
567,765

Accumulated deficit
(491,207
)
 
(453,601
)
Accumulated other comprehensive income
2,625

 
1,488

Total stockholders’ equity
$
96,754

 
$
112,793

Total liabilities and stockholders’ equity
$
402,067

 
$
359,684

The accompanying notes are an integral part of these condensed consolidated financial statements.

1


ENDOLOGIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except per share amounts)
(Unaudited)

Three Months Ended June 30,
 
Six Months Ended June 30,
 
2017

2016
 
2017

2016
Revenue
$
48,556


$
50,974

 
$
91,168


$
93,340

Cost of goods sold
16,332


21,515

 
30,302


35,940

Gross profit
32,224


29,459

 
60,866


57,400

Operating expenses:



 



Research and development
5,734


7,714

 
11,264


15,559

Clinical and regulatory affairs
2,740


4,022

 
6,575


7,905

Marketing and sales
23,781


28,824

 
49,681


56,742

General and administrative
7,904


10,210

 
16,777


20,156

Restructuring costs
(29
)

790

 
137


8,114

Settlement costs
—


—

 
—


4,650

Contract termination and business acquisition expenses
—


1,127

 
—


5,905

Total operating expenses
40,130


52,687

 
84,434


119,031

Loss from operations
(7,906
)

(23,228
)
 
(23,568
)

(61,631
)
Other income (expense):



 



Interest income
28


48

 
72


110

Interest expense
(5,803
)

(3,815
)
 
(10,098
)

(7,597
)
Other income (expense), net
223


(556
)
 
176


(912
)
Change in fair value of contingent consideration related to acquisition
3,800


(100
)
 
2,600


(100
)
Loss on debt extinguishment
(6,512
)

—


(6,512
)

—

Change in fair value of derivative liabilities
—


(38,743
)
 
—


(43,831
)
Total other income (expense)
(8,264
)

(43,166
)
 
(13,762
)

(52,330
)
Net loss before income tax expense
(16,170
)

(66,394
)
 
(37,330
)

(113,961
)
Income tax expense
(122
)

(443
)
 
(276
)

(546
)
Net loss
$
(16,292
)

$
(66,837
)
 
$
(37,606
)

$
(114,507
)
Other comprehensive income (loss) foreign currency translation
781


1,019

 
1,137


914

Comprehensive loss
$
(15,511
)

$
(65,818
)
 
$
(36,469
)

$
(113,593
)






 





Basic and diluted net loss per share
$
(0.20
)

$
(0.81
)
 
$
(0.45
)

$
(1.44
)
Shares used in computing basic and diluted net loss per share
83,247


82,072

 
83,087


79,368

The accompanying notes are an integral part of these condensed consolidated financial statements.


2


ENDOLOGIX, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

Six Months Ended June 30,
 
2017

2016
Cash flows from operating activities:



Net loss
$
(37,606
)

$
(114,507
)
Adjustments to reconcile net loss to net cash used in operating activities:



Bad debt expense
(89
)

—

Depreciation and amortization
4,645


4,229

Stock-based compensation
6,188


6,768

Change in fair value of derivative liabilities
—


43,831

Change in fair value of contingent consideration related to acquisition
(2,600
)

100

Accretion of interest & amortization of deferred financing costs on debt
5,004


4,603

Non-cash foreign exchange loss (gain)
(206
)

810

Non-cash loss on debt extinguishment
3,997


—

Changes in operating assets and liabilities:





Restricted cash
(876
)

—

Accounts receivable and other receivables
3,470


(2,445
)
Inventories
(2,174
)

3,557

Prepaid expenses and other current assets
(762
)

1,100

Accounts payable
(3,486
)

(5,812
)
Accrued payroll
(3,220
)

6,922

Accrued expenses and other liabilities
(1,092
)

1,889

Net cash used in operating activities
$
(28,807
)

$
(48,955
)
Cash flows from investing activities:





Purchases of marketable securities
—


(5,017
)
Maturities of marketable securities
11,000


19,350

Purchases of property and equipment
(833
)

(1,304
)
Acquisition of business, net of cash acquired of $0 and $24,012, respectively
—


(60,622
)
Net cash (used in) provided by investing activities
$
10,167


$
(47,593
)
Cash flows from financing activities:





Net proceeds from revolving line of credit
24,297


—

Deferred financing costs
(6,285
)

—

Proceeds from sale of common stock under employee stock purchase plan
1,681


1,826

Proceeds from exercise of stock options
449


1,777

Proceeds from issuance of debt
120,000


—

Repayment of debt
(66,613
)

—

Minimum tax withholding paid on behalf of employees for restricted stock units
—


(134
)
Net cash provided by financing activities
$
73,529


$
3,469

Effect of exchange rate changes on cash and cash equivalents
632


(26
)
Net (decrease) in cash and cash equivalents
$
55,521


$
(93,105
)
Cash and cash equivalents, beginning of period
26,120


124,553

Cash and cash equivalents, end of period
$
81,641


$
31,448

Supplemental disclosure of cash flow information:



Cash paid for interest
$
2,956


$
2,994

       Cash paid for income taxes
$
565


$
167

Non-cash investing and financing activities:



       Acquisition of property and equipment included in accounts payable
$
26


$
—

       Fair value of common stock issued for business acquisition
$
—


$
100,812

Fair value of warrants issued for business acquisition
$
—


$
44

Fair value of warrants issued in connection with the Facility Agreement
$
14,704


$
—

The accompanying notes are an integral part of these condensed consolidated financial statements.

3


ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)
1. Description of Business, Basis of Presentation, and Operating Segment
(a) Description of Business
Endologix, Inc. (the "Company") is a Delaware corporation with corporate headquarters in Irvine, California and production facilities located in Irvine, California and Santa Rosa, California. The Company develops, manufactures, markets, and sells innovative medical devices for the treatment of aortic disorders. The Company's products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms ("AAA"). The Company's AAA products include innovations for minimally-invasive endovascular aneurysm repair ("EVAR") or endovascular aneurysm sealing (“EVAS”), the Company's innovative solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The Company's current EVAR products include the Ovation® Abdominal Stent Graft System (the “Ovation” System), and the AFX® Endovascular AAA System (the “AFX” System) which features the VELA™ Proximal Endograft System, and the AFX2 Bifurcated Endograft System (the “AFX2” System). The Company's current EVAS product is the Nellix® EndoVascular Aneurysm Sealing System (the “Nellix EVAS System”). Sales of the Company's EVAR and EVAS platforms (including extensions and accessories) to hospitals in the U.S. and Europe, and to third-party international distributors worldwide, provide the sole source of the Company's reported revenue.
On February 3, 2016, the Company completed its previously announced merger with TriVascular Technologies, Inc. (“TriVascular”). The merger with TriVascular expanded the Company's product offering and intellectual property, increased the Company's sales force, and enhanced our product development capabilities.
The Company’s Ovation System consist of a radiopaque nitinol stent for suprarenal fixation and a low-permeability polytetrafluoroethylene (PTFE) graft. The stent is designed with integral anchors to enable fixation to the aortic wall. To seal the graft and to provide support for the aortic body legs into which the iliac limbs are deployed, the graft contains a network of inflatable rings that are filled with a liquid polymer that solidifies during the deployment procedure.
The Company's AFX System consist of (i) a cobalt chromium alloy stent covered by polytetrafluoroethylene (commonly referred to as "ePTFE") graft material and (ii) accompanying delivery systems. Once fixed in its proper position within the abdominal aortic bifurcation, the Company's AFX System provides a conduit for blood flow, thereby relieving pressure within the weakened or “aneurysmal” section of the vessel wall, which greatly reduces the potential for the AAA to rupture.
The Company's Nellix EVAS System consists of (i) bilateral covered stents with endobags, (ii) a biocompatible polymer injected into the endobags to seal the aneurysm and (iii) a delivery system and polymer dispenser. The Company's Nellix EVAS System seals the entire aneurysm sac effectively excluding the aneurysm reducing the likelihood of future aneurysm rupture. Additionally, the Nellix EVAS System has the potential to reduce post procedural re-interventions.
(b) Basis of Presentation
The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2017 and 2016, there were no related party transactions.
The interim financial data as of June 30, 2017 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three and six months ended June 30, 2017. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The interim financial data includes the results of TriVascular, beginning on February 3, 2016, the effective date of the merger.
The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 1, 2017.
(c) Operating Segment
The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three and six months ended June 30,
2017, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.

2. Use of Estimates and Summary of Significant Accounting Policies
The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.
For a complete summary of the Company's significant accounting policies, please refer to Note 2, "Use of Estimates and Summary of Significant Accounting Policies", in Part II, Item 8, of the Company's 2016 Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 1, 2017. There have been no material changes to the Company's significant accounting policies during the three and six months ended June 30, 2017.

3. Balance Sheet Account Detail
(a) Property and Equipment
Property and equipment consisted of the following:
 
June 30,
2017
 
December 31,
2016
Production equipment, molds, and office furniture
$
11,908

 
$
11,714

Computer hardware and software
8,746

 
8,162

Leasehold improvements
15,495

 
15,495

Construction in progress (software and related implementation, production equipment, and leasehold improvements)
842

 
839

Property and equipment, at cost
$
36,991

 
$
36,210

Accumulated depreciation
(15,691
)
 
(12,945
)
Property and equipment, net
$
21,300

 
$
23,265

Depreciation expense for property and equipment for the three months ended June 30, 2017 and 2016 was $1.3 million and $1.3 million, respectively. For the six months ended June 30, 2017 and 2016 depreciation expense for property and equipment was $2.7 million and $2.6 million, respectively.
(b) Inventories
Inventories consisted of the following:
 
June 30,
2017
 
December 31,
2016
Raw materials
$
11,291

 
$
13,133

Work-in-process
11,767

 
10,139

Finished goods
20,497

 
17,888

Total Inventories
$
43,555

 
$
41,160

(c) Goodwill and Intangible Assets
The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization: 

4
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)




June 30,
2017

December 31,
2016
Goodwill
$
120,845


$
120,711







Intangible assets:





Indefinite lived intangibles





Trademarks and trade names
$
2,708


$
2,708

In-process research and development
11,200

 
11,200

 
 
 
 
Finite lived intangibles





Developed technology
$
67,600


$
67,600

Accumulated amortization
(5,375
)

(3,810
)
Developed technology, net
$
62,225


$
63,790







Customer relationships
$
7,500


$
7,500

Accumulated amortization
(1,063
)

(687
)
 Customer relationships, net
$
6,437


$
6,813







Intangible assets (excluding goodwill), net
$
82,570


$
84,511

The change in the carrying amount of goodwill for the six months ended June 30, 2017 is as follows (in thousands):
Balance at January 1, 2017
120,711

Foreign currency translation adjustment
134

Balance at June 30, 2017
$
120,845

Amortization expense for intangible assets for the three months ended June 30, 2017 and 2016 was $1.0 million and $0.7 million, respectively. For the six months ended June 30, 2017 and 2016 amortization expense for intangible assets was $1.9 million and $1.6 million, respectively.
Estimated amortization expense for the five succeeding years and thereafter is as follows:
Remainder of 2017
$
1,940

2018
3,978

2019
3,978

2020
4,996

2021
6,557

2022 & Thereafter
47,213

Total
$
68,662



5
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



(d) Marketable securities
Investments in held-to-maturity marketable securities consist of the following at June 30, 2017 and December 31, 2016:

June 30, 2017

Amortized
Cost

Gross
Unrealized
Gain
 
Gross
Unrealized
Loss
 
Fair Value
Agency bonds
$
3,999


$
—


$
(1
)

$
3,998

Corporate bonds
6,001


—


(2
)

5,999

Total
$
10,000


$
—


$
(3
)

$
9,997










December 31, 2016

Amortized
Cost

Gross
Unrealized
Gain
 
Gross
Unrealized
Loss
 
Fair Value
Agency bonds
$
6,488


$
2


$
—


$
6,490

Corporate bonds
10,513


—


(21
)

10,492

Commercial paper
3,987


—


—


3,987

Total
$
20,988


$
2


$
(21
)

$
20,969


At June 30, 2017, the Company’s investments included 4 held-to-maturity debt securities in unrealized loss positions with a total unrealized loss of approximately $3 thousand and a total fair market value of approximately $10.0 million. All investments with gross unrealized losses have been in unrealized loss positions for less than 11 months. The unrealized losses were caused by interest rate fluctuations. There was no change in the credit risk of the securities. The Company does not intend to sell the securities and it is not likely that the Company will be required to sell the securities before the expected recovery of their amortized cost bases. There were no realized gains or losses on the investments for the three and six months ended June 30, 2017. All of the Company's investments of held-to-maturity securities will mature within less than 12 months with an average maturity of 1 month.
(e) Fair Value Measurements
The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016:

 Fair value measurement at reporting date using:
 
Quoted prices in
active markets for
identical assets
(Level 1)

Significant other
observable
inputs
(Level 2)

Significant
unobservable
inputs
(Level 3)

Total
At June 30, 2017











Cash and cash equivalents
$
81,641


$
—


$
—


$
81,641

Restricted cash
$
2,877


$
—


$
—


$
2,877

Contingently issuable common stock
$
—


$
—


$
9,600


$
9,600

At December 31, 2016











Cash and cash equivalents
$
26,120


$
—


$
—


$
26,120

Restricted cash
$
2,001


$
—


$
—


$
2,001

Contingently issuable common stock
$
—


$
—


$
12,200


$
12,200



6
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



There were no re-measurements to fair value during the six months ended June 30, 2017 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers between Level 1, Level 2 or Level 3 securities during the six months ended June 30, 2017.
(f) Financial Instruments Not Recorded at Fair Value on a Recurring Basis
The Company measures the fair value of its 2.25% Convertible Senior Notes due 2018 and 3.25% Convertible Senior Notes due 2020 (collectively, the “Senior Notes”) carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Senior Notes is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar securities. Based on the market prices, the fair value of our long-term debt was $123.2 million as of June 30, 2017 and $187.6 million as of December 31, 2016.
The Company measures the fair value of its Term Loan carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Term Loan is determined by Level 3 inputs and is based primarily on unobservable inputs that are not corroborated by market data. The fair value of our Term Loan was $100.2 million as of June 30, 2017.
Due to short-term nature, the Company believes that the carrying value of its revolving line of credit approximated its fair value at June 30, 2017.
The Company measures the fair value of its held-to-maturity marketable securities carried at amortized cost quarterly for disclosure purposes. The fair value of marketable securities is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar instruments.

4. Stock-Based Compensation

The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss, based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the three and six months ended June 30, 2017 and 2016, was as follows:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Cost of goods sold
$
304


$
259

 
$
473


$
532

Operating expenses:





 





Research and development
323


434

 
583


797

Clinical and regulatory affairs
160


593

 
420


493

Marketing and sales
1,283


1,261

 
2,341


2,391

General and administrative
1,164


1,339

 
2,371


2,555

Total operating expenses
$
2,930


$
3,627

 
$
5,715


$
6,236

Total
$
3,234


$
3,886

 
$
6,188


$
6,768


5. Net Loss Per Share
Net loss per share was calculated by dividing net loss by the weighted average number of common shares outstanding for the three and six months ended June 30, 2017 and 2016.

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016
Net loss
$
(16,292
)

$
(66,837
)

$
(37,606
)

$
(114,507
)
Shares used in computing basic and diluted net loss per share
83,247


82,072


83,087


79,368

Basic and diluted net loss per share
$
(0.20
)

$
(0.81
)

$
(0.45
)

$
(1.44
)

7
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)




The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Common stock options
574


1,620

 
636


1,193

Restricted stock awards
121


135

 
120


131

Restricted stock units
207


438

 
248


299

  Total
902


2,193

 
1,004


1,623


Conversion of Senior Notes
As discussed in Note 6, in December 2013, the Company issued $86.3 million in aggregate principal amount of 2.25% Convertible Senior Notes due 2018 (the “2.25% Senior Notes”) in an underwritten public offering. In November 2015, the Company also issued $125.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2020 (the “3.25% Senior Notes”) in an underwritten public offering. Upon any conversion, the 2.25% Senior Notes and/or 3.25% Senior Notes, (collectively the "Senior Notes") may be settled, at the Company’s election, in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. For purposes of calculating the maximum dilutive impact, the Company presumed that the Senior Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Senior Notes is excluded from the calculation of diluted loss per share because the impact of these securities would be anti-dilutive.

Deerfield Warrants
On April 3, 2017, the Company entered into a Facility Agreement (the “Facility Agreement”) with affiliates of Deerfield Management Company, L.P. (collectively, “Deerfield”), pursuant to which Deerfield agreed to loan to the Company up to $120.0 million, subject to the terms and conditions set forth in the Facility Agreement (the “Term Loan”). As part of the Facility Agreement, the Company also issued warrants to Deerfield to purchase an aggregate of 6,470,000 shares of common stock of the Company at an exercise price of $9.23 per share (the “Deerfield Warrants”). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company. Refer to Note 6 of the Notes to the Condensed Consolidated Financial Statements for further discussion.
The potential dilutive effect of these securities is shown in the chart below:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Conversion of the Notes
11,939


14,767

 
11,939


14,767

Deerfield Warrants
6,470


—

 
6,470


—

The effect of the contingently issuable common stock is excluded from the calculation of basic net loss per share until all necessary conditions for issuance have been satisfied. Refer to Note 9 of the Notes to the Condensed Consolidated Financial Statements for further discussion.

6. Credit Facilities
2.25% Convertible Senior Notes
On December 10, 2013, the Company issued $86.3 million in aggregate principal amount of 2.25% Convertible Senior Notes (the “2.25% Senior Notes”). The 2.25% Senior Notes mature on December 15, 2018 unless earlier repurchased by the Company or

8
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



converted. The Company received net proceeds of approximately $82.6 million from the sale of the 2.25% Senior Notes, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Interest is payable on the 2.25% Senior Notes on June 15 and December 15 of each year, beginning June 15, 2016.
The 2.25% Senior Notes are governed by the terms of a base indenture (the “Base Indenture”), as supplemented by the first supplemental indenture relating to the 2.25% Senior Notes (the “First Supplemental Indenture,” and together with the Base Indenture, the “Indenture”), between the Company and Wells Fargo Bank, National Association (the “Trustee”), each of which were entered into on December 10, 2013.
The 2.25% Senior Notes are senior unsecured obligations and are: (a) senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the 2.25% Senior Notes; (b) equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; (c) effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and (d) and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries.
The Company could not redeem the 2.25% Senior Notes prior to December 15, 2016. On or after December 15, 2016, the Company may redeem for cash all or any portion of the 2.25% Senior Notes, at its option, but only if the closing sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds 130% of the conversion price on each applicable trading day. The redemption price will equal 100% of the principal amount of the 2.25% Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2.25% Senior Notes.
Holders may convert their 2.25% Senior Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014, if the closing sale price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the 2.25% Senior Notes in effect on each applicable trading day; (2) during the five consecutive business-day period following any five consecutive trading-day period in which the trading price for the 2.25% Senior Notes for each such trading day was less than 98% of the closing sale price of the Company’s common stock on such date multiplied by the then-current conversion rate; (3) if the Company calls all or any portion of the notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2018 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their 2.25% Senior Notes for conversion at any time, regardless of the foregoing circumstances.
Upon conversion, the Company will, at its election, pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
The initial conversion rate of the 2.25% Senior Notes will be 41.6051 shares of the Company’s common stock for each $1,000 principal amount of 2.25% Senior Notes, which represents an initial conversion price of approximately $24.04 per share. Following certain corporate transactions that occur on or prior to the stated maturity date or the Company’s delivery of a notice of redemption, the Company will increase the conversion rate for a holder that elects to convert its 2.25% Senior Notes in connection with such a corporate transaction.
If a fundamental change (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their 2.25% Senior Notes at a fundamental change purchase price equal to 100% of the principal amount of the 2.25% Senior Notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.
The 2.25% Senior Notes Indenture contains customary terms and covenants and events of default with respect to the 2.25% Senior Notes. If an event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding 2.25% Senior Notes may declare the principal amount of the 2.25% Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to us, the principal amount of the 2.25% Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable.
The Company was not required to separate the conversion option in the 2.25% Senior Notes under ASC 815, "Derivatives and Hedging", and has the ability to settle the 2.25% Senior Notes in cash, common stock or a combination of cash and common stock, at its option. In accordance with cash conversion guidance contained in ASC 470-20, "Debt with Conversion and Other

9
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



Options", the Company accounted for the 2.25% Senior Notes by allocating the issuance proceeds between the liability and the equity component. The equity component is classified in stockholders’ equity and the resulting discount on the liability component is accreted such that interest expense equals the Company’s nonconvertible debt borrowing rate. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the 2.25% Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was $66.9 million resulting in a $19.3 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders’ equity and as debt discount, to be subsequently accreted to interest expense over the term of the 2.25% Senior Notes. Underwriting discounts and commissions and offering expenses totaled $3.7 million and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, $2.9 million attributable to the indebtedness was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the 2.25% Senior Notes, and $0.8 million attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders’ equity. During the three months ended March 31, 2016, the Company adopted ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" utilizing retrospective application as permitted. As a result, the Company reclassified $1.9 million of debt issuance costs from current and non-current other assets to reduce the 2.25% Senior Notes as of December 31, 2015.
On April 3, 2017, the Company entered into a Facility with affiliates of Deerfield Management Company, L.P., pursuant to which Deerfield agreed to loan to the Company up to $120 million, subject to the terms and conditions set forth in the Facility Agreement. The Company used a portion of the proceeds from the Term Loan to repurchase $68 million aggregate principal amount of outstanding 2.25% Senior Notes, plus the accrued but unpaid interest thereon, from the holders thereof in privately negotiated transactions. Refer to section Deerfield Facility Agreement below for further discussion. The embedded conversion option of the 2.25% Senior Notes, which was originally recorded in additional paid-in capital, was reduced by $2.2 million. Additionally, $3.2 million related to the reduction of outstanding principal related to the 2.25% Senior Notes was charged to loss on debt extinguishment on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss.
As of June 30, 2017, the Company had outstanding borrowings of $18.3 million, and deferred financing costs of $0.2 million, related to the 2.25% Senior Notes. There are no principal payments due during the term. Annual interest expense on these notes will range from $1.1 million to $1.5 million through maturity.
Capped Call Transactions
On December 10, 2013, in connection with the pricing of the 2.25% Senior Notes and the exercise in full of their overallotment option by the underwriters, the Company entered into privately-negotiated capped call transactions (the “Capped Call Transactions”) with Bank of America, N.A., an affiliate of Merrill Lynch, Pierce, Fenner & Smith Incorporated. The Capped Call Transactions initial conversion rate and number of options substantially corresponds to each $1,000 principal amount of 2.25% Senior Notes. The Company used approximately $7.4 million of the net proceeds from the 2.25% Senior Notes offering to pay for the cost of the Capped Call Transactions.
The Capped Call Transactions are separate transactions entered into by the Company with Bank of America, N.A., are not part of the terms of the 2.25% Senior Notes and will not change the holders’ rights under the 2.25% Senior Notes. The Capped Call Transactions have anti-dilution adjustments substantially similar to those applicable to the 2.25% Senior Notes. The Capped Call Transactions are derivative instruments that are recorded within stockholders’ equity because they meet an exemption from mark-to-market derivative accounting.
The Capped Call Transactions are expected generally to reduce the potential dilution and/or offset potential cash payments that the Company is required to make in excess of the principal amount upon conversion of the 2.25% Senior Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions, which initially corresponds to the $24.04 conversion price of the 2.25% Senior Notes. If, however, the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the initial cap price of $29.02, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the Capped Call Transactions.
The Company will not be required to make any cash payments to Bank of America, N.A. or any of its affiliates upon the exercise of the options that are a part of the Capped Call Transactions, but will be entitled to receive from Bank of America, N.A. (or an affiliate thereof) a number of shares of the Company’s common stock and/or an amount of cash generally based on the amount by which the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions during the relevant valuation period under the Capped

10
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



Call Transactions. However, if the market price of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the cap price of the Capped Call Transactions during such valuation period under the Capped Call Transactions, the number of shares of common stock and/or the amount of cash the Company expects to receive upon exercise of the Capped Call Transactions will be capped based on the amount by which the cap price exceeds the strike price of the Capped Call Transactions.
For any conversions of 2.25% Senior Notes prior to the close of business on the 55th scheduled trading day immediately preceding the stated maturity date of the 2.25% Senior Notes, including without limitation upon an acquisition of the Company or similar business combination, a corresponding portion of the Capped Call Transactions will be terminated. Upon such termination, the portion of the Capped Call Transactions being terminated will be settled at fair value (subject to certain limitations), as determined by Bank of America, N.A., in its capacity as calculation agent under the Capped Call Transactions, which the Company expects to receive from Bank of America, N.A., and no payments will be due Bank of America, N.A. The capped call expires on December 13, 2018.
In connection with the Company’s repurchase of approximately $68 million aggregate principal amount of outstanding 2.25% Senior Notes in April 2017, the Company and Bank of America, N.A. unwound a portion of the Capped Call Transactions relating to the repurchased 2.25% Senior Notes. These Capped Call Transactions were originally classified in stockholders’ equity and continued to meet the criteria for classification thereof while outstanding, and therefore were not subsequently measured at fair value. The Company did not pay or receive any amount related to the unwind of the Capped Call Transactions. Therefore, the Company accounted for the unwind of the Capped Call Transactions by removing these options at their carrying value in additional paid-in capital and recording an offsetting entry to additional paid-in capital. As a result, the Company did not recognize any gain or loss, and the unwind had no net impact on additional paid-in capital.
3.25% Convertible Senior Notes due 2020
On November 2, 2015, the Company issued $125.0 million aggregate principal amount of 3.25% Senior Convertible Notes due 2020 (the “3.25% Senior Notes”). The 3.25% Senior Notes are governed by the Base Indenture, as amended and supplemented by the second supplemental indenture relating to the 3.25% Senior Notes (the “Second Supplemental Indenture,” and together with the Base Indenture, the “3.25% Senior Notes Indenture”), dated as of November 2, 2015, by and between the Company and the Trustee.
The 3.25% Senior Notes are senior unsecured obligations and are: senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the 3.25% Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, including the 2.25% Senior Notes; effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries.
The 3.25% Senior Notes accrue interest at a rate of 3.25% per year, payable semi-annually in arrears on May 1 and November 1 of each year, commencing May 1, 2016. The 3.25% Senior Notes mature on November 1, 2020, unless earlier purchased, redeemed or converted into shares of common stock in accordance with the terms of the 3.25% Senior Notes Indenture.
The Company may not redeem the 3.25% Senior Notes prior to November 1, 2018. On or after November 1, 2018, the Company may redeem for cash all or any portion of the 3.25% Senior Notes, at its option, but only if the closing sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds 130% of the conversion price on each applicable trading day. The redemption date can be no sooner than 30 trading days from the date on which notice of redemption is provided to the holders, during which time, up until two trading days prior to the redemption, the holders may elect to convert all or a portion of the 3.25% Senior Notes into shares of the Company’s common stock. The redemption price will equal 100% of the principal amount of the 3.25% Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 3.25% Senior Notes.
The 3.25% Senior Notes are convertible at the option of the holders: (1) in the calendar quarter following any quarter in which, for at least 20 out of the 30 consecutive trading days (whether or not consecutive) ending on the last day of the quarter, the closing price of the Company’s common stock is more than 130% of the then-current conversion price of the 3.25% Senior Notes; (2) in the five business days following any five day period in which the trading price per $1,000 note was less than 98% of the product of the closing sale price of the Company’s common stock and the current conversion rate; (3) in the event that the Company has provided notice of redemption, but no later than two trading days prior to Company’s proposed redemption date; or (4) upon the occurrence of specified corporate events. On or after August 1, 2020 until the close of business on the second scheduled trading day

11
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



immediately preceding the stated maturity date, holders may surrender their 3.25% Senior Notes for conversion at any time, regardless of the foregoing circumstances.
The initial conversion rate of the 3.25% Senior Notes is 89.4314 shares of the Company’s common stock per 1,000 principal amount of the 3.25% Senior Notes, which is equivalent to an initial conversion price of approximately $11.18 per share. The conversion rate is subject to adjustment upon the occurrence of certain specified events. Upon conversion, the Company will at its election pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
If a fundamental change (as defined in the 3.25% Senior Notes Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their 3.25% Senior Notes at a fundamental change purchase price equal to 100% of the principal amount of the 3.25% Senior Notes to be purchased, plus accrued and unpaid interest.
The 3.25% Senior Notes Indenture contains customary terms and covenants and events of default with respect to the 3.25% Senior Notes. If an event of default (as defined in the 3.25% Senior Notes Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding 3.25% Senior Notes may declare the principal amount of the 3.25% Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the 3.25% Senior Notes Indenture) occurs with respect to us, the principal amount of the 3.25% Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable.
Upon issuance and through December 31, 2015, the Company was not required to separate the conversion option from the 3.25% Senior Notes under ASC 815, "Derivatives and Hedging". However, because the Company has the ability to settle the 3.25% Senior Notes in cash, common stock or a combination of cash and common stock, the Company applied the cash conversion guidance contained in ASC 470-20, "Debt With Conversion and other Options", and accounted for the 3.25% Senior Notes by allocating the issuance proceeds between the liability-classified debt component and a separate equity component attributable to the conversion option. The equity component is classified in stockholders’ equity and the resulting discount on the liability component is accreted such that interest expense equals the Company’s borrowing rate for nonconvertible loan products of similar duration. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the 3.25% Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was $97.8 million resulting in a $27.2 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders’ equity and as a debt discount, to be subsequently accreted to interest expense over the term of the 3.25% Senior Notes. Underwriting discounts and commissions and offering expenses totaled $3.7 million and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, $2.9 million attributable to the indebtedness was recorded as deferred financing costs  in other assets, to be subsequently amortized as interest expense over the term of the 3.25% Senior Notes, and $0.8 million attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders’ equity. The company adopted ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" during the first quarter of 2016, utilizing retrospective application as permitted. As a result, the Company reclassified $2.9 million of debt issuance costs from other assets to reduce the convertible notes as of December 31, 2015.
As of June 30, 2017, the Company had outstanding borrowings of $105.5 million, and deferred financing costs of $2.1 million, related to the 3.25% Senior Notes. There are no principal payments due during the term. Annual interest expense on these 3.25% Senior Notes will range from $9.1 million to $10.7 million through maturity.
In connection with its merger with TriVascular in February 2016, the Company issued 13.6 million shares of common stock as consideration to the former stockholders of TriVascular. As a result of the Company's issuance of such shares in the merger, the quantity of authorized common shares available for future issuance was reduced to a level insufficient to honor all of the potential common shares underlying instruments then outstanding. Such instruments include the conversion options related to the 3.25% Senior Notes and 2.25% Senior Notes, employee stock options, restricted stock units, contingently issuable common stock relating to the prior Nellix acquisition, and stock warrants. The creation of this authorized share deficiency in February 2016 required the Company, during the first quarter of 2016, to separate as a stand-alone derivative the 3.25% Senior Notes conversion option and a portion of the 2.25% Senior Notes conversion option for which no authorized shares are available to effect share settlement in the event of a conversion. Accordingly, in February 2016 the Company re-classed $24.8 million of the conversion features originally recorded in stockholder’s equity of the Senior Notes to derivative liabilities which will be marked to market each period until the Company authorizes sufficient new common shares to alleviate the deficiency.
On June 2, 2016, the Company amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 135,000,000, which is currently at a level sufficient to alleviate the share

12
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



deficiency. Accordingly, on June 2, 2016, the Company re-classed $68.6 million of the conversion features of the Senior Notes from derivative liabilities to additional paid-in capital.
For the three and six months ended June 30, 2016, the Company recorded $38.7 million as a fair value adjustment of derivative liabilities. The primary factor causing the change in the fair value of the derivative liability was during the period February 3, 2016 through June 2, 2016 when the Company's stock price increased. Adjustments to the fair value of the derivative liabilities are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
The value of the derivative liabilities were estimated using a “with” and “without” approach utilizing observable and unobservable inputs causing this to be a Level 3 measurement. In the “with” scenario, the value of the Senior Notes were estimated in a binomial lattice model that considers all terms of the Senior Notes, including the conversion features, with a range of probabilities and assumptions related to the timing and likelihood of the conversion features being exercised by either the Company or the holders of the Senior Notes. In the “without” scenario the value of the Senior Notes absent the conversion options were estimated. The difference between the values estimated in the “with” and “without” scenarios represents the value of the derivative liabilities. Changes in the value of the derivative liabilities were driven by changes in the Company’s stock price, expected volatility, credit spreads, and market yields.
Bank of America line of credit
On July 21, 2015, the Company entered into a revolving credit facility with Bank of America, N.A. (“BOA”), whereby the Company could borrow up to $20.0 million (the “BOA Credit Facility”). All amounts owing under the BOA Credit Facility would become due and payable upon its expiration on July 21, 2017. A sub-feature in the line of credit allowed for the issuance of up to $10.0 million in letters of credit. The BOA Credit Facility was collateralized by all of the Company's assets, except its intellectual property. The BOA Credit Facility could be terminated at any time during the two year term by the Company upon three business days’ notice. The BOA Credit Facility usage was priced at a spread over the one, two, three and six month LIBOR rates, and was subject to a covenant related to timely providing publicly reported information and a liquidity covenant tied to “Unencumbered Liquid Assets” ("ULA") of not less than $30.0 million. If not in default, the Company had the ability to reduce the ULA covenant requirement by reducing the BOA Credit Facility, with the ULA maintained at 1.5 times the BOA Credit Facility.
The Company terminated the BOA Credit Facility on July 29, 2016 concurrent with its entry into a credit and security agreement with MidCap.
MidCap Credit Facility
On July 29, 2016, the Company entered into a credit and security agreement with MidCap Financial Trust ("MidCap"), as agent for the lenders party thereto and as a lender, whereby the Company could borrow up to the lesser of $50.0 million or its applicable borrowing base of asset-based revolving loans (the “MidCap Credit Facility”). All amounts owing under the MidCap Credit Facility accrued interest at a rate equal to the LIBOR Rate plus four and one tenth percent (4.10%). For purposes of the MidCap Credit Facility, LIBOR Rate meant a per annum rate of interest equal to the greater of (a) one half of one percent (0.50%) and (b) the rate determined by MidCap by dividing (i) the Base LIBOR Rate, meaning the base London interbank offer rate for the applicable interest period, by (ii) the sum of one minus the daily average during such interest period of the aggregate maximum reserve requirement then imposed under Regulation D of the Board of Governors of the Federal Reserve System for “Eurocurrency Liabilities” (as defined therein).
The MidCap Credit Facility was secured by substantially all of the Company's assets, excluding its intellectual property (“Collateral”), and placed customary limitations on indebtedness, liens, distributions, acquisitions, investments, and other activities of the Company in a manner designed to protect the Collateral.
Deferred financing costs directly related to the MidCap Credit Facility such as legal, origination, and professional services fees totaled $0.9 million. In conjunction with the Company’s adoption of ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs” during the first quarter of 2016, the Company also adopted an update thereof or ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of Credit Arrangements.” As a result, $0.9 million attributable to the MidCap Credit Facility was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the MidCap Credit Facility. The MidCap Credit Facility also contains a lockbox arrangement clause requiring the Company to maintain a lockbox bank account in favor of the MidCap Credit Facility; Company cash receipts remitted to the lockbox bank account are swept on a regular basis to reduce outstanding borrowings related to the MidCap Credit Facility.

13
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



In conjunction with the Company’s termination of the BOA Credit Facility and concurrent entry into a credit and security agreement with MidCap in July 2016, the Company entered into a corporate credit card agreement whereby the Company is required to maintain a $2.0 million deposit in favor of the credit card issuer. The deposit account related to these credit cards will be presented as restricted cash on the Company’s Condensed Consolidated Balance Sheet.
On April 3, 2017, the Company replaced the MidCap Credit Facility with a new revolving line of credit with Deerfield ELGX Revolver, LLC. As a result, and as of June 30, 2017, the Company wrote off approximately $0.8 million in deferred financing costs and was required to pay a $2.5 million termination fee to Midcap; the foregoing were charged to loss on debt extinguishment on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss.

Deerfield Facility Agreement
On April 3, 2017, the Company entered into a Facility Agreement (the “Deerfield Facility Agreement” or “Facility Agreement”) with affiliates of Deerfield Management Company, L.P. (collectively, “Deerfield”), pursuant to which Deerfield agreed to loan to the Company up to $120.0 million, subject to the terms and conditions set forth in the Facility Agreement (the “Term Loan”). The Company drew the entire principal amount of the Term Loan on the Agreement Date. The Company agreed to pay Deerfield a yield enhancement fee equal to 2.25% of the principal amount of the funds disbursed on the Agreement Date. The Company also agreed to reimburse Deerfield for all reasonable out-of-pocket expenses incurred by Deerfield in connection with the negotiation and documentation of the Facility Agreement up to a capped amount. Accordingly, deferred financing costs of $5.1 million was recorded on the Company’s Condensed Consolidated Balance Sheet as a direct reduction of the Term Loan, to be subsequently amortized as interest expense over the effective period of the Term Loan. Concurrently with entering into the Facility Agreement, the Company entered into a Guaranty and Security Agreement with Deerfield (the “Security Agreement”), pursuant to which, as security for the repayment of the Company’s obligations under the Facility Agreement, the Company granted to Deerfield a first priority security interest in substantially all of the Company’s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted pursuant to the Facility Agreement.
Any amounts drawn under the Facility Agreement accrue interest at a rate of 6.87% per annum, payable quarterly in arrears beginning on July 1, 2017 and on the first business day of each calendar quarter thereafter and on the Maturity Date, unless repaid earlier. The Company will be required to pay Deerfield on each of April 2, 2021, April 2, 2022 and April 2, 2023 (the “Maturity Date”), an amortization payment equal to $40 million (or, if on the Maturity Date, the remaining outstanding principal amount of the Term Loan).
Upon a change of control of the Company, if the acquirer satisfies certain conditions set forth in the Facility Agreement, such acquirer may assume the outstanding principal amount under the Facility Agreement without penalty. If such acquirer does not satisfy the conditions set forth in the Facility Agreement, Deerfield may, at its option, require the Company to repay the outstanding principal balance under the Facility Agreement plus, depending on the timing of the change of control transaction, the Company may be required to pay a make-whole premium and will be required to pay a change of control fee.
At any time on or after the fourth anniversary of the Agreement Date, the Company has the right to prepay any amounts owed under the Facility Agreement without premium or penalty, unless such prepayment occurs in connection with a change of control of the Company, in which case the Company must pay Deerfield a change of control fee unless such change of control occurs beyond a certain period after the Maturity Date. At any time prior to the fourth anniversary of the Agreement Date, any prepayment made by the Company will be subject to a make-whole premium and, if such prepayment occurs in connection with a change of control of the Company, a change of control fee.
Any amounts drawn under the Facility Agreement may become immediately due and payable upon customary events of default, as defined in the Facility Agreement, or the consummation of certain change of control transactions, as described above.
The Facility Agreement contains various representations and warranties, events of default, and affirmative and negative covenants, customary for financings of this type, including reporting requirements, requirements that the Company maintain timely reporting with the SEC and restrictions on the ability of the Company and its subsidiaries to incur additional liens on their assets, incur additional indebtedness and acquire and dispose of assets outside the ordinary course of business.
As of June 30, 2017, the Company had outstanding borrowings of $105.3 million, and deferred financing costs of $4.9 million, related to the Term Loan. Annual interest expense on these notes will range from $1.4 million to $8.4 million through maturity.
Warrants

14
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



In connection with the execution of the Facility Agreement, the Company issued to Deerfield warrants to purchase an aggregate of 6,470,000 shares of common stock of the Company at an exercise price of $9.23 per share (the “Deerfield Warrants”). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company.
The Warrants expire on the seventh anniversary of the Agreement Date. Subject to certain exceptions, the Warrants contain limitations such that the Company may not issue shares of common stock of the Company to Deerfield upon the exercise of the Warrants if such issuance would result in Deerfield beneficially owning in excess of 4.985% of the total number of shares of common stock of the Company then issued and outstanding.
The holders of the Warrants may exercise the Warrants for cash, on a cashless basis or through a reduction of an amount of principal outstanding under the Term Loan. In connection with certain major transactions, the holders may have the option to convert the Warrants, in whole or in part, into the right to receive the transaction consideration payable upon consummation of such major transaction in respect of a number of shares of common stock of the Company equal to the Black-Scholes value of the Warrants, as defined therein, and in the case of other major transactions, the holders may have the right to exercise the Warrants, in whole or in part, for a number of shares of common stock of the Company equal to the Black-Scholes value of the Warrants.
The Company measured the initial fair value of the 6,470,000 shares underlying the Deerfield Warrants at $14.3 million, net of issuance costs of $0.4 million, and recorded the amount in additional paid-in-capital and as a direct reduction of the Term Loan, to be subsequently amortized as interest expense over the effective period of the Term Loan.
Registration Rights Agreement
In connection with the Term Loan and the issuance of the Warrants, the Company entered into a Registration Rights Agreement with Deerfield (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, the Company has agreed to file a registration statement on Form S-3 (or if Form S-3 is not then available, such other form of registration statement as is then available) with the Commission on or prior to the 30th day following the Agreement Date, to register for resale the shares of common stock of the Company issuable upon the exercise of the Warrants. The aforementioned registration statement was filed on Form S-3 on May 2, 2017.
Credit and Security Agreement
On the Agreement Date, the Company entered into a Credit and Security Agreement (the “Credit Agreement”) with Deerfield ELGX Revolver, LLC (“Deerfield Revolver”), pursuant to which the Company may borrow up to the lesser of $50 million or its applicable borrowing base from time to time prior to March 31, 2020 (the “Revolver”). Any outstanding principal under the Revolver will accrue interest at a rate equal to 3-month LIBOR (with a 1% floor) plus 4.60%, payable monthly in arrears on the first business day of the immediately succeeding calendar month and on the maturity date. The Company is subject to other fees in addition to interest on the outstanding principal amount under the Revolver, including in connection with an early termination of the Revolver.
The Revolver replaces the Company’s $50.0 million asset-based revolving line of credit with MidCap Financial Trust. In conjunction with the Company’s adoption of ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs” during the first quarter of 2016, the Company also adopted an update thereof or ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of Credit Arrangements.” As a result, the Company recorded $1.2 million in deferred financing costs related to the Revolver and presents these costs as a deferred asset, to be subsequently amortized as interest expense over the term of the Revolver, on the Company’s Condensed Consolidated Balance Sheets. The Company’s obligations under the Credit Agreement are secured by a first priority security interest in substantially all of the Company’s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted pursuant to the Term Loan. As of June 30, 2017, the Company had outstanding borrowings of $24.3 million, and deferred financing costs of $1.1 million related to the revolver.
In conjunction with the Company’s entry into the Credit Agreement, the Company entered into a corporate credit card agreement whereby the Company is required to maintain a $2.0 million deposit in favor of the credit card issuer. The deposit account related to these credit cards will be presented as restricted cash on the Company’s Condensed Consolidated Balance Sheet.


15
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



7. Revenue by Geographic Region
The Company's revenue by geographic region, was as follows:

Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017

2016
 
2017

2016
United States
$
31,906


65.7%

$
36,283


71.2%
 
$
62,795


68.9%

$
66,151


70.9%
Total International
$
16,650


34.3%

$
14,691


28.8%
 
$
28,373


31.1%

$
27,189


29.1%
Revenue
$
48,556


100.0%

$
50,974


100.0%
 
$
91,168

 
100.0%
 
$
93,340

 
100.0%

8. Commitments and Contingencies
(a) Leases
The Company leases its administrative, research, and manufacturing facilities located in Irvine, California, Santa Rosa, California and an administrative office located in Rosmalen, The Netherlands. These facility lease agreements require the Company to pay operating costs, including property taxes, insurance and maintenance. In addition, the Company has certain equipment under long-term agreements that are accounted for as operating leases.
In conjunction with the TriVascular merger, the Company assumed the lease for TriVascular's facility in Santa Rosa, California. The Company uses the Santa Rosa facility for manufacturing, research & development, and administrative purposes and the facility consists of 110,000 square feet under an operating lease scheduled to expire in February 2018. In July 2017, the Company renewed the lease for an additional 5 years.
Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of June 30, 2017:
Remainder of 2017
$
1,856

2018
3,317

2019
3,435

2020
3,659

2021
3,692

2022 and thereafter
21,821

Total
$
37,780


Facilities rent expense for the three months ended June 30, 2017 and 2016 was $1.0 million and $0.9 million, respectively. For the six months ended June 30, 2017 and 2016 facilities rent expense was $1.9 million and $1.6 million, respectively.
(b) Employment Agreements and Retention Plan
The Company has employment agreements with certain of its executive officers under which payment and benefits would become payable in the event of termination by the Company for any reason other than cause, death or disability or termination by the employee for good reason (collectively, an “Involuntary Termination”) prior to, upon or following a change in control of the Company. The severance payment will generally be in a range of six to eighteen months of the employee’s then current salary for an Involuntary Termination prior to a change in control of the Company, and will generally be in a range of eighteen to twenty-four months of the employee’s then current salary for an Involuntary Termination upon or following a change in control of the Company.
(c) Legal Matters

16
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



We are from time to time involved in various claims and legal proceedings of a nature we believe are normal and incidental to a medical device business. These matters may include product liability, intellectual property, employment, and other general claims. Such cases and claims may raise complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. We accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.
LifePort Sciences LLC v. Endologix, Inc.
On December 28, 2012, LifePort Sciences, LLC ("LifePort") filed a complaint against the Company in the U.S. District Court, District of Delaware, alleging that certain of the Company's products infringe U.S. Patent Nos. 5,489,295, 5,676,696, 5,993,481, 6,117,167, 6,302,906, and 8,192,482, which were alleged to be owned by LifePort. On March 17, 2016, the Company entered into a Settlement and Patent License Agreement with LifePort (the “Settlement Agreement”) whereby LifePort granted the Company license rights to patents in exchange for a settlement of $4.7 million. The Settlement Agreement resolves this litigation and fully and finally releases the Company and LifePort from any claims arising out of or in connection with the litigation or the subject patents. The Settlement Agreement also contained a covenant not to sue for other patents owned by LifePort. However, since the subject patents were all expired and the Company was not currently using and has no plans to use the other patents owned by LifePort in products that could reach technological feasibility during the covenant not to sue period, there is no alternative future use and the full amount was recorded as settlement costs in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.
Shareholder Securities Litigation
In January 2017, two stockholders purporting to represent a class of persons who purchased the Company’s securities between August 2, 2016 and November 16, 2016, filed lawsuits against the Company and certain of its officers in the United States District Court for the Central District of California. The lawsuits allege that the Company made materially false and misleading statements and failed to disclose material adverse facts about its business, operational and financial performance, in violation of federal securities laws, relating to U.S. Food and Drug Administration Premarket Approval for the Company’s Nellix EVAS System. On May 26, 2017, the plaintiffs filed an amended complaint extending the class period to include persons who purchased the Company’s securities between May 5, 2016 and May 18, 2017 and adding certain factual assertions and allegations regarding the Nellix EVAS System. The Company believes the lawsuits are without merit and intends to defend itself vigorously.

Shareholder Derivative Litigation

On May 22, 2017, a purported stockholder of the Company filed a shareholder derivative complaint in the Superior Court for the State of California, County of Los Angeles, naming certain executive officers and the directors of the Company as defendants and alleging, among other things, breach of fiduciary duty by such executive officers and director. The Company believes this lawsuit is without merit and intends to defend itself vigorously.

SEC Investigation

In July 2017, the Company learned that the United States Securities and Exchange Commission (SEC) has issued a Formal Order of Investigation to investigate, among other things, events surrounding  the Nellix EVAS System and the prospect of its FDA pre-market approval.  The Company intends to fully cooperate with the investigation, but cannot predict its outcome or the timing of the investigation’s conclusion.

(d) Contract Termination
In the three and six months ended June 30, 2016, the Company sent notices of termination to certain of its distributors providing for the termination of the respective distribution agreements. In accordance with ASC No. 420 “Exit or Disposal Cost Obligations”, the Company expensed distributor termination costs in the period in which the written notification of termination occurred. As a result, the Company incurred termination costs of $1.1 million and $2.7 million for the three and six months ended June 30, 2016. Such termination costs are included in contract termination and business acquisition expenses for the three and six months ended June 30, 2016.

9. Contingently Issuable Common Stock
On October 27, 2010, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Nepal Acquisition Corporation, a wholly-owned subsidiary of the Company (“Merger Sub”), Nellix, Inc. ("Nellix"), certain of Nellix’s stockholders named therein and Essex Woodlands Health Ventures, Inc., as representative of the former Nellix stockholders. On December 10, 2010 (the “Nellix Closing Date”), the Company completed the merger (the “Merger”) of Merger Sub with and into Nellix pursuant to the terms of the Merger Agreement. The purchase price consisted of 3.2 million shares of the Company's common stock, issuable to the former Nellix stockholders as of the Nellix Closing Date, then representing a value of $19.4 million. Under the agreement, additional payments, solely in the form of shares of the Company's common stock (the “Contingent Payment”), could be made upon the achievement of a revenue milestone and a regulatory approval milestone (collectively, the “Nellix Milestones”).
Under the merger agreement, the ultimate value of each Contingent Payment would be determined on the date that each Nellix Milestone is achieved. The number of issuable shares would be established using an applicable per share price, which is subject to a ceiling and/or floor, resulting at the closing of the merger in a potential maximum of 10.2 million shares issuable upon the achievement of the Nellix Milestones. As of the Closing Date, the aggregate fair value of the cash Contingent Payment was estimated to be $28.2 million.

The Merger Agreement provides that, in addition to the shares of common stock of the Company (the “Common Stock”) issued to the former Nellix stockholders at the closing of the Merger, if the Company receives approval from the FDA to sell the Nellix Product in the United States (the “PMA Milestone”), the Company will issue additional shares of the Common Stock to the former stockholders of Nellix. The dollar value of the shares of the Common Stock to be issued upon achievement of the PMA Milestone will be equal to $15.0 million (less the dollar value of certain cash payments and other deductions). The price per share of the shares of the Common Stock to be issued upon achievement of the PMA Milestone is subject to a stock price floor of $4.50 per share, but not subject to a stock price ceiling.

17
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



As of June 30, 2017 the Company's stock price last closed at $4.86 per share. Thus, had the PMA Milestone been achieved on June 30, 2017 the Contingent Payment would have comprised 3.0 million shares (based on the 30-day average closing stock price ending 5 days prior to the announcement), representing a value of $14.5 million.
The value of the Contingent Payment is derived using a discounted income approach model, with a range of probabilities and assumptions related to the timing and likelihood of achievement of the PMA Milestone (which include Level 3 inputs - see Note 3(e) and the Company's stock price (Level 1 input) as of the balance sheet date). These varying probabilities and assumptions and changes in the Company's stock price have required fair value adjustments of the Contingent Payment in periods subsequent to the Nellix Closing Date.
The Contingent Payment fair value will continue to be evaluated on a quarterly basis until milestone achievement occurs, or until the expiration of the "earn-out period," as defined within the Nellix purchase agreement. Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
 
Fair Value of Contingently Issuable Common Stock
December 31, 2016
$
12,200

Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017
(2,600
)
June 30, 2017
$
9,600


10. Income Tax Expense
The Company applied an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods. The Company recorded a provision for income taxes of $0.1 million and $0.3 million for the three and six months ended June 30, 2017, respectively. The Company's ETR was (0.7)% for the three and six months ended June 30, 2017. The Company's ETR for the three and six months ended June 30, 2017 differs from the U.S. federal statutory tax rate of 34% primarily as a result of nondeductible expenses (including the Nellix Contingent Payment), state income taxes, foreign income taxes, and the impact of a full valuation allowance on its deferred tax assets.
The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made.

11. Restructuring Charges
In the six months ended June 30, 2017, the Company recorded $0.1 million in restructuring costs within operating expenses related to focused reductions of its workforce. The Company began substantially formulating plans around this workforce reduction during the first quarter of 2016 in conjunction with its merger of TriVascular. The targeted reductions and other restructuring activities were initiated to provide efficiencies and realign resources as well as to allow for continued investment in strategic areas and drive growth. The Company expects to incur a total of $11.2 million in restructuring charges upon the completion of the plan, which represents the Company’s best estimate as of June 30, 2017. In the year ended December 31, 2016, the Company recorded $11.1 million in restructuring costs. The recognition of restructuring charges requires that the Company make certain judgments and estimates regarding the nature, timing and amount of costs associated with the planned reductions of workforce. At the end of each reporting period, the Company will evaluate the remaining accrued balance to ensure that no excess accruals are retained and the utilization of the provisions are for their intended purpose in accordance with developed plans. The following table reflects the movement of activity of the restructuring reserve for the six months ended June 30, 2017:

18
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)




One-time Termination Benefits
Accrual balance as of December 31, 2016
$
2,754

Restructuring charges
137

Utilization
(2,656
)
Accrual balance as of June 30, 2017
$
235

The accrual balance as of June 30, 2017 is classified within accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheet.

12. TriVascular Merger
On February 3, 2016, the Company completed its merger with TriVascular pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated October 26, 2015, by and among Endologix, TriVascular and Teton Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Endologix (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Endologix acquired all of TriVascular’s outstanding capital stock through the merger of Merger Sub with and into TriVascular (the “Merger”), with TriVascular surviving the Merger as a wholly-owned subsidiary of Endologix. The Company completed the merger in order to become the innovation leader with broad clinical indications for the treatment of AAA, leverage the combined company’s commercial capabilities, and provide an accelerated path to profitability. The total purchase consideration given related to the acquisition follows:
Cash consideration
$
84,634

Common stock consideration
100,812
Fair value of assumed TriVascular stock warrants
44
Total purchase consideration
$
185,490

Common stock consideration consisted of 13,586,503 shares of Endologix common stock, worth $100.8 million based on the market value of $7.42 per share as of the effective date of the Merger on February 3, 2016.
In connection with the Merger, the Company assumed stock warrants, originally issued by TriVascular, and converted them to Endologix stock warrants. The fair value of the stock warrants represents a component of the total consideration for the Merger. Stock warrants assumed were valued using the Black-Scholes option pricing model as of the effective date of the Merger.
The acquisition was recorded by allocating the costs of the net assets acquired based on their estimated fair values at the acquisition date. The excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. The fair values were based on management’s analysis, including work performed by third-party valuation specialists. The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 3, 2016 (in thousands):

19
ENDOLOGIX, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(all tabular amounts presented in thousands, except per share, per unit, and number of years)
(Unaudited)



  Cash and cash equivalents
$
24,012

  Short-term investments
3,008

  Accounts receivable
5,780

  Inventories
17,765

  Prepaid expenses and other current assets
1,895

  Property and equipment
3,152

  Intangible assets
46,200

  Other assets
317

  Accounts payable
(2,214
)
  Accrued liabilities and other
(6,450
)
  Notes payable
(61
)
  Net assets acquired
$
93,404

Goodwill
$
92,086

Total purchase consideration
$
185,490

The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of TriVascular, such as broadening the product portfolio for the treatment of AAA and leveraging the combined company’s technology and commercial capabilities. The goodwill is not deductible for tax purposes.
Pro Forma Condensed Combined Financial Information (Unaudited)
The following unaudited pro forma combined financial information summarizes the results of operations for the period indicated as if the TriVascular merger had been completed as of January 1, 2015. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect, among other things, the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of January 1, 2015 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

Three Months Ended
 
Six Months Ended

June 30, 2016
 
June 30, 2016
Combined net sales
$
50,974

 
$
96,011

Combined net loss from continuing operations
(62,507
)
 
(110,730
)
Combined basic and diluted net loss per share
$
(0.76
)
 
$
(1.35
)

20

Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Note Concerning Forward-Looking Statements

In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward looking statements are intended to qualify for the safe harbor established by the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by the use of forward-looking terminology such as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should” or “will” or the negative of these terms or other comparable terminology, or by discussions of strategies, opportunities, plans or intentions. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. We have based these forward-looking statements largely on our current expectations based on information currently available to us and projections about future events and trends affecting the financial condition of our business. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. These forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Actual results could differ materially from those projected in forward-looking statements as a result of the following factors, among others:

•
risks associated with our merger with TriVascular Technologies, Inc. (“TriVascular”);
•
failure to realize the anticipated benefits from previous business combination transactions, including our acquisition
of Nellix, Inc. (“Nellix”);
•
continued market acceptance, use and endorsement of our products;
•
quality problems with our products;
•
consolidation in the health care industry;
•
the success of our clinical trials relating to products under development;
•
our ability to maintain strong relationships with certain key physicians;
•
continued growth in the number of patients qualifying for treatment of abdominal aortic aneurysms through our products;
•
our ability to effectively compete with the products offered by our competitors;
•
the level and availability of third party payor reimbursement for our products;     
•
our ability to effectively develop new or complementary products and technologies;
•
our ability to manufacture our endovascular systems to meet demand;
•
changes to our international operations including currency exchange rate fluctuations;
•
our ability to effectively manage our business and keep pace with our anticipated growth;
•
our ability to develop and retain a direct sales force in the United States and select European countries;
•
the nature of and any changes to domestic and foreign legislative, regulatory and other legal requirements that apply to us, our products, our suppliers and our competitors;     
•
the timing of and our ability to obtain and maintain any required regulatory clearances and approvals;
•
our ability to protect our intellectual property rights and proprietary technologies;
•
our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties;
•
product liability claims;
•
pending and future litigation;
•
reputational damage to our products caused by the use, mis-use or off-label use of our products or government or voluntary recalls of our products;
•
our utilization of single source supplier for specialized components of our product lines;
•
our ability to attract, retain, and motivate qualified personnel;
•
our ability to make future acquisitions and successfully integrate any such future-acquired businesses;
•
our ability to maintain adequate liquidity to fund our operational needs and research and developments expenses;
•
our ability to identify and manage risks; and
•
general macroeconomic and world-wide business conditions.

Our actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied from such forward-looking statements. Important factors that could cause our actual results, performance or achievements to differ materially from our expectations are disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 1, 2017, including but not limited to those factors discussed in “Management's Discussion and Analysis of Financial Condition and Results of Operations,” “Risk Factors,” “Consolidated Financial Statements” and “Notes to Consolidated Financial Statements.” All subsequent written

21

and oral forward-looking statements attributable to us or by persons acting on our behalf are expressly qualified in their entirety by these cautionary statements.

Our forward-looking statements speak only as of the date each such statement is made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations, except as required by applicable law or the rules and regulations of the SEC and The NASDAQ Stock Market, LLC.

Overview
Our Business
Our corporate headquarters is located in Irvine, California and we have manufacturing facilities located in Irvine and Santa Rosa, California. We develop, manufacture, market, and sell innovative medical devices for the treatment of aortic disorders. Our principal products are intended for the treatment of abdominal aortic aneurysms ("AAA"). Our AAA products are built on one of two platforms: (a) traditional minimally-invasive endovascular aneurysm repair ("EVAR") or (b) endovascular aneurysm sealing (“EVAS”), our innovative solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. Our current EVAR products include the AFX® Endovascular AAA System, or the AFX System, the VELA® Proximal Endograft, and the Ovation® Abdominal Stent Graft System, or the Ovation System. Our current EVAS product is the Nellix ® Endovascular Aneurysm Sealing System, or the Nellix EVAS System. We sell our products through our direct U.S. and European sales forces and third-party international distributors and agents in other parts of the world.
See Item 1. of our Annual Report on Form 10-K for the year ended December 31, 2016, entitled "Business," for a discussion of:
•
Market Overview and Opportunity
•
Our Products
•
Manufacturing and Supply
•
Marketing and Sales
•
Competition
•
Product Developments and Clinical Trials
When used in this report, “we,” “our,” “us” or “Endologix,” refer to Endologix, Inc. and our consolidated subsidiaries, unless otherwise expressly stated or the context otherwise requires. Endologix®, AFX®, Nellix®, IntuiTrak®, Ovation®, VELA®, Ovation Prime®, Duraply®, Ovation Alto®, and CustomSeal®, are registered trademarks of Endologix, Inc. and its subsidiaries. ActiveSeal™ and the respective product logos are trademarks of Endologix, Inc. and its subsidiaries.
The Nellix System has obtained CE Mark approval in the European Union and is only approved as an investigational device in the United States. The Ovation Alto System is only approved as an investigational device and currently not approved in any market.
Highlights of Our Product Development Initiatives, Clinical Trials and Regulatory Approvals
Nellix EVAS System
The Nellix EVAS System consists of (i) bilateral covered stents with endobags, (ii) a biocompatible polymer injected into the endobags to seal the aneurysm and (iii) a delivery system and associated accessories. The Nellix EVAS System is intended to seal the entire aneurysm sac effectively excluding the aneurysm and reducing the likelihood of future aneurysm rupture. We have the following trials in process to build independent and collective clinical and economic evidence of clinical safety and effectiveness:

•
EVAS FORWARD Global Registry - The objective of this registry was to assess the clinical outcomes of the Nellix® System for the endovascular repair of infrarenal abdominal aortic aneurysms (AAA) in an ‘all-comers,’ real world patient population. The first phase of the registry included 300 patients enrolled in 18 international centers. The first patient in the registry was treated in October 2013. In September 2014, we announced completion of patient enrollment in the EVAS FORWARD Global Registry. In November 2016, we announced updated data on 300 patients with a mean follow-up of 25 months. In November 2016, we also announced positive 2-year results from the Nellix EVAS FORWARD Global Registry. The following outcomes were presented at the annual VEITH meeting:

•37% of the patients had complex anatomies;
•98% freedom from any persistent endoleaks at latest follow-up;
•No secondary interventions for Type II endoleaks;
•97% freedom from aneurysm-related mortality; and
•99% freedom from cardiovascular mortality

22



In 2017, the EVAS FORWARD Global Registry 2 commenced a post market evaluation of the Nellix Gen2 EVAS System, our second generation device design.

•
EVAS FORWARD IDE - We developed this pivotal clinical trial to evaluate the safety and effectiveness of the Nellix EVAS System. This study is a prospective single arm study which enrolled 179 patients at 29 centers in the United States and Europe. In November 2014, we completed enrollment in the EVAS FORWARD IDE, and we submitted the one year results to the U.S. Food and Drug Administration (the “FDA”) in March 2016. In May 2016, we announced the results of the one year clinical data from the EVAS FORWARD IDE study that demonstrate that the Nellix EVAS System met the study primary endpoints for major adverse events at 30 days (safety) and treatment success at one year (effectiveness).

Subsequently, the two-year results from the trial were announced with key highlights from the two-year clinical data from the Nellix US IDE trial are included below:


•
Freedom from all endoleaks (95%), all-cause mortality (92%), device-related reintervention (96%), AAA Sac growth (98%), migration (98%), and cardiovascular mortality (98%), among all patients.
•Highest freedom of type II endoleaks, of 96%, ever reported at two years, among all patients.


•
ASCEND Registry - In April 2016, we announced the first data presentation with one-year outcomes from the ASCEND Registry (Aneurysm Study for Complex AAA: Evaluation of Nellix Durability), a physician-initiated registry of the Nellix EVAS System used with aortic branch stent grafts for the treatment of patients with complex AAAs.

In November 2016, we provided an update on the Nellix premarket approval (“PMA”) process. In that update, we reported that the FDA had requested that we provide current patient follow-up data at two-years from the EVAS FORWARD IDE Study. We also reported that we expected this data to be available and submitted to the FDA in the second quarter of 2017, followed by a possible FDA Advisory Committee Panel meeting by the end of 2017, and potential PMA of the Nellix EVAS System in the second quarter of 2018.

In May 2017, we met with the FDA regarding the Nellix EVAS System.  Based upon our meeting with the FDA, and our further internal analysis, we determined that we will seek PMA of the Nellix EVAS System by conducting a confirmatory clinical study with the previously updated Instructions for Use and the second generation device design which is currently sold in Europe and other international markets. We will collaborate with the FDA over the coming months on the confirmatory clinical study protocol, and we anticipate beginning patient enrollment in the confirmatory clinical study in the fourth quarter of 2017 or early 2018, with PMA approval estimated to occur in 2020.

AFX
The AFX System consists of (i) a cobalt chromium alloy stent covered by expanded polytetrafluoroethylene (commonly referred to as “ePTFE”) graft material and (ii) accompanying delivery systems. Once fixed in its proper position within the abdominal aortic bifurcation, the AFX System provides a conduit for blood flow, thereby relieving pressure within the weakened or “aneurysmal” section of the vessel wall, which greatly reduces the potential for the AAA to rupture. In February 2014, we launched a new proximal extension in the United States, VELA, designed to be used in conjunction with our AFX bifurcated device. VELA features a circumferential graft line marker and controlled delivery system that enable predictable deployment and final positional adjustments. We began a commercial introduction of VELA in Europe in January 2015.
In September 2014, we announced a new clinical study called LEOPARD (Looking at EVAR Outcomes by Primary Analysis of Randomized Data). This study will provide a real-world comparison of the AFX System versus other commercially available EVAR devices. We designed the LEOPARD study to randomize and enroll up to 800 patients at 80 leading centers throughout the United States and commenced enrollment in the first quarter of 2015. The centers are a mix of our current and new customers, with each investigator selecting one competitive device to randomize against the AFX System. The LEOPARD study is being led by an independent steering committee of leading physicians who are involved with the study and responsible for presenting the results over the five-year follow-up period.
In December 2015, we announced that the AFX System received Shonin approval from the Japanese Ministry of Health, Labor and Welfare.
In February 2016, we announced the completion of the first United States commercial implant of our AFX2 Bifurcated Endograft System (“AFX2”). AFX2 reduces procedure steps for the delivery and deployment of the bifurcated endograft. AFX2 also facilitates percutaneous endovascular aneurysm repair (“PEVAR”) by providing the lowest profile contralateral access through

23


a 7F introducer. These improvements bring together our ActiveSeal™ technology, DuraPly® PTFE graft material and VELA Proximal Endograft, into an integrated new EVAR system.
In December 2016, we received notice from our Notified Body in the European Union that the CE Mark for the AFX System and AFX2 would be suspended due to reports of Type III endoleaks with a prior generation of the device. We had, for our current generation of AFX products, implemented device and graft material improvements and updated instructions for use resulting in a substantial reduction in reported Type III endoleaks. We provided documentation of the foregoing reduction in Type III endoleaks to our Notified Body. In January 2017, we received notice from our Notified Body that the CE Mark for the AFX System and AFX2 had been re-instated, effective immediately.
In addition, in December 2016, we placed a temporary hold on shipments of the AFX System and AFX2 to complete an investigation of a manufacturing issue with some sizes of these devices. In late December 2016, we removed the temporary hold on, and resumed shipments of, all sizes of the AFX System and some sizes of AFX2, and in January 2017 we removed the temporary hold on, and resumed shipments of, all sizes of AFX2.
Ovation
The Ovation System consists of (i) a radiopaque nitinol suprarenal stent with integral anchors, (ii) a low-permeability polytetrafluoroethylene (“PTFE”), aortic body graft that contains a network of inflatable rings filled with a liquid polymer that solidifies during the deployment procedure, (iii) nitinol iliac limb stents encapsulated with PTFE, and (iv) accompanying ultra-low profile delivery systems, auto injector and fill polymer kit. The Ovation System creates a custom seal that conforms to anatomical irregularities and the ultra-low profile system navigates tortuous anatomies.
In May 2011, TriVascular initiated a three-year European Post Market Registry to enroll 500 patients across 30 European Centers. Enrollment ended in December 2013. In January 2017, we announced positive three-year results from the Ovation EU Post Market Registry. The data was presented at the 2017 LINC meeting and showed that the Ovation platform has the broadest range of patient applicability on Instructions for Use of all commercially available infrarenal endovascular AAA devices. The resulting outcomes included:

•
99% freedom from aneurysm-related mortality;
•
99% freedom from migration, rupture, and conversion;
•
97% freedom from Type I/III endoleak; and
•
Excellent freedom from secondary intervention for occlusion (97%), Type I endoleak (97%) and Type II endoleak 95%.

In October 2014, TriVascular initiated the LIFE Study to illustrate the potential advantages of a fast tract protocol including PEVAR, no general anesthesia, no time in ICU and a one night stay in the hospital with the Ovation System. In May 2016, we announced the completion of enrollment of 250 patients at 34 sites participating in the LIFE Study. In September 2016, we announced the results of the one-month clinical data from the LIFE Study that demonstrate that the Ovation System met the study primary endpoint for major adverse events at 30 days and the following highlights of the presentation, with outcomes covering one-month follow-up, include:

•
Low major adverse event (MAE) rate of 0.4%;
•
No ruptures, conversion, or secondary interventions;
•
99% and 100% freedom from type I and type III endoleak;
•
Fast-Track completed in 216 (87%) patients, with positive results compared to non-Fast-Track patients;
•
Procedure time of 84 minutes vs. 110 minutes;
•
General anesthesia use 0% vs. 18%;
•
ICU stay 0% vs. 32%; and
•
Mean hospital stay 1.2 vs. 1.9 days.

In early 2015, TriVascular initiated the LUCY Study, a multi-center post-market registry designed to explore the clinical benefits associated with EVAR using the Ovation Abdominal Stent Graft Platform in female patients with AAA, as compared to males. It is the first prospective study evaluating EVAR in females, a population that has historically been underrepresented in EVAR clinical trials. We announced completion of enrollment of 225 patients in the LUCY study in February 2017.
The 30-day LUCY data showed that, in women, the ultra-low profile (14F) Ovation device resulted in:
•
At least 28% greater EVAR eligibility for women with AAA
•
1.3% major adverse events, the lowest rate reported for EVAR, compared to other contemporary, prospective, post-market registries
•
No deaths
•
No proximal endoleaks

24


•
No limb occlusion
•
Low readmission rate of 3.9%
•
100% procedural success

In June 2015, the FDA approved the next generation Ovation iX Iliac Stent Graft for the Ovation System, and in July 2015, the FDA approved the Ovation iX Abdominal Stent Graft System. In September 2015, the first patients were treated with the Ovation iX Abdominal Stent Graft System in Europe, and in August 2015, TriVascular initiated the launch of the Ovation iX System in the United States.
In November 2016, we announced at VEITH that the five-year results from the Global Ovation Pivotal Trial were positive and showed the following outcomes:

•
Broad patient applicability, with 40% of the patients treated outside the labeled indications of other endovascular aortic repair (EVAR) devices;
•
Stable aortic neck diameters with an average expansion of 0.1%, compared to 25% as reported with other EVAR devices;
•
Lowest reported MAE rate across EVAR investigational device exemption (“IDE”) trials;
•
97% Freedom from secondary interventions related to type I endoleak; and
•
No migration, type III endoleaks or conversions.

In August 2016, we announced that the first two patients were treated with the Ovation Alto® Abdominal Stent Graft System(“Ovation Alto”), which is the newest device in the Ovation System. Ovation Alto expands EVAR to include the treatment of patients with complex AAAs, specifically patients with very short or otherwise challenging aortic neck anatomy. This is achieved by the conformable O-rings with CustomSeal® polymer that have been repositioned near the top of the endograft, providing seal just below the renal arteries. In November 2016, we received IDE approval from the FDA to conduct a clinical study with Ovation Alto in the United States.
In March 2017, we announced the enrollment of the first patients in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study, our pivotal clinical trial to evaluate the safety and effectiveness of Ovation Alto for the repair of infrarenal AAAs. The ELEVATE IDE clinical trial is approved to enroll 75 patients at up to 12 centers in the United States.
Characteristics of Our Revenue and Expenses
Revenue
We derive revenue from sales of our EVAR and EVAS products (including extensions and accessories) to hospitals upon completion of AAA repair procedures, or from sales to distributors upon title transfer (which is typically at shipment), provided our other revenue recognition criteria have been met.
Cost of Goods Sold
Cost of goods sold includes compensation (including stock-based compensation) and benefits of production personnel and production support personnel. Cost of goods sold also includes depreciation expense for production equipment, production materials and supplies expense, allocated facilities-related expenses and certain direct costs such as shipping.
Research and Development
Research and development expenses consist of compensation (including stock-based compensation) and benefits for research and development personnel, materials and supplies, research and development consultants, outsourced and licensed research and development costs and allocated facilities-related costs. Our research and development activities primarily relate to the development and testing of new devices and methods to treat aortic disorders.
Clinical and Regulatory
Clinical and regulatory expenses consist of compensation (including stock-based compensation) and benefits for clinical and regulatory personnel, regulatory and clinical payments related to studies, regulatory costs related to registration and approval activities and allocated facilities-related costs. Our clinical and regulatory activities primarily relate to gaining regulatory approval for the commercialization of our devices.
Marketing and Sales

25


Marketing and Sales expenses primarily consist of compensation (including stock-based compensation) and benefits for our sales force, clinical specialists, internal sales support functions and marketing personnel. It also includes costs attributable to marketing our products to our customers and prospective customers.
General and Administrative
General and administrative expenses primarily include compensation (including stock-based compensation) and benefits for personnel that support our general operations such as information technology, executive management, financial accounting, and human resources. General and administrative expenses also include bad debt expense, patent and legal fees, financial audit fees, insurance, recruiting fees, other professional services, the federal Medical Device Excise Tax and allocated facilities-related expenses.


26


Results of Operations
Operations Overview - Three Months Ended June 30, 2017 versus 2016
The following table presents our results of continuing operations and the related percentage of the period's revenue (in thousands):

Three Months Ended June 30,
 
Six Months Ended June 30,

2017

2016
 
2017

2016
Revenue
$
48,556


100.0%

$
50,974


100.0%
 
$
91,168

 
100.0%
 
$
93,340

 
100.0%
Cost of goods sold
16,332


33.6%

21,515


42.2%
 
30,302

 
33.2%
 
35,940

 
38.5%
Gross profit
32,224


66.4%

29,459


57.8%
 
60,866

 
66.8%
 
57,400

 
61.5%
Operating expenses:









 
 
 
 
 
 
 
 
Research and development
5,734


11.8%

7,714


15.1%
 
11,264


12.4%

15,559


16.7%
Clinical and regulatory affairs
2,740


5.6%

4,022


7.9%
 
6,575


7.2%

7,905


8.5%
Marketing and sales
23,781


49.0%

28,824


56.5%
 
49,681


54.5%

56,742


60.8%
General and administrative
7,904


16.3%

10,210


20.0%
 
16,777


18.4%

20,156


21.6%
Restructuring costs
(29
)

(0.1)%

790


1.5%
 
137


0.2%

8,114


8.7%
Settlement costs
—


—%

—


—%
 
—


—%

4,650


5.0%
Contract termination and business acquisition expenses
—


—%

1,127


2.2%
 
—


—%

5,905


6.3%
Total operating expenses
40,130


82.6%

52,687


103.4%
 
84,434


92.6%

119,031


127.5%
Loss from operations
(7,906
)

(16.3)%

(23,228
)

(45.6)%
 
(23,568
)

(25.9)%

(61,631
)

(66.0)%
Total other income (expense)
(8,264
)

(17.0)%

(43,166
)

(84.7)%
 
(13,762
)

(15.1)%

(52,330
)

(56.1)%
Net loss before income tax expense
(16,170
)

(33.3)%

(66,394
)

(130.3)%
 
(37,330
)

(40.9)%

(113,961
)

(122.1)%
Income tax expense
(122
)

(0.3)%

(443
)

(0.9)%
 
(276
)

(0.3)%

(546
)

(0.6)%
Net loss
$
(16,292
)

(33.6)%

$
(66,837
)

(131.1)%
 
$
(37,606
)

(41.2)%

$
(114,507
)

(122.7)%
Comparison of the Three Months Ended June 30, 2017 versus 2016
Revenue

Three Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Revenue
$
48,556


$
50,974


$
(2,418
)

(4.7)%

US Sales. Net sales totaled $31.9 million in the three months ended June 30, 2017, a (12.1)% decrease from $36.3 million in three months ended June 30, 2016, driven by a decline in sales of our AFX products due to lower than expected customer recapture and sales force attrition partially offset by strong sales growth for the Ovation System.
International Sales. Net sales of products in our international regions totaled $16.7 million in the three months ended June 30, 2017, a 13.3% increase from $14.7 million in the three months ended June 30, 2016. Both AFX and Ovation product lines posted strong growth which was partially offset by a decline in Nellix sales reflecting the narrowed IFU. Our international sales for the three months ended June 30, 2017 included an unfavorable foreign currency impact of approximately $0.2 million when compared to the net sales for the three months ended June 30, 2016, which had a 1.5 percentage point unfavorable impact on the growth rate representing constant currency increase of 14.8%.

27


Cost of Goods Sold, Gross Profit, and Gross Margin

Three Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Cost of goods sold
$
16,332


$
21,515


$
(5,183
)

(24.1
)%
Gross profit
32,224


29,459


2,765


9.4
 %
Gross margin percentage (gross profit as a percent of revenue)
66.4
%

57.8
%




Gross margin percentage for the three months ended June 30, 2017 increased to 66.4% from 57.8% for the three months ended June 30, 2016. The three months ended June 30, 2016 included purchase price accounting impact for inventory acquired in the TriVascular merger of $4.6 million. Excluding this impact, cost of goods decreased $0.6 million in the three months ended June 30, 2017 versus 2016. This decrease is driven by lower revenue of 4.7% in the three months ended June 30, 2017 versus the three months ended June 30, 2016.
Operating Expenses

Three Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Research and development
$
5,734


$
7,714


$
(1,980
)

(25.7)%
Clinical and regulatory affairs
2,740


4,022


(1,282
)

(31.9)%
Marketing and sales
23,781


28,824


(5,043
)

(17.5)%
General and administrative
7,904


10,210


(2,306
)

(22.6)%
Restructuring costs
(29
)

790


(819
)

(103.7)%
Contract termination and business acquisition expenses
—


1,127


(1,127
)

(100.0)%
Research and Development. The $2.0 million decrease in research and development expenses was attributable to timing of project spending and synergies related to the TriVascular merger.
Clinical and Regulatory Affairs. The decrease in clinical and regulatory affairs expenses are due to synergies related to the TriVascular merger.
Marketing and Sales. The $5.0 million decrease in marketing and sales expenses for the three months ended June 30, 2017, as compared to the prior year period, was driven by synergies as a result of the integration of the TriVascular sales and marketing organization.
General and Administrative. The $2.3 million decrease in general and administrative expenses is primarily attributable to a decrease in headcount related to synergies as a result of the TriVascular merger. The targeted reductions were initiated to provide efficiencies and realign resources as well as to allow for continued investment in strategic areas and drive growth.
Restructuring Costs. The $0.8 million decrease in restructuring costs for the three months ended June 30, 2017, as compared to the prior year period is comprised of costs associated with TriVascular executive change in control agreements, severance and retention bonuses as a result of the TriVascular merger.
Contract Termination and Business Acquisition Expenses. The $1.1 million decrease in contract termination and business acquisition expenses for the three months ended June 30, 2017, as compared to the prior year period, was primarily related to termination of some of our international distributors in 2016.
Other income (expense), net

Three Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Other income (expense), net
$
(8,264
)

$
(43,166
)

$
34,902


(80.9)%
Other Income (Expense), Net. Other expense of $8.3 million for the three months ended June 30, 2017 consists mainly of loss on debt extinguishment of $6.5 million, interest expense of $5.8 million and a favorable change in fair value of contingent

28


consideration related to the Nellix acquisition of $3.8 million. Other expense for the three months ended June 30, 2016 consists mainly of interest expense of $3.8 million associated with our convertible notes and the change in fair value of derivative of $38.7 million.
Provision for Income Taxes

Three Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Income tax expense
$
(122
)

$
(443
)

$
321


(72.5)%
Our income tax expense was $122 thousand and our effective tax rate was (0.7)% for the three months ended June 30, 2017 due to our tax positions in various jurisdictions. During the three months ended June 30, 2017 and 2016, we had operating legal entities in the U.S., Canada, Italy, New Zealand, Poland and the Netherlands (including registered sales branches in certain countries in Europe).
Comparison of the Six Months Ended June 30, 2017 versus 2016
Revenue

Six Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Revenue
$
91,168


$
93,340


$
(2,172
)

(2.3)%
US Sales. Net sales totaled $62.8 million in the six months ended June 30, 2017, a 5.1% decrease from $66.2 million in six months ended June 30, 2016, driven by a decline in sales of our AFX products due to lower than expected customer recapture and sales force attrition partially offset by strong sales growth for the Ovation System.
International Sales. Net sales of products in our international regions totaled $28.4 million in the six months ended June 30, 2017, a 4.4% increase from $27.2 million in the six months ended June 30, 2016. Both AFX and Ovation product lines posted strong growth which was partially offset by a decline in Nellix sales reflecting the narrowed IFU. Our international sales for the six months ended June 30, 2017 included an unfavorable foreign currency impact of approximately $0.5 million when compared to the net sales for the six months ended June 30, 2016, which had a 1.8 percentage point unfavorable impact on the growth rate representing constant currency decline of 6.2%.
Cost of Goods Sold, Gross Profit, and Gross Margin

Six Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Cost of goods sold
$
30,302


$
35,940


$
(5,638
)

(15.7)%
Gross profit
60,866


57,400


3,466


6.0%
Gross margin percentage (gross profit as a percent of revenue)
66.8
%

61.5
%





Gross margin percentage for the six months ended June 30, 2017 increased to 66.8% from 61.5% for the six months ended June 30, 2016. The six months ended June 30, 2016 included a $6.8 million impact of purchase price accounting for inventory acquired in the TriVascular merger. Excluding this impact, cost of goods increased $1.2 million in the six months ended June 30, 2017 versus 2016. This increase is driven by less leverage of fixed overhead due to lower production volume in 2017.
Operating Expenses

29



Six Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Research and development
$
11,264


$
15,559


$
(4,295
)

(27.6)%
Clinical and regulatory affairs
6,575


7,905


(1,330
)

(16.8)%
Marketing and sales
49,681


56,742


(7,061
)

(12.4)%
General and administrative
16,777


20,156


(3,379
)

(16.8)%
Restructuring costs
137


8,114


(7,977
)

(98.3)%
Settlement costs
—


4,650


(4,650
)

(100.0)%
Contract termination and business acquisition expenses
—


5,905


(5,905
)

(100.0)%
Research and Development. The $4.3 million decrease in research and development expenses was attributable to timing of project spending and synergies related to the TriVascular merger.
Clinical and Regulatory Affairs. The $1.3 million decrease in clinical and regulatory affairs expenses are due to synergies related to the TriVascular merger.
Marketing and Sales. The $7.1 million decrease in marketing and sales expenses for the six months ended June 30, 2017, as compared to the prior year period, was driven by synergies as a result of the integration of the TriVascular sales and marketing organization.
General and Administrative. The $3.4 million decrease in general and administrative expenses is primarily attributable to a decrease in headcount related to synergies as a result of the TriVascular merger. The targeted reductions were initiated to provide efficiencies and realign resources as well as to allow for continued investment in strategic areas and drive growth.
Restructuring Costs. The $8.0 million decrease in restructuring costs for the six months ended June 30, 2017, as compared to the prior year period is comprised of costs associated with TriVascular executive change in control agreements, severance and retention bonuses as a result of the TriVascular merger.
Settlement Costs. The $4.7 million decrease in settlement costs for the six months ended June 30, 2017, as compared to the prior year period, was a result of the LifePort settlement in 2016.
Contract Termination and Business Acquisition Expenses. The $5.9 million decrease in contract termination and business acquisition expenses for the six months ended June 30, 2017, as compared to the prior year period, was primarily related to termination of some of our international distributors as well as deal related expenses associated with the TriVascular merger.
Other income (expense), net

Six Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Other income (expense), net
$
(13,762
)

$
(3,809
)

$
(9,953
)

>100%
Other Income (Expense), Net. Other expense of $13.8 million for the six months ended June 30, 2017 consists mainly of loss on debt extinguishment of $6.5 million, interest expense of $10.1 million and a favorable change in fair value of contingent consideration related to the Nellix acquisition of $2.6 million. Other expense for the six months ended June 30, 2016 consists mainly of interest expense of $7.6 million associated with our convertible notes and the change in fair value of derivative of $43.8 million, foreign currency loss of $0.8 million and a non-cash expense of $0.1 million which reflects an increase in the fair value of the Nellix Contingent consideration.
Provision for Income Taxes

Six Months Ended June 30,





2017

2016

Variance

Percent Change

(in thousands)




Income tax (expense) benefit
$
(276
)

$
(175
)

$
(101
)

57.7%
Our income tax expense was $276 thousand and our effective tax rate was (0.7)% for the six months ended June 30, 2017 due to our tax positions in various jurisdictions. During the six months ended June 30, 2017 and 2016, we had operating legal

30


entities in the U.S., Canada, Italy, New Zealand, Poland and the Netherlands (including registered sales branches in certain countries in Europe).

Liquidity and Capital Resources
The chart provided below summarizes selected liquidity data and metrics as of June 30, 2017, December 31, 2016, and June 30, 2016:

June 30, 2017

December 31, 2016

June 30, 2016

(in thousands, except financial metrics data)
Cash and cash equivalents
$
81,641


$
26,120


$
31,448

Marketable securities
$
10,000


$
20,988


$
41,490

Accounts receivable, net
$
33,118


$
34,430


$
36,057

Total current assets
$
175,816


$
129,845


$
155,253

Total current liabilities
$
62,261


$
44,902


$
59,005

Working capital surplus (a)
$
113,555


$
84,943


$
96,248

Current ratio (b)
2.8


2.9


2.6

Days sales outstanding ("DSO") (c)
62


67


64

Inventory turnover (d)
1.5


2.0


2.0

(a) total current assets minus total current liabilities as of the corresponding balance sheet date.
(b) total current assets divided by total current liabilities as of the corresponding balance sheet date.
(c) net accounts receivable at period end divided by revenue for the current period multiplied by the number of days in the period.
(d) cost of goods sold divided by the average inventory balance for the corresponding period.
Operating Activities
In the six months ended June 30, 2017, our operating activities used $28.8 million in cash. This was primarily the result of a net loss of $37.6 million, non-cash operating expenses of $16.9 million, and changes in operating assets and liabilities of $8.1 million. In the six months ended June 30, 2016, our operating activities used $49.0 million in cash. This was primarily the result of a net loss of $114.5 million, non-cash operating expenses of $60.3 million, and changes in operating assets and liabilities of $5.2 million.
During the six months ended June 30, 2017 and 2016, our cash collections from customers totaled $94.4 million and $92.1 million, respectively, representing 103.5% and 98.6% of reported revenue for the same periods.
Investing Activities
Cash provided by investing activities for the six months ended June 30, 2017 was $10.2 million, as compared to cash used in investing activities of $47.6 million in the prior year period. For the six months ended June 30, 2017, cash provided by investing activities consisted of $11.0 million in maturities of marketable securities; offset by $0.8 million used for machinery and equipment purchases. For the six months ended June 30, 2016, cash used in investing activities consisted of $60.6 million used for the acquisition of TriVascular, $5.0 million used to purchase marketable securities and $1.3 million used for machinery and equipment purchases. This was offset by proceeds from the maturities of marketable securities of $19.4 million.

31


Financing Activities
Cash provided by financing activities was $73.5 million for the six months ended June 30, 2017, as compared to cash provided by financing activities of $3.5 million in the prior year period. For the six months ended June 30, 2017, cash provided by financing activities for six months ended June 30, 2017 consisted of (i) net proceeds from issuance of debt of $113.7 million, (ii) net proceeds from revolving line of credit of $24.3 million; (iii) proceeds of $2.1 million from the exercise of stock options and proceeds from sales of common stock under our employee stock purchase plan; and (iv) offset by $66.6 million used for repayment of debt. For the six months ended June 30, 2016, cash provided by financing activities consisted of $3.6 million from the exercise of stock options and proceeds from sales of common stock under our employee stock purchase plan, offset by $0.1 million used to pay minimum tax withholdings on behalf of employees for restricted stock units vested during the period. 
Credit Arrangements
See Notes 6 and 13 of the Notes to the Condensed Consolidated Financial Statements.
Future Capital Requirements
We believe that the future growth of our business will depend upon our ability to successfully develop new technologies for the treatment of aortic disorders and successfully bring these technologies to market. We expect to incur significant expenditures in completing product development and clinical trials.
The timing and amount of our future capital requirements will depend on many factors, including:

•
the need for working capital to support our sales growth;
•
the need for additional capital to fund future development programs;
•
the need for additional capital to fund our sales force expansion;
•
the need for additional capital to fund strategic acquisitions;
•
our requirements for additional facility space or manufacturing capacity;
•
our requirements for additional information technology infrastructure and systems; and
•
adverse outcomes from potential litigation and the cost to defend such litigation.
We believe that our world-wide cash resources are adequate to operate our business. We presently have several operating subsidiaries and branches outside of the U.S. As of June 30, 2017, these subsidiaries and branches held an aggregate of $8.4 million in foreign bank accounts to fund their local operations. A portion of these balances relate to undistributed earnings, and are deemed by management to be permanently reinvested in the corresponding country in which our subsidiary operates. Management has no present or planned intention to repatriate foreign earnings into the U.S. However, in the event that we require additional funds in the U.S. and must repatriate any foreign earnings to meet those needs, we would then need to accrue, and ultimately pay, incremental income tax expenses on such “deemed dividend,” unless we then had sufficient net operating losses to offset this potential tax liability.
In the event we require additional financing in the future, it may not be available on commercially reasonable terms, if at all. Even if we are able to obtain financing, it may cause substantial dilution (in the case of an equity financing), or may contain burdensome restrictions on the operation of our business (in the case of debt financing). If we are not able to obtain required financing, we may need to curtail our operations and/or our planned product development.

32


Contractual Obligations
Contractual obligation payments by year with initial terms in excess of one year were as follows as of June 30, 2017 (in thousands):

Payments due by period


Contractual Obligations
Total
Remainder of 2017
2018
2019
2020
2021
2022 and thereafter
Long-term debt obligations
$
263,278

$
—

$
18,278

$
—

$
125,000

$
40,000

$
80,000

Interest on Senior Notes and Term Loan
56,613

6,382

12,832

12,421

12,444

6,962

5,572

Operating lease obligations
37,780

1,856

3,317

3,435

3,659

3,692

21,821

Total
$
357,671

$
8,238

$
34,427

$
15,856

$
141,103

$
50,654

$
107,393

Refer to Notes 6 and 13 of the Notes to the Condensed Consolidated Financial Statements for a discussion of long-term debt obligations and Note 8 of the Notes to the Condensed Consolidated Financial Statements for a discussion of operating lease obligations.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements (except for operating leases) that provide financing, liquidity, market or credit risk support, or involve derivatives. In addition, we have no arrangements that may expose us to liability that are not expressly reflected in the accompanying Condensed Consolidated Financial Statements.
As of June 30, 2017, we did not have any relationships with unconsolidated entities or financial partnerships, often referred to as "structured finance" or "special purpose entities," established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As such, we are not subject to any material financing, liquidity, market or credit risk that could arise if we had engaged in such relationships.
Critical Accounting Policies and Estimates
We have prepared the accompanying unaudited condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States. The preparation of the financial statements requires the use of judgments and estimates that affect the reported amounts of revenues, expenses, assets, liabilities and shareholders’ equity. We have adopted accounting policies and practices that are generally accepted in the industry in which we operate. If these estimates differ significantly from actual results, the impact to the condensed consolidated financial statements may be material.
There have been no material changes in our critical accounting policies and estimates from those disclosed in our Annual Report on Form 10-K for our fiscal year ended December 31, 2016. Please refer to Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016 for a discussion of our critical accounting policies and estimates.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU ") No. 2014-09, "Revenue from Contracts with Customers", which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU No. 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The FASB agreed to a one-year deferral of the revenue recognition standard's effective date for all entities. The new revenue standard is effective for us on January 1, 2018. Early application is permitted, but not before the original effective date, which would have been January 1, 2017 for us. The new revenue standard permits the use of either the full retrospective or modified retrospective transition method; these methods may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application.
Accordingly, in 2016, we established a cross-functional implementation team to analyze the impact of the new revenue standard. This preliminary analysis included the review of an initial sample of contracts, as well as reviewing current accounting policies and customary business practices to identify potential differences that would result from applying the requirements of the new standard to our revenue contracts. As we continue to assess all potential effects of the new revenue standard, we currently expect revenue related to the completion of an EVAR or EVAS procedure in hospitals, when the EVAR or EVAS products are implanted in a patient, to remain substantially unchanged. We also plan to select a larger sample from our

33


population of contracts in search of additional attributes. In addition, we identified, and are in the process of implementing, appropriate changes to our business processes, systems and controls to support recognition and disclosure under the new revenue standard. We currently expect to adopt the new revenue standard in our first quarter of 2018 utilizing the modified retrospective adoption method. We currently do not expect the new revenue standard to have a material impact on the amount and timing of revenue recognized in our consolidated financial statements. We are currently assessing the impact this guidance will have on our financial statement disclosure. The foregoing preliminary assessments or expectations are subject to change pending further analysis through the 2017 year.
In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which requires an entity to measure inventory within the scope of the amendment at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. We adopted this new accounting standard prospectively in the first quarter of 2017. This new accounting standard did not have a significant impact on our consolidated financial statements.
In February 2016, the FASB issued ASU No. 2016-02, which amends the FASB Accounting Standards Codification and creates Topic 842, “Leases.” The new topic supersedes Topic 840, “Leases,” and increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosures of key information about leasing arrangements. The guidance is effective for reporting periods beginning after December 15, 2018. ASU 2016-02 mandates a modified retrospective transition method. We are currently assessing the impact this guidance will have on our consolidated financial statements.
In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting,” which modifies certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards, and classification in the statement of cash flows. We adopted this standard effective January 1, 2017. As a result, excess tax benefits are no longer recorded in additional paid-in capital and instead are applied against taxes payable or recognized in the condensed consolidated statements of operations. In addition, our income tax expense and associated effective tax rate will be impacted by fluctuations in stock price between the grant dates and vesting dates of equity awards. We also determined that there were no significant changes to disclosure or financial statement presentation and changes in accounting for excess tax benefits and deficiencies were not material as a result of adoption.
In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows – Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 provides guidance on the presentation and classification of specific cash flow items to improve consistency within the statement of cash flows. This guidance is effective for fiscal years, and interim periods within those fiscal years beginning after December 15, 2017, with early adoption permitted. We are currently evaluating the effect that ASU 2016-15 will have on our consolidated financial statements and related disclosures.
In October 2016, the FASB issued ASU No. 2016-16, “Intra-Entity Transfers of Assets Other Than Inventory,” which requires an entity to immediately recognize the tax consequences of intercompany transfer other than inventory. The guidance is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. We are currently assessing the impact this guidance will have on our consolidated financial statements.
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment”. This accounting standards update changes the procedural steps in applying the goodwill impairment test. A goodwill impairment will now be the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The guidance is effective prospectively for annual and interim periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the impact this guidance will have on our consolidated financial statements.
In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation: Scope of Modification Accounting,” which clarifies and aims to reduce the cost and complexity when applying the stock compensation modification accounting guidance. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. ASU 2017-09 will be effective for public companies for fiscal years beginning after December 15, 2017, including interim periods. Early adoption is permitted. We are currently assessing the impact this guidance will have on our consolidated financial statements.

34



Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We do not believe that we currently have material exposure to interest rate or foreign currency transaction risks.
Interest Rate and Market Risk. We have investments in U.S. Government and agency securities, corporate bonds and other debt securities. As a result, we are exposed to potential loss from market risks that may occur as a result of changes in interest rates, changes in credit quality of the issuer or otherwise.
We generally place our marketable security investments in high quality credit instruments, as specified in our investment policy guidelines. A hypothetical 100 basis point increase in interest rates would result in an approximate $7 thousand decrease in the fair value of our investments as of June 30, 2017. We believe, however, that the conservative nature of our investments mitigates our interest rate exposure, and our investment policy limits the amount of our credit exposure to any one issuer (with the exception of United States agency obligations) and type of instrument. We do not expect any material loss from our marketable security investments and therefore believe that our potential interest rate exposure is limited. We intend to hold the majority of our investments to maturity, in accordance with our business plans.
We do not use derivative financial instruments in our investment portfolio. We are averse to principal loss and try to ensure the safety and preservation of our invested funds by limiting default risk, market risk, and reinvestment risk. We attempt to mitigate default risk by investing in only high credit quality securities and by positioning our portfolio to appropriately respond to a significant reduction in the credit rating of any investment issuer or guarantor.
We were exposed to market risk for changes in interest rates on the MidCap Credit Facility. All outstanding amounts under the MidCap Credit Facility bore interest at a variable rate equal to LIBOR, plus 4.10%. On April 3, 2017, we replaced the MidCap Credit Facility with a new revolving line of credit with Deerfield ELGX Revolver, LLC and paid $2.5 million in termination fees to MidCap.
Our 3.25% Senior Notes and 2.25% Senior Notes bear fixed interest rates, and therefore, would not be subject to interest rate risk. The Capped Call Transactions are derivative instruments that qualify for classification within stockholders’ equity because they meet an exemption from mark-to-market derivative accounting. The settlement amounts for the capped call transactions are each determined based upon the difference between a strike price and a traded price of our common stock.
Foreign Currency Transaction Risk. While a majority of our business is denominated in the U.S. dollar, a portion of our revenue and expenses are denominated in foreign currencies. Fluctuations in the rate of exchange between the U.S. dollar and the Euro or the British Pound Sterling may affect our results of operations and the period-to-period comparisons of our operating results. Foreign currency transaction gains and losses are caused by transactions denominated in a currency other than the functional currency and must be remeasured at each balance sheet date or upon settlement. Foreign currency transaction realized and unrealized gains and losses resulted in approximately $0.2 million of loss during the three and six months ended June 30, 2017, primarily related to intercompany payables and receivables associated with our European operations. We expect to reduce our exposure through future settlements.
Market Price Sensitive Instruments. In connection with our merger with TriVascular in February 2016, we issued 13.6 million shares of our common stock as consideration to the former stockholders of TriVascular. As a result of our issuance of such shares in the merger, the quantity of authorized common shares available for future issuance at that time was reduced to a level insufficient to honor all of the potential common shares underlying instruments then outstanding. Such instruments included the conversion options related to the 3.25% Senior Notes and 2.25% Senior Notes, employee stock options, restricted stock units, contingently issuable common stock relating to the Nellix acquisition, and stock warrants. The creation of this authorized share deficiency in February 2016 required us, during the first quarter of 2016, to separate as a stand-alone derivative the 3.25% Senior Notes conversion option and a portion of the 2.25% Senior Notes conversion option for which no authorized shares are available to effect share settlement in the event of a conversion. Accordingly, in February 2016 we re-classed $24.8 million of the equity component of the Senior Notes to derivative liabilities which will be marked to market each period.  For the six months ended June 30, 2016, we recorded $5.1 million as a fair value adjustment of derivative liabilities primarily based on our stock price increasing from $7.42 to $8.36 from the date of reclassification. The value of the derivative liability and our earnings was subject to market price risk until we increased the number of our authorized common shares to alleviate the deficiency. In June 2016, upon the approval of our stockholders, we amended our certificate of incorporation to increase the number of our authorized common shares eliminating the authorized share deficiency.


35


Item 4.
CONTROLS AND PROCEDURES.
We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based on that evaluation, our chief executive officer and chief financial officer have concluded that our disclosure controls and procedures, as of the end of the period covered by this report, were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. Other Information 

Item 1.
Legal Proceedings.
Refer to Note 8 of the Notes to the Condensed Consolidated Financial Statements for a discussion of our legal proceedings.
We are from time to time involved in various other legal proceedings, most of which are routine litigation in the normal course of our business. We believe that the resolution of the legal proceedings in which we are involved will not have a material adverse effect on our financial position or results of operations.

Item 1A.
Risk Factors.
In evaluating an investment in our common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 1, 2017, as well as the information contained in this Quarterly Report and our other reports we file with the SEC.  There have been no material changes in the risk factors as previously disclosed under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.


36


Item 6.
Exhibit Index.
The following exhibits are filed or furnished herewith: 
 
 
 
 
Incorporated by Reference

 
 
Exhibit Number

 
Exhibit Description

 
Form
 
File No.
 
Exhibit
 
Filing Date
 
Filed Herewith
4.1
 
Form of Warrant to Purchase Common Stock of Endologix, Inc., issued to Deerfield Private Design Fund IV, L.P., Deerfield International Master Fund, L.P., Deerfield Partners, L.P., and Deerfield Private Design Fund III, L.P., together with a schedule of holders and amounts (issued April 3, 2017).

 
8-K
 
000-28440
 
4.1
 
2017-04-05

 
 
4.2
 
Registration Rights Agreement, dated April 3, 2017, by and among Endologix, Inc., Deerfield Private Design Fund IV, L.P., Deerfield International Master Fund, L.P., Deerfield Partners, L.P., and Deerfield Private Design Fund III, L.P.

 
8-K
 
000-28440
 
4.2
 
2017-04-05

 
 
10.1
 
Facility Agreement, dated April 3, 2017, by and among Endologix, Inc., certain subsidiaries of Endologix, Inc., Deerfield Private Design Fund IV, L.P., Deerfield International Master Fund, L.P., Deerfield Partners, L.P., and Deerfield Private Design Fund III, L.P.

 
8-K
 
000-28440
 
10.1
 
2017-04-05

 
 
10.2
 
Credit and Security Agreement, dated April 3, 2017, by and among Endologix, Inc., certain subsidiaries of Endologix, Inc. and Deerfield ELGX Revolver, LLC.

 
8-K
 
000-28440
 
10.2
 
2017-04-05

 
 
10.3
 
2015 Stock Incentive Plan, as amended

 
8-K
 
000-28440

 
10.1
 
2017-06-02

 
 
10.4
 
Addendum No. 3 to Lease - Net, by and between Endologix, Inc. and Sonoma Airport Properties LLC, dated July 3, 2017.


 
 
 
 
 
 
 
 
 
X
31.1
 
Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 
 
 
 
 
 
 
 
 
X
31.2
 
Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 
 
 
 
 
 
 
 
 
X
32.1*

 
Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 
 
 
 
 
 
 
 
 
X
32.2*

 
Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 
 
 
 
 
 
 
 
 
X
101.INS

 
XBRL Instance Document.

 
 
 
 
 
 
 
 
 
X

37


101.SCH

 
XBRL Taxonomy Extension Schema

 
 
 
 
 
 
 
 
 
X
101.CAL

 
XBRL Taxonomy Extension Calculation Linkbase Document.

 
 
 
 
 
 
 
 
 
X
101.LAB

 
XBRL Taxonomy Extension Label Linkbase Document.

 
 
 
 
 
 
 
 
 
X
101.PRE

 
XBRL Taxonomy Extension Presentation Link Base Document
 
 
 
 
 
 
 
 
 
X
101.DEF

 
XBRL Taxonomy Extension Definition Linkbase Document.

 
 
 
 
 
 
 
 
 
X
*
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, shall not be deemed “filed” by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the registrant’s filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such filing.



 

38



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
ENDOLOGIX, INC.
 
 
 
Date:
August 4, 2017
/s/ John McDermott
 
 
Chief Executive Officer
(Principal Executive Officer)
 
 
 
 
 
 
Date:
August 4, 2017
 /s/ Vaseem Mahboob
 
 
Chief Financial Officer (Principal Financial and Accounting Officer)
 
 
 


39
 EX-10.4 2 elgx_ex104xleasexamendment.htm EXHIBIT 10.4 Exhibit
Exhibit 10.4


THIRD AMENDMENT TO LEASE


THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is dated as of July 3, 2017 (the “Effective Date”) by and between Sonoma Airport Properties LLC, a California limited liability company (“Landlord”), and TriVascular, Inc., a California corporation (“Tenant”).

R E C I T A L S:

WHEREAS, Carmel River, LLC, a Delaware limited liability company, Carlsen Investments, LLC, a California limited liability company, and Rieger Investments, LLC, a Delaware limited liability company (collectively, “Original Landlord”) entered into that certain Lease Agreement dated June 16, 2005 (the “Original Lease”) with Tenant (in that capacity, “Original Tenant”), pursuant to which Original Tenant leased from Original Landlord a total of 110,250 square feet of warehouse and office space located at 3910 Brickway Boulevard, Santa Rosa, California (the “Premises”).

WHEREAS, Original Landlord and Boston Scientific Santa Rosa Corp., a California corporation (formerly known as TriVascular, Inc. i.e., the same legal entity as the Original Tenant) (“BSSRC”) and Boston Scientific Corporation, a Delaware corporation (“BSC”) entered into that certain Consent, Assignment, First Amendment To Lease and Non-Disturbance Agreement (the “First Amendment”) dated as of March 28, 2008, pursuant to which: (i) BSSRC assigned its right, title and interest under the Original Lease, as the tenant thereunder, to BSC, and (ii) other terms and conditions of the Original Lease were amended.

WHEREAS, BSC subleased the Premises to Tenant (then known as TriVascular2, Inc., a California corporation) pursuant to that certain Sublease Agreement dated as of March 28, 2008 (the “Sublease”).

WHEREAS, Landlord has succeeded to the interest of Original Landlord as the owner of the Premises and the landlord under the Lease.

WHEREAS, Landlord, Tenant and BSC entered into that certain Second Amendment to Lease dated as of December 6, 2011 (the “Second Amendment”) pursuant to which: (i) the term of the Lease was extended until February 28, 2018, inclusive; (ii) effective March 1, 2013 BSC assigned all of its right, title and interest as tenant under the Lease to Tenant; (iii) Tenant assumed all obligations of “Tenant” under the Lease; and (iv) the Sublease terminated effective as of February 28, 2013. The Original Lease as amended by the First Amendment and as further amended by the Second Amendment shall be referenced herein as the “Lease.”

WHEREAS, the Lease by its terms expires on February 28, 2018, and Landlord and Tenant desire to extend the term of the Lease and to modify certain other terms and provisions of the Lease, as more particularly set forth herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements of the parties, and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows:

1.Recitals; Defined Terms. The foregoing recitals are true and are incorporated herein by this reference as though set forth in full. Unless otherwise expressly defined herein, all initially-capitalized terms used herein shall have the meanings ascribed to them in the Lease.
2.Term of Lease. The Term of the Lease shall be extended for an additional period of five (5) years commencing on March 1, 2018, and continuing through February 28, 2023, inclusive (the “Extended Term”).
3.Monthly Base Rent. The Base Rent for the Extended Term shall be as follows:

Months                            Monthly Rent
3/1/2018 to 2/28/2019                    $81,270 ($0.86/sf) (See Section 5)
3/1/2019 to 2/28/2020                    $83,160 ($0.88/sf) (See Section 5)
3/1/2020 to 2/28/2021                    $97,020 ($0.88/sf)
3/1/2021 to 2/28/2023                    $101,430 ($0.92/sf)


Exhibit 10.4


4.Additional Rent. In addition to the obligation to pay the Base Rent provided above, the Tenant shall be obligated to pay any and all additional rent and other charges payable under the terms of the Lease as computed and provided for under the terms of the Lease (except as otherwise amended by Section 5 of this Amendment) during the entire Extended Term.
5.Free Base Rent Period. In consideration of Tenant’s election to extend the Lease pursuant to this Amendment, Landlord has agreed that the Tenant shall be entitled to a free Base Rent period for the months of March and April of 2018 (the “Free Base Rent Period”). During the Free Base Rent Period, Tenant shall have no obligation to pay any Base Rent but Tenant shall remain obligated to pay all other Additional Rent as required under Article Four of the Lease. Also in consideration of Tenant’s election to extend the Lease pursuant to this Amendment, Tenant shall be exempt from paying Base Rent on the mezzanine space consisting of 15,750 square feet located within the Premises for a period of twenty-four (24 months) commencing on March 1, 2018, through February 28, 2020 (the “Reduced Base Rent Period”); thus, for purposes of calculating Tenant’s Base Rent obligation (and not Tenant’s Additional Rent obligation) during the Reduced Base Rent Period, the Premises shall be deemed to consist of 94,500 square feet.
6.Option to Renew. Tenant shall have one (1) option to extend the Term of the Lease beyond the Extended Term provided in Section 2 of this Amendment pursuant to the terms and provisions of Article 16 of the Lease except that the parties hereto agree that said Article 16 is hereby amended to: (i) acknowledge that the additional extended term referenced in this paragraph shall be for the period commencing on March 1, 2023, through February 28, 2028; (ii) the Renewal Notice Deadline (as referenced in Section A of Article 16) shall be no later than six (6) months before the expiration of the Extended Term (or August 31, 2022); and (iii) the last sentence of Subsection (A)(1) of Article 16 shall be modified to read in part, “…provided, however, that Base Rent payable during the first year of such extended Term shall in no event be less than $.87 per square foot, increased thereafter as stated herein.” Aside from the option to renew provided in this Section 6, Tenant shall have no further right to extend the term of the Lease.
7.Amortization of Certain Capital Improvements. Pursuant to Section 4.05(e) of the Lease, Tenant is required to pay Tenant’s Pro-Rata Share of all Common Area costs in the manner described in Section 4.05(e) of the Lease. Landlord and Tenant hereby amend the Lease to provide that to the extent any Common Area costs are for single items considered to be capital improvements or capital replacements under generally accepted accounting and management practices each with a value of Fifteen Thousand Dollars ($15,000.00) or more, the cost of such capital improvements/replacements shall be amortized over the useful life of such improvement/replacement, or twelve (12) years, whichever is greater.
8.AS-IS Condition. Tenant acknowledges that Tenant has been occupying the Premises pursuant to the Lease and Tenant accepts the Premises in its AS-IS condition and “WITH ALL FAULTS” for the Extended Term and that, except for Landlord’s ongoing maintenance obligations pursuant to Section 6.03 of the Lease, repair obligations pursuant to Article 7 of the Lease and compliance obligations pursuant to Article 15 of the Lease, Landlord shall have no obligation to improve, remodel, alter, repair, replace or otherwise modify the Premises or provide or pay for any tenant improvements during the Extended Term.
9.Tenant Status. As a material inducement to Landlord entering into this Amendment, Tenant certifies to Landlord that as of the Effective Date: (i) the Lease, as modified hereby, contains the entire agreement between the parties hereto relating to the Premises and that there are no other agreements between the parties relating to the Premises, the Lease or the Project which are not contained herein or in the Lease; (ii) to the best of Tenant’s knowledge, Landlord is not in default in any respect in any of the terms, covenants and conditions of the Lease; and (iii) to the best of Tenant’s knowledge, Tenant has no setoffs, counterclaims or defenses against Landlord under the Lease.
10.Landlord Status. As a material inducement to Tenant entering into this Amendment, Landlord certifies to Tenant that as of the Effective Date: (i) the Lease, as modified hereby, contains the entire agreement between the parties hereto relating to the Premises and that there are no other agreements between the parties relating to the Premises, the Lease or the Project which are not contained herein or in the Lease; (ii) to the best of Landlord’s knowledge, Tenant is not in default in any respect in any of the terms, covenants and conditions of the Lease; and (iii) to the best of Landlord’s knowledge, Landlord has no claims against Tenant under the Lease.
11.Confidentiality. The parties covenant and agree to keep the terms and conditions of the Lease and this Amendment in confidence and expressly agree not to disclose the terms of the Lease or this Amendment to any person whatsoever, including, without limitation, the general public; provided, however, that the parties may disclose such information to their respective employees, attorneys, or accountants provided such recipient agrees to keep such information confidential, as required by this Section 11.
12.No Broker. Except for CBRE, Inc. (“Tenant’s Broker”) who is representing Tenant relative to this Amendment, Landlord and Tenant each represent and warrant to the other that it has had no dealings with any other broker, finder, or similar person who is or might be entitled to a commission or other fee in connection with this Amendment. Each party shall indemnify, defend, protect and hold harmless the other party from and against any and all obligations or liabilities to pay any real estate broker’s commission, finder’s fee, or other compensation to any person or entity arising from or in connection with this Amendment which results from any act or agreement of such party. Notwithstanding the foregoing, Landlord shall be responsible to pay a commission to Tenant’s Broker for this transaction pursuant to the terms and conditions of a separate written agreement between Landlord and Tenant’s Broker.


Exhibit 10.4


13.Conflict. This Amendment is and shall be construed as a part of the Lease. In case of any inconsistency between this Amendment and the Lease, the provisions containing such inconsistency shall first be reconciled with one another to the maximum extent possible and then, to the extent of any remaining inconsistency, the terms of this Amendment shall be controlling.
14.Force and Effect. Except as set forth in this Amendment, the terms and conditions of the Lease shall remain unchanged and in full force and effect.
15.Counterparts; Authority; Electronic Signatures. The parties agree that this Amendment may be executed in multiple counterparts which, when signed by all parties, shall constitute a binding agreement. The parties further represent and warrant that each natural person who is executing this Amendment on its behalf has the full power and authority to execute this Amendment and to bind it to the terms hereof. Signatures to this Amendment transmitted by telecopy or electronic mail shall be valid and effective to bind the party so signing. Each party agrees to promptly deliver an execution original of this Amendment with its actual signature to the other party, but a failure to do so shall not affect the enforceability of this Amendment, it being expressly agreed that each party to this Amendment shall be bound by its own telecopied or electronically-mailed signature and shall accept the telecopied or electronically-mailed signature of the other party to this Amendment.
IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date indicated above.
LANDLORD:
TENANT:
SONOMA AIRPORT PROPERTIES LLC,
a California limited liability company



By: /s/ Ron Profili
Name: Ron Profili
Title: Owner/Manager
TRIVASCULAR, INC.,
a California corporation



By: /s/ Vaseem Mahboob
Name: Vaseem Mahboob
Title: CFO




 EX-31.1 3 elgx_ex311x6302017-q2.htm EXHIBIT 31.1 Exhibit
Exhibit 31.1



Certification of Chief Executive Officer
I, John McDermott, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Endologix, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principals;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:
August 4, 2017
By:
/s/ John McDermott
 
 
 
John McDermott
 
 
 
Chief Executive Officer


 EX-31.2 4 elgx_ex312x6302017-q2.htm EXHIBIT 31.2 Exhibit
Exhibit 31.2



Certification of Chief Financial Officer
I, Vaseem Mahboob, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Endologix, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principals;
c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date:
August 4, 2017
By:
/s/ Vaseem Mahboob
 
 
 
Vaseem Mahboob
 
 
 
Chief Financial Officer (Principal Financial and Accounting Officer)



 EX-32.1 5 elgx_ex321x6302017-q2.htm EXHIBIT 32.1 Exhibit
Exhibit 32.1


 

Certification of Chief Executive Officer
Pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, John McDermott, certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 that:
(1)
The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 780(d)); and
(2)
The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:
August 4, 2017
By:
/s/ John McDermott
 
 
 
John McDermott
 
 
 
Chief Executive Officer
This certification accompanies the Quarterly Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.



 EX-32.2 6 elgx_ex322x6302017-q2.htm EXHIBIT 32.2 Exhibit
Exhibit 32.2


 

Certification of Chief Financial Officer
Pursuant to 18 U.S.C Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

I, Vaseem Mahboob, certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 that:
(1)
The Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2017 (the “Quarterly Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 780(d)); and
(2)
The information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
  
Date:
August 4, 2017
By:
/s/ Vaseem Mahboob
 
 
 
Vaseem Mahboob
 
 
 
Chief Financial Officer (Principal Financial and Accounting Officer)
This certification accompanies the Quarterly Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.



 EX-101.INS 7 elgx-20170630.xml XBRL INSTANCE DOCUMENT 0001013606 2017-01-01 2017-06-30 0001013606 2017-08-01 0001013606 2017-06-30 0001013606 2016-12-31 0001013606 us-gaap:ConvertiblePreferredStockMember 2017-06-30 0001013606 us-gaap:ConvertiblePreferredStockMember 2016-12-31 0001013606 2017-04-01 2017-06-30 0001013606 2016-04-01 2016-06-30 0001013606 2016-01-01 2016-06-30 0001013606 2015-12-31 0001013606 2016-06-30 0001013606 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001013606 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001013606 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001013606 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001013606 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-12-31 0001013606 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-06-30 0001013606 elgx:FacilityAgreementDue2023Member us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:SecuredDebtMember 2017-06-30 0001013606 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2017-06-30 0001013606 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsNonrecurringMember 2016-12-31 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2015-11-02 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2013-12-10 0001013606 us-gaap:LeaseholdImprovementsMember 2016-12-31 0001013606 elgx:ProductionEquipmentMoldsandOfficeFurnitureMember 2017-06-30 0001013606 us-gaap:ComputerEquipmentMember 2016-12-31 0001013606 us-gaap:LeaseholdImprovementsMember 2017-06-30 0001013606 us-gaap:ConstructionInProgressMember 2017-06-30 0001013606 us-gaap:ConstructionInProgressMember 2016-12-31 0001013606 us-gaap:ComputerEquipmentMember 2017-06-30 0001013606 elgx:ProductionEquipmentMoldsandOfficeFurnitureMember 2016-12-31 0001013606 us-gaap:InProcessResearchAndDevelopmentMember 2016-12-31 0001013606 us-gaap:CustomerRelationshipsMember 2016-12-31 0001013606 us-gaap:InProcessResearchAndDevelopmentMember 2017-06-30 0001013606 elgx:DevelopedTechnologyMember 2016-12-31 0001013606 elgx:DevelopedTechnologyMember 2017-06-30 0001013606 us-gaap:CustomerRelationshipsMember 2017-06-30 0001013606 us-gaap:TrademarksAndTradeNamesMember 2017-06-30 0001013606 us-gaap:TrademarksAndTradeNamesMember 2016-12-31 0001013606 us-gaap:CorporateBondSecuritiesMember 2017-06-30 0001013606 us-gaap:CorporateBondSecuritiesMember 2016-12-31 0001013606 us-gaap:BondsMember 2017-06-30 0001013606 us-gaap:CommercialPaperMember 2016-12-31 0001013606 us-gaap:BondsMember 2016-12-31 0001013606 elgx:ClinicalAndRegulatoryAffairsMember 2017-01-01 2017-06-30 0001013606 us-gaap:CostOfSalesMember 2016-01-01 2016-06-30 0001013606 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-06-30 0001013606 elgx:ClinicalAndRegulatoryAffairsMember 2017-04-01 2017-06-30 0001013606 us-gaap:CostOfSalesMember 2017-04-01 2017-06-30 0001013606 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-06-30 0001013606 us-gaap:OperatingExpenseMember 2017-04-01 2017-06-30 0001013606 us-gaap:ResearchAndDevelopmentExpenseMember 2016-04-01 2016-06-30 0001013606 elgx:ClinicalAndRegulatoryAffairsMember 2016-04-01 2016-06-30 0001013606 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0001013606 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-06-30 0001013606 us-gaap:OperatingExpenseMember 2017-01-01 2017-06-30 0001013606 us-gaap:SellingAndMarketingExpenseMember 2016-04-01 2016-06-30 0001013606 us-gaap:OperatingExpenseMember 2016-01-01 2016-06-30 0001013606 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-06-30 0001013606 us-gaap:OperatingExpenseMember 2016-04-01 2016-06-30 0001013606 us-gaap:SellingAndMarketingExpenseMember 2017-04-01 2017-06-30 0001013606 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0001013606 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-06-30 0001013606 elgx:ClinicalAndRegulatoryAffairsMember 2016-01-01 2016-06-30 0001013606 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0001013606 us-gaap:GeneralAndAdministrativeExpenseMember 2016-04-01 2016-06-30 0001013606 us-gaap:CostOfSalesMember 2017-01-01 2017-06-30 0001013606 us-gaap:GeneralAndAdministrativeExpenseMember 2017-04-01 2017-06-30 0001013606 elgx:FacilityAgreementDue2023Member us-gaap:SecuredDebtMember 2017-04-03 0001013606 elgx:FacilityAgreementDue2023DeerfieldWarrantsMember elgx:FacilityAgreementDue2023Member us-gaap:CommonStockMember 2017-04-03 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2015-11-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2017-06-30 0001013606 us-gaap:RestrictedStockMember 2017-04-01 2017-06-30 0001013606 us-gaap:EmployeeStockOptionMember 2016-04-01 2016-06-30 0001013606 us-gaap:RestrictedStockMember 2016-04-01 2016-06-30 0001013606 us-gaap:EmployeeStockOptionMember 2017-04-01 2017-06-30 0001013606 us-gaap:RestrictedStockUnitsRSUMember 2017-04-01 2017-06-30 0001013606 us-gaap:RestrictedStockUnitsRSUMember 2016-04-01 2016-06-30 0001013606 us-gaap:RestrictedStockMember 2017-01-01 2017-06-30 0001013606 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0001013606 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0001013606 us-gaap:RestrictedStockMember 2016-01-01 2016-06-30 0001013606 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-06-30 0001013606 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-06-30 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:BankofAmericaMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:DeerfieldELGXRevolverLLCMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-04-03 2017-04-03 0001013606 us-gaap:OtherAssetsMember elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2013-12-10 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001013606 2016-06-02 2016-06-02 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleConditionTwoMember elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 elgx:FacilityAgreementDue2023Member us-gaap:SecuredDebtMember 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2017-04-03 2017-04-03 0001013606 elgx:ConvertibleConditionOneMember elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:DeerfieldELGXRevolverLLCMember 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2013-12-10 2013-12-10 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember 2017-06-30 0001013606 us-gaap:AccountingStandardsUpdate201503Member us-gaap:OtherAssetsMember us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember 2017-06-30 0001013606 us-gaap:AdditionalPaidInCapitalMember elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2015-11-02 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:DeerfieldELGXRevolverLLCMember 2017-04-03 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember 2016-07-29 0001013606 us-gaap:LetterOfCreditMember elgx:BankofAmericaMember 2017-01-01 2017-06-30 0001013606 elgx:FacilityAgreementDue2023DeerfieldWarrantsMember elgx:FacilityAgreementDue2023Member 2017-01-01 2017-06-30 0001013606 2013-12-10 2013-12-10 0001013606 us-gaap:AdditionalPaidInCapitalMember elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2013-12-10 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember 2017-04-04 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2017-04-03 0001013606 us-gaap:OtherAssetsMember elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2015-11-02 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2015-11-02 2015-11-02 0001013606 us-gaap:LetterOfCreditMember elgx:BankofAmericaMember 2015-07-21 2015-07-21 0001013606 elgx:FacilityAgreementDue2023Member us-gaap:SecuredDebtMember us-gaap:MaximumMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:BankofAmericaMember 2017-01-01 2017-06-30 0001013606 us-gaap:LetterOfCreditMember elgx:BankofAmericaMember 2015-07-21 0001013606 elgx:FacilityAgreementDue2023Member us-gaap:SecuredDebtMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2017-06-30 0001013606 elgx:ConvertibleConditionThreeMember elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 2016-06-01 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-29 0001013606 us-gaap:AccountingStandardsUpdate201503Member us-gaap:OtherAssetsMember elgx:ConvertibleSeniorNotesDue2020Member 2015-12-31 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:DebtInstrumentRedemptionPeriodTwoMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001013606 us-gaap:AccountingStandardsUpdate201503Member us-gaap:OtherAssetsMember elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2015-12-31 0001013606 us-gaap:ConvertibleDebtMember 2016-02-01 2016-02-29 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:DebtInstrumentRedemptionPeriodOneMember us-gaap:ConvertibleDebtMember 2017-01-01 2017-06-30 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:BankofAmericaMember 2015-07-21 0001013606 2016-06-02 0001013606 elgx:TriVascularTechnologiesInc.Member 2016-02-03 2016-02-03 0001013606 elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember us-gaap:MinimumMember 2017-01-01 2017-06-30 0001013606 us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember us-gaap:LondonInterbankOfferedRateLIBORMember 2016-07-29 2016-07-29 0001013606 elgx:FacilityAgreementDue2023Member us-gaap:SecuredDebtMember 2017-04-03 2017-04-03 0001013606 us-gaap:AccountingStandardsUpdate201503Member us-gaap:LongTermDebtMember elgx:ConvertibleSeniorNotesDue2020Member us-gaap:ConvertibleDebtMember 2015-12-31 0001013606 us-gaap:AccountingStandardsUpdate201503Member us-gaap:LongTermDebtMember elgx:ConvertibleSeniorNotesdue2018Member us-gaap:ConvertibleDebtMember 2015-12-31 0001013606 us-gaap:AccountingStandardsUpdate201503Member us-gaap:LongTermDebtMember us-gaap:RevolvingCreditFacilityMember elgx:MidCapFinancialTrustMember 2017-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember 2016-04-01 2016-06-30 0001013606 country:US 2017-01-01 2017-06-30 0001013606 country:US 2016-01-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2017-04-01 2017-06-30 0001013606 country:US 2017-04-01 2017-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember country:US 2016-04-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2016-01-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember 2017-01-01 2017-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember 2017-04-01 2017-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember country:US 2017-01-01 2017-06-30 0001013606 us-gaap:NonUsMember 2017-04-01 2017-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember 2016-01-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember country:US 2017-04-01 2017-06-30 0001013606 us-gaap:NonUsMember 2016-01-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember country:US 2016-01-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2016-04-01 2016-06-30 0001013606 country:US 2016-04-01 2016-06-30 0001013606 us-gaap:SalesMember us-gaap:GeographicConcentrationRiskMember us-gaap:NonUsMember 2017-01-01 2017-06-30 0001013606 us-gaap:NonUsMember 2017-01-01 2017-06-30 0001013606 us-gaap:NonUsMember 2016-04-01 2016-06-30 0001013606 us-gaap:MaximumMember 2017-01-01 2017-06-30 0001013606 elgx:TriVascularTechnologiesInc.Member us-gaap:ManufacturingFacilityMember 2017-06-30 0001013606 us-gaap:ContractTerminationMember 2016-01-01 2016-06-30 0001013606 elgx:TriVascularTechnologiesInc.Member us-gaap:SubsequentEventMember 2017-07-01 2017-07-31 0001013606 us-gaap:ContractTerminationMember 2016-04-01 2016-06-30 0001013606 us-gaap:MinimumMember 2017-01-01 2017-06-30 0001013606 elgx:PMAMilestoneMember 2017-06-30 0001013606 elgx:PMAMilestoneMember 2017-01-01 2017-06-30 0001013606 elgx:NelixMilestonesMember 2010-12-10 2010-12-10 0001013606 elgx:NelixMilestonesMember 2010-12-10 0001013606 elgx:NellixMember 2010-12-10 0001013606 elgx:NellixMember 2010-12-10 2010-12-10 0001013606 2016-01-01 2016-12-31 0001013606 elgx:TriVascularTechnologiesInc.Member 2016-02-03 0001013606 elgx:TriVascularTechnologiesInc.Member 2016-04-01 2016-06-30 0001013606 elgx:TriVascularTechnologiesInc.Member 2016-01-01 2016-06-30 0001013606 2016-02-03 0001013606 elgx:TriVascularTechnologiesInc.Member 2017-04-01 2017-06-30 xbrli:pure elgx:segment utreg:D utreg:sqft iso4217:USD elgx:security iso4217:USD xbrli:shares elgx:security xbrli:shares iso4217:USD false --12-31 Q2 2017 2017-06-30 10-Q 0001013606 83434656 Yes Large Accelerated Filer ENDOLOGIX INC /DE/ 14500000 4.86 P5D 12200000 0 0 12200000 9600000 0 0 9600000 0.04985 P7Y 4022000 7905000 2740000 6575000 1127000 5905000 0 0 1.5 5 5 P5D P30D 0.25 0.25 P3D 0.01 0.005 0.0225 4 P1M P11M 0 -3997000 110000 2000000 2000000 P24M P18M P18M P6M 24800000 44000 0 0 14704000 P30D 13237000 11030000 34430000 33118000 4603000 5004000 11668000 10001000 12945000 15691000 1488000 2625000 567765000 588194000 68600000 3886000 593000 259000 1339000 3627000 434000 1261000 6768000 493000 532000 2555000 6236000 797000 2391000 3234000 160000 304000 1164000 2930000 323000 1283000 6188000 420000 473000 2371000 5715000 583000 2341000 1037000 994000 700000 1600000 1000000 1900000 2193000 1620000 135000 438000 1623000 1193000 131000 299000 902000 574000 121000 207000 1004000 636000 120000 248000 359684000 402067000 129845000 175816000 15000000 19400000 100800000 3200000 13586503 13600000 -0.76 -1.35 -0.76 4.5 -62507000 -110730000 50974000 96011000 185490000 100812000 44000 100000 100000 -3800000 -2600000 12200000 9600000 12200000 9600000 24012000 3008000 1895000 5780000 2214000 6450000 46200000 17765000 93404000 61000 317000 3152000 185490000 24012000 0 124553000 31448000 26120000 81641000 26120000 26120000 0 0 81641000 81641000 0 0 -93105000 55521000 9.23 6470000 0.001 0.001 135000000 135000000 100000000 135000000 82986244 83638895 82774005 83426656 83000 84000 -65818000 -113593000 -15511000 -36469000 1 0.712 0.288 1 0.709 0.291 1 0.657 0.343 1 0.689 0.311 28200000 105500000 18300000 86300000 125000000 21515000 35940000 16332000 30302000 30000000 0.041 0.046 105300000 19300000 27200000 -2200000 24.04 24.04 11.18 89.4314 41.6051 30 30 30 5 1.3 0.98 1.3 0.98 20 2 30 2 20 20 86250000 125000000.0 120000000.0 66900000 97800000 0.0225 0.0687 0.0225 0.0325 40000000 10700000 9100000 1500000 1100000 8400000 1400000 0 0 1 1 1 68000000 P2Y 800000 2900000 3700000 800000 3700000 2900000 900000 2100000 400000 1200000 2900000 1900000 -2900000 -1900000 900000 -900000 1100000 200000 4900000 5100000 7949000 7859000 879000 879000 1300000 2600000 1300000 2700000 4229000 4645000 29.02 -0.81 -1.44 -0.20 -0.45 -26000 632000 0.007 0.007 0.34 0.34 19997000 16933000 3810000 687000 5375000 1063000 47213000 1940000 6557000 4996000 3978000 3978000 67600000 7500000 67600000 7500000 63790000 6813000 68662000 62225000 6437000 -810000 206000 -38700000 -38743000 -43831000 0 0 0 -4650000 0 0 -3200000 0 0 -6512000 -6512000 10210000 20156000 7904000 16777000 120711000 120845000 92086000 134000 29459000 57400000 32224000 60866000 2000 2000 0 0 0 0 0 21000 0 0 21000 3000 1000 2000 20988000 6488000 3987000 10513000 10000000 3999000 6001000 20969000 6490000 3987000 10492000 10000000 9997000 3998000 5999000 0 0 -66394000 -113961000 -16170000 -37330000 443000 546000 100000 122000 300000 276000 167000 565000 -5812000 -3486000 2445000 -3470000 1889000 -1092000 6922000 -3220000 -3557000 2174000 -1100000 762000 0 876000 0 0 6470000 6470000 14767000 14767000 11939000 11939000 11200000 2708000 11200000 2708000 84511000 82570000 3815000 7597000 5803000 10098000 2994000 2956000 17888000 20497000 41160000 43555000 13133000 11291000 10139000 11767000 48000 110000 28000 72000 900000 1600000 1000000 1900000 P5Y0M0D 246891000 305313000 359684000 402067000 44902000 62261000 24300000 10000000 20000000 50000000.0 50000000 0 24297000 187600000 100200000 123200000 177178000 220520000 20988000 10000000 3469000 73529000 -47593000 10167000 -48955000 -28807000 -66837000 -114507000 -16292000 -37606000 0 26000 -43166000 -52330000 -8264000 -13762000 1 1 52687000 119031000 40130000 84434000 -23228000 -1100000 -61631000 -2700000 -7906000 -23568000 37780000 3692000 3659000 3435000 3317000 21821000 1856000 3359000 4235000 1352000 1536000 1019000 914000 781000 1137000 3783000 4194000 -556000 -912000 223000 176000 1787000 390000 2500000 7400000 0 6285000 134000 0 84634000 60622000 0 5017000 0 1304000 833000 0.001 0.001 5000000 5000000 0 0 0 0 0 0 82600000 0 120000000 1826000 1681000 0 24297000 19350000 11000000 1777000 449000 36210000 11714000 8162000 839000 15495000 36991000 11908000 8746000 842000 15495000 23265000 21300000 0 -89000 0 66613000 7714000 15559000 5734000 11264000 2001000 2001000 0 0 2877000 2877000 0 0 11200000 790000 8114000 11100000 -29000 137000 2754000 235000 2656000 -453601000 -491207000 50974000 36283000 14691000 93340000 66151000 27189000 48556000 31906000 16650000 91168000 62795000 28373000 28824000 56742000 23781000 49681000 6768000 6188000 7.42 100812000 0 112793000 96754000 212239 212239 2942000 2942000 14300000 82072000 79368000 83247000 83087000 10200000 3000000 800000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue by geographic region, was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.1%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, there were no related party transactions. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim financial data as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules&#160;and regulations relating to interim financial statements. The interim financial data includes the results of TriVascular, beginning on February 3, 2016, the effective date of the merger. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on March 1, 2017.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma combined financial information summarizes the results of operations for the period indicated as if the TriVascular merger had been completed as of </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect, among other things, the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;"> or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Combined net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Combined net loss from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,507</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Combined basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingently Issuable Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> On October 27, 2010, the Company entered into an Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) with Nepal Acquisition Corporation, a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Nellix, Inc. ("Nellix"), certain of Nellix&#8217;s stockholders named therein and Essex Woodlands Health Ventures, Inc., as representative of the former Nellix stockholders. On December 10, 2010 (the &#8220;Nellix Closing Date&#8221;), the Company completed the merger (the &#8220;Merger&#8221;) of Merger Sub with and into Nellix pursuant to the terms of the Merger Agreement. The purchase price consisted of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock, issuable to the former Nellix stockholders as of the Nellix Closing Date, then representing a value of $</font><font style="font-family:inherit;font-size:10pt;">19.4 million</font><font style="font-family:inherit;font-size:10pt;">. Under the agreement, additional payments, solely in the form of shares of the Company's common stock (the &#8220;Contingent Payment&#8221;), could be made upon the achievement of a revenue milestone and a regulatory approval milestone (collectively, the &#8220;Nellix Milestones&#8221;). </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the merger agreement, the ultimate value of each Contingent Payment would be determined on the date that each Nellix Milestone is achieved. The number of issuable shares would be established using an applicable per share price, which is subject to a ceiling and/or floor, resulting at the closing of the merger in a potential maximum of </font><font style="font-family:inherit;font-size:10pt;">10.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares issuable upon the achievement of the Nellix Milestones. As of the Closing Date, the aggregate fair value of the cash Contingent Payment was estimated to be $</font><font style="font-family:inherit;font-size:10pt;">28.2 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Merger Agreement provides that, in addition to the shares of common stock of the Company (the &#8220;Common Stock&#8221;) issued to the former Nellix stockholders at the closing of the Merger, if the Company receives approval from the FDA to sell the Nellix Product in the United States (the &#8220;PMA Milestone&#8221;), the Company will issue additional shares of the Common Stock to the former stockholders of Nellix. The dollar value of the shares of the Common Stock to be issued upon achievement of the PMA Milestone will be equal to </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> (less the dollar value of certain cash payments and other deductions). The price per share of the shares of the Common Stock to be issued upon achievement of the PMA Milestone is subject to a stock price floor of </font><font style="font-family:inherit;font-size:10pt;">$4.50</font><font style="font-family:inherit;font-size:10pt;"> per share, but not subject to a stock price ceiling.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> the Company's stock price last closed at </font><font style="font-family:inherit;font-size:10pt;">$4.86</font><font style="font-family:inherit;font-size:10pt;"> per share. Thus, had the PMA Milestone been achieved on </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> the Contingent Payment would have comprised </font><font style="font-family:inherit;font-size:10pt;">3.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares (based on the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-day average closing stock price ending </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> days prior to the announcement), representing a value of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The value of the Contingent Payment is derived using a discounted income approach model, with a range of probabilities and assumptions related to the timing and likelihood of achievement of the PMA Milestone (which include Level 3 inputs - see Note 3(e) and the Company's stock price (Level 1 input) as of the balance sheet date). These varying probabilities and assumptions and changes in the Company's stock price have required fair value adjustments of the Contingent Payment in periods subsequent to the Nellix Closing Date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Contingent Payment fair value will continue to be evaluated on a quarterly basis until milestone achievement occurs, or until the expiration of the "earn-out period," as defined within the Nellix purchase agreement. Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Contingently Issuable Common Stock</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a) Leases</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases its administrative, research, and manufacturing facilities located in Irvine, California, Santa Rosa, California and an administrative office located in Rosmalen, The Netherlands. These facility lease agreements require the Company to pay operating costs, including property taxes, insurance and maintenance. In addition, the Company has certain equipment under long-term agreements that are accounted for as operating leases. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the TriVascular merger, the Company assumed the lease for TriVascular's facility in Santa Rosa, California. The Company uses the Santa Rosa facility for manufacturing, research &amp; development, and administrative purposes and the facility consists of </font><font style="font-family:inherit;font-size:10pt;">110,000</font><font style="font-family:inherit;font-size:10pt;"> square feet under an operating lease scheduled to expire in February 2018. In July 2017, the Company renewed the lease for an additional </font><font style="font-family:inherit;font-size:10pt;">5 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Facilities rent expense for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the&#160;</font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> facilities rent expense was&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b) Employment Agreements and Retention Plan</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has employment agreements with certain of its executive officers under which payment and benefits would become payable in the event of termination by the Company for any reason other than cause, death or disability or termination by the employee for good reason (collectively, an &#8220;Involuntary Termination&#8221;) prior to, upon or following a change in control of the Company. The severance payment will generally be in a range of </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> months of the employee&#8217;s then current salary for an Involuntary Termination prior to a change in control of the Company, and will generally be in a range of </font><font style="font-family:inherit;font-size:10pt;">eighteen</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">twenty-four</font><font style="font-family:inherit;font-size:10pt;"> months of the employee&#8217;s then current salary for an Involuntary Termination upon or following a change in control of the Company.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(c) Legal Matters</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are from time to time involved in various claims and legal proceedings of a nature we believe are normal and incidental to a medical device business. These matters may include product liability, intellectual property, employment, and other general claims. Such cases and claims may raise complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. We accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LifePort Sciences LLC v. Endologix, Inc.</font></div><div style="line-height:120%;padding-top:8px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 28, 2012, LifePort Sciences, LLC ("LifePort") filed a complaint against the Company in the U.S. District Court, District of Delaware, alleging that certain of the Company's products infringe U.S. Patent Nos. 5,489,295, 5,676,696, 5,993,481, 6,117,167, 6,302,906, and 8,192,482, which were alleged to be owned by LifePort.&#160;On March 17, 2016, the Company entered into a Settlement and Patent License Agreement with LifePort (the &#8220;Settlement Agreement&#8221;) whereby LifePort granted the Company license rights to patents in exchange for a settlement of </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;The Settlement Agreement resolves this litigation and fully and finally releases the Company and LifePort from any claims arising out of or in connection with the litigation or the subject patents.&#160;The Settlement Agreement also contained a covenant not to sue for other patents owned by LifePort. However, since the subject patents were all expired and the Company was not currently using and has no plans to use the other patents owned by LifePort in products that could reach technological feasibility during the covenant not to sue period, there is no alternative future use and the full amount was recorded as settlement costs in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Securities Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, two stockholders purporting to represent a class of persons who purchased the Company&#8217;s securities between August 2, 2016 and November 16, 2016, filed lawsuits against the Company and certain of its officers in the United States District Court for the Central District of California. The lawsuits allege that the Company made materially false and misleading statements and failed to disclose material adverse facts about its business, operational and financial performance, in violation of federal securities laws, relating to U.S. Food and Drug Administration Premarket Approval for the Company&#8217;s Nellix EVAS System. On May 26, 2017, the plaintiffs filed an amended complaint extending the class period to include persons who purchased the Company&#8217;s securities between May 5, 2016 and May 18, 2017 and adding certain factual assertions and allegations regarding the Nellix EVAS System. The Company believes the lawsuits are without merit and intends to defend itself vigorously.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Shareholder Derivative Litigation</font></div><div style="line-height:120%;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2017, a purported stockholder of the Company filed a shareholder derivative complaint in the Superior Court for the State of California, County of Los Angeles, naming certain executive officers and the directors of the Company as defendants and alleging, among other things, breach of fiduciary duty by such executive officers and director. The Company believes this lawsuit is without merit and intends to defend itself vigorously.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SEC Investigation</font></div><div style="line-height:120%;text-align:left;text-indent:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, the Company learned that the United States Securities and Exchange Commission (SEC) has issued a Formal Order of Investigation to investigate, among other things, events surrounding &#160;the Nellix EVAS System and the prospect of its FDA pre-market approval.&#160; The Company intends to fully cooperate with the investigation, but cannot predict its outcome or the timing of the investigation&#8217;s conclusion.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(d) Contract Termination</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company sent notices of termination to certain of its distributors providing for the termination of the respective distribution agreements. In accordance with ASC No. 420 &#8220;Exit or Disposal Cost Obligations&#8221;, the Company expensed distributor termination costs in the period in which the written notification of termination occurred. As a result, the Company incurred termination costs of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">. Such termination costs are included in contract termination and business acquisition expenses for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss, based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cost of goods sold</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Research and development</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical and regulatory affairs</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Marketing and sales</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total operating expenses</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share was calculated by dividing net loss by the weighted average number of common shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net loss </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Basic and diluted net loss per share </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conversion of Senior Notes </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 6, in December 2013, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$86.3 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2018 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes&#8221;) in an underwritten public offering. In November 2015, the Company also issued </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2020 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes&#8221;) in an underwritten public offering. Upon any conversion, the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes and/or </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, (collectively the "Senior Notes") may be settled, at the Company&#8217;s election, in cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock. For purposes of calculating the maximum dilutive impact, the Company presumed that the Senior Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Senior Notes is excluded from the calculation of diluted loss per share because the impact of these securities would be anti-dilutive. </font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deerfield Warrants</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2017, the Company entered into a Facility Agreement (the &#8220;Facility Agreement&#8221;) with affiliates of Deerfield Management Company, L.P. (collectively, &#8220;Deerfield&#8221;), pursuant to which Deerfield agreed to loan to the Company up to </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to the terms and conditions set forth in the Facility Agreement (the &#8220;Term Loan&#8221;). As part of the Facility Agreement, the Company also issued warrants to Deerfield to purchase an aggregate of&#160;</font><font style="font-family:inherit;font-size:10pt;">6,470,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of common stock of the Company at an exercise price of&#160;</font><font style="font-family:inherit;font-size:10pt;">$9.23</font><font style="font-family:inherit;font-size:10pt;">&#160;per share (the &#8220;Deerfield Warrants&#8221;). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company. Refer to Note 6 of the Notes to the Condensed Consolidated Financial Statements for further discussion.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The potential dilutive effect of these securities is shown in the chart below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Conversion of the Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deerfield Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of the contingently issuable common stock is excluded from the calculation of basic net loss per share until all necessary conditions for issuance have been satisfied. Refer to Note 9 of the Notes to the Condensed Consolidated Financial Statements for further discussion.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;Fair value measurement at reporting date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted prices in<br clear="none"/>active markets for<br clear="none"/>identical assets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant other<br clear="none"/>observable<br clear="none"/>inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant<br clear="none"/>unobservable<br clear="none"/>inputs<br clear="none"/>(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">At June 30, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingently issuable common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">At December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingently issuable common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Tax Expense</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company applied an estimated annual effective tax rate (&#8220;ETR&#8221;) approach for calculating a tax provision for interim periods. The Company recorded a provision for income taxes of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company's ETR was </font><font style="font-family:inherit;font-size:10pt;">(0.7)%</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;The Company's ETR for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> differs from the U.S. federal statutory tax rate of </font><font style="font-family:inherit;font-size:10pt;">34%</font><font style="font-family:inherit;font-size:10pt;"> primarily as a result of nondeductible expenses (including the Nellix Contingent Payment), state income taxes, foreign income taxes, and the impact of a full valuation allowance on its deferred tax assets.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when&#160;the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in held-to-maturity marketable securities consist of the following at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Agency bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,999</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Agency bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TriVascular Merger</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February&#160;3, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company completed its merger with TriVascular pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated </font><font style="font-family:inherit;font-size:10pt;">October&#160;26, 2015</font><font style="font-family:inherit;font-size:10pt;">, by and among Endologix, TriVascular and Teton Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Endologix (&#8220;Merger Sub&#8221;). Pursuant to the terms of the Merger Agreement, Endologix acquired all of TriVascular&#8217;s outstanding capital stock through the merger of Merger Sub with and into TriVascular (the &#8220;Merger&#8221;), with TriVascular surviving the Merger as a wholly-owned subsidiary of Endologix. The Company completed the merger in order to become the innovation leader with broad clinical indications for the treatment of AAA, leverage the combined company&#8217;s commercial capabilities, and provide an accelerated path to profitability. The total purchase consideration given related to the acquisition follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cash consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock consideration</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,812</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Fair value of assumed TriVascular stock warrants </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock consideration consisted of&#160;</font><font style="font-family:inherit;font-size:10pt;">13,586,503</font><font style="font-family:inherit;font-size:10pt;"> shares of Endologix common stock, worth </font><font style="font-family:inherit;font-size:10pt;">$100.8 million</font><font style="font-family:inherit;font-size:10pt;"> based on the market value of </font><font style="font-family:inherit;font-size:10pt;">$7.42</font><font style="font-family:inherit;font-size:10pt;"> per share as of the effective date of the Merger on </font><font style="font-family:inherit;font-size:10pt;">February&#160;3, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, the Company assumed stock warrants, originally issued by TriVascular, and converted them to Endologix stock warrants. The fair value of the stock warrants represents a component of the total consideration for the Merger. Stock warrants assumed were valued using the Black-Scholes option pricing model as of the effective date of the Merger.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquisition was recorded by allocating the costs of the net assets acquired based on their estimated fair values at the acquisition date. The excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. The fair values were based on management&#8217;s analysis, including work performed by third-party valuation specialists. The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on </font><font style="font-family:inherit;font-size:10pt;">February&#160;3, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,765</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Accrued liabilities and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of TriVascular, such as broadening the product portfolio for the treatment of AAA and leveraging the combined company&#8217;s technology and commercial capabilities. The goodwill is not deductible for tax purposes. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pro Forma Condensed Combined Financial Information (Unaudited)</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following unaudited pro forma combined financial information summarizes the results of operations for the period indicated as if the TriVascular merger had been completed as of </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;">. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect, among other things, the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2015</font><font style="font-family:inherit;font-size:10pt;"> or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended<br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Combined net sales</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96,011</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Combined net loss from continuing operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(62,507</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(110,730</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Combined basic and diluted net loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business, Basis of Presentation, and Operating Segment</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a) Description of Business</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Endologix, Inc. (the "Company") is a Delaware corporation with corporate headquarters in Irvine, California and production facilities located in Irvine, California and Santa Rosa, California. The Company develops, manufactures, markets, and sells innovative medical devices for the treatment of aortic disorders. The Company's products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms ("AAA"). The Company's AAA products include innovations for minimally-invasive endovascular aneurysm repair ("EVAR") or endovascular aneurysm sealing (&#8220;EVAS&#8221;), the Company's innovative solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The Company's current EVAR products include the Ovation&#174; Abdominal Stent Graft System (the &#8220;Ovation&#8221; System), and the AFX&#174; Endovascular AAA System (the &#8220;AFX&#8221; System) which features the VELA&#8482; Proximal Endograft System, and the AFX2 Bifurcated Endograft System (the &#8220;AFX2&#8221; System). The Company's current EVAS product is the Nellix&#174; EndoVascular Aneurysm Sealing System (the &#8220;Nellix EVAS System&#8221;). Sales of the Company's EVAR and EVAS platforms (including extensions and accessories) to hospitals in the U.S. and Europe, and to third-party international distributors worldwide, provide the sole source of the Company's reported revenue.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;3, 2016, the Company completed its previously announced merger with TriVascular Technologies, Inc. (&#8220;TriVascular&#8221;). The merger with TriVascular expanded the Company's product offering and intellectual property, increased the Company's sales force, and enhanced our product development capabilities. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Ovation System consist of a radiopaque nitinol stent for suprarenal fixation and a low-permeability polytetrafluoroethylene (PTFE) graft. The stent is designed with integral anchors to enable fixation to the aortic wall. To seal the graft and to provide support for the aortic body legs into which the iliac limbs are deployed, the graft contains a network of inflatable rings that are filled with a liquid polymer that solidifies during the deployment procedure. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's AFX System consist of (i) a cobalt chromium alloy stent covered by polytetrafluoroethylene (commonly referred to as "ePTFE") graft material and (ii) accompanying delivery systems. Once fixed in its proper position within the abdominal aortic bifurcation, the Company's AFX System provides a conduit for blood flow, thereby relieving pressure within the weakened or &#8220;aneurysmal&#8221; section of the vessel wall, which greatly reduces the potential for the AAA to rupture. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's Nellix EVAS System consists of (i) bilateral covered stents with endobags, (ii) a biocompatible polymer injected into the endobags to seal the aneurysm and (iii) a delivery system and polymer dispenser. The Company's Nellix EVAS System seals the entire aneurysm sac effectively excluding the aneurysm reducing the likelihood of future aneurysm rupture. Additionally, the Nellix EVAS System has the potential to reduce post procedural re-interventions.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b)</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, there were no related party transactions. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interim financial data as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules&#160;and regulations relating to interim financial statements. The interim financial data includes the results of TriVascular, beginning on February 3, 2016, the effective date of the merger. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form&#160;10-K for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on March 1, 2017. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(c) Operating Segment</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment, molds, and office furniture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress (software and related implementation, production equipment, and leasehold improvements)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Charges</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> in restructuring costs within operating expenses related to focused reductions of its workforce. The Company began substantially formulating plans around this workforce reduction during the first quarter of 2016 in conjunction with its merger of TriVascular. The targeted reductions and other restructuring activities were initiated to provide efficiencies and realign resources as well as to allow for continued investment in strategic areas and drive growth. The Company expects to incur a total of </font><font style="font-family:inherit;font-size:10pt;">$11.2 million</font><font style="font-family:inherit;font-size:10pt;"> in restructuring charges upon the completion of the plan, which represents the Company&#8217;s best estimate as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. In the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;"> in restructuring costs. The recognition of restructuring charges requires that the Company make certain judgments and estimates regarding the nature, timing and amount of costs associated with the planned reductions of workforce. At the end of each reporting period, the Company will evaluate the remaining accrued balance to ensure that no excess accruals are retained and the utilization of the provisions are for their intended purpose in accordance with developed plans. The following table reflects the movement of activity of the restructuring reserve for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:none;">One-time Termination Benefits</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrual balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Utilization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance as of June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accrual balance as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is classified within accrued expenses and other current liabilities in the Company&#8217;s Condensed Consolidated Balance Sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive:</font></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Common stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,620</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,193</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock awards</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Restricted stock units</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">438</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">902</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,193</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,004</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The potential dilutive effect of these securities is shown in the chart below:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Conversion of the Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,939</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,767</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deerfield Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:76%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value of Contingently Issuable Common Stock</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,600</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total purchase consideration given related to the acquisition follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cash consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,634</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock consideration</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,812</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Fair value of assumed TriVascular stock warrants </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share was calculated by dividing net loss by the weighted average number of common shares outstanding for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Net loss </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(16,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(66,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,606</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(114,507</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares used in computing basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,072</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,368</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Basic and diluted net loss per share </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense included in cost of goods sold and operating expenses during the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2016</font><font style="font-family:inherit;font-size:10pt;">, was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30,</font></div></td></tr><tr><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Cost of goods sold</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">304</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Research and development</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">323</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">434</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">797</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical and regulatory affairs</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">593</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Marketing and sales</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,341</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,164</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,555</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total operating expenses</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,886</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,768</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,856</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,659</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,692</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,780</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance at January 1, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Intangible assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,810</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Developed technology, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,063</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Customer relationships, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,813</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Intangible assets (excluding goodwill), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,888</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,555</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on </font><font style="font-family:inherit;font-size:10pt;">February&#160;3, 2016</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,780</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,765</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,895</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,152</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">317</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,214</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Accrued liabilities and other</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">&#160;&#160;Notes payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;Net assets acquired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,404</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total purchase consideration</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185,490</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table reflects the movement of activity of the restructuring reserve for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:23%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:none;">One-time Termination Benefits</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Accrual balance as of December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring charges</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">137</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Utilization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance as of June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization expense for the five succeeding years and thereafter is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022 &amp; Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,662</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue by Geographic Region</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue by geographic region, was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24" rowspan="1"></td></tr><tr><td style="width:29%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:6%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,906</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65.7%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71.2%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.9%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,151</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70.9%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total International</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34.3%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.8%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,373</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,189</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.1%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,556</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,974</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,168</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100.0%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Segment</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Credit Facilities</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> 2.25% Convertible Senior Notes</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 10, 2013, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$86.3 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes (the &#8220;</font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes&#8221;). The </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes mature on December 15, 2018 unless earlier repurchased by the Company or converted. The Company received net proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$82.6 million</font><font style="font-family:inherit;font-size:10pt;"> from the sale of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Interest is payable on the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes on June 15 and December 15 of each year, beginning </font><font style="font-family:inherit;font-size:10pt;">June&#160;15, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes are governed by the terms of a base indenture (the &#8220;Base Indenture&#8221;), as supplemented by the first supplemental indenture relating to the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes (the &#8220;First Supplemental Indenture,&#8221; and together with the Base Indenture, the &#8220;Indenture&#8221;), between the Company and Wells Fargo Bank, National Association (the &#8220;Trustee&#8221;), each of which were entered into on </font><font style="font-family:inherit;font-size:10pt;">December&#160;10, 2013</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes are senior unsecured obligations and are: (a) senior in right of payment to the Company&#8217;s future indebtedness that is expressly subordinated in right of payment to the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes; (b) equal in right of payment to the Company&#8217;s existing and future unsecured indebtedness that is not so subordinated; (c) effectively junior to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness; and (d) and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company&#8217;s subsidiaries.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company could not redeem the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes prior to </font><font style="font-family:inherit;font-size:10pt;">December&#160;15, 2016</font><font style="font-family:inherit;font-size:10pt;">. On or after </font><font style="font-family:inherit;font-size:10pt;">December&#160;15, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company may redeem for cash all or any portion of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, at its option, but only if the closing sale price of the Company&#8217;s common stock for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day. The redemption price will equal </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Holders may convert their </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes at any time prior to the close of business on the business day immediately preceding </font><font style="font-family:inherit;font-size:10pt;">September&#160;15, 2018</font><font style="font-family:inherit;font-size:10pt;"> only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014, if the closing sale price of the Company&#8217;s common stock, for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) in the period of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes in effect on each applicable trading day; (2) during the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> consecutive business-day period following any </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading-day period in which the trading price for the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes for each such trading day was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the closing sale price of the Company&#8217;s common stock on such date multiplied by the then-current conversion rate; (3) if the Company calls all or any portion of the notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events. On or after </font><font style="font-family:inherit;font-size:10pt;">September&#160;15, 2018</font><font style="font-family:inherit;font-size:10pt;"> until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes for conversion at any time, regardless of the foregoing circumstances. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon conversion, the Company will, at its election, pay or deliver, as the case may be, cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial conversion rate of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes will be </font><font style="font-family:inherit;font-size:10pt;">41.6051</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock for each </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, which represents an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$24.04</font><font style="font-family:inherit;font-size:10pt;"> per share. Following certain corporate transactions that occur on or prior to the stated maturity date or the Company&#8217;s delivery of a notice of redemption, the Company will increase the conversion rate for a holder that elects to convert its </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes in connection with such a corporate transaction. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a fundamental change (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes at a fundamental change purchase price equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;Senior Notes&#160;Indenture contains customary terms and covenants and events of default with respect to the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. If an event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of the outstanding </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes may declare the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to us, the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was not required to separate the conversion option in the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes under ASC 815, "Derivatives and Hedging", and has the ability to settle the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes in cash, common stock or a combination of cash and common stock, at its option. In accordance with cash conversion guidance contained in ASC 470-20, "Debt with Conversion and Other Options", the Company accounted for the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes by allocating the issuance proceeds between the liability and the equity component. The equity component is classified in stockholders&#8217; equity and the resulting discount on the liability component is accreted such that interest expense equals the Company&#8217;s nonconvertible debt borrowing rate. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was </font><font style="font-family:inherit;font-size:10pt;">$66.9 million</font><font style="font-family:inherit;font-size:10pt;"> resulting in a </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;"> allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders&#8217; equity and as debt discount, to be subsequently accreted to interest expense over the term of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. Underwriting discounts and commissions and offering expenses totaled </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to the indebtedness was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, and&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders&#8217; equity. During the three months ended March 31, 2016, the Company adopted ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" utilizing retrospective application as permitted. As a result, the Company reclassified </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#160;of debt issuance costs from current and non-current other assets to reduce the&#160;</font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;">&#160;Senior Notes as of&#160;December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;3, 2017, the Company entered into a Facility with affiliates of Deerfield Management Company, L.P., pursuant to which Deerfield agreed to loan to the Company up to </font><font style="font-family:inherit;font-size:10pt;">$120 million</font><font style="font-family:inherit;font-size:10pt;">, subject to the terms and conditions set forth in the Facility Agreement. The Company used a portion of the proceeds from the Term Loan to repurchase </font><font style="font-family:inherit;font-size:10pt;">$68 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of outstanding </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, plus the accrued but unpaid interest thereon, from the holders thereof in privately negotiated transactions. Refer to section Deerfield Facility Agreement below for further discussion. The embedded conversion option of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, which was originally recorded in additional paid-in capital, was reduced by </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">. Additionally, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> related to the reduction of outstanding principal related to the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes was charged to loss on debt extinguishment on the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding borrowings of </font><font style="font-family:inherit;font-size:10pt;">$18.3 million</font><font style="font-family:inherit;font-size:10pt;">, and deferred financing costs of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, related to the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. There are </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> principal payments due during the term. Annual interest expense on these notes will range from </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> through maturity. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Capped Call Transactions</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 10, 2013, in connection with the pricing of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes and the exercise in full of their overallotment option by the underwriters, the Company entered into privately-negotiated capped call transactions (the &#8220;Capped Call Transactions&#8221;) with Bank of America, N.A., an affiliate of Merrill Lynch, Pierce, Fenner &amp; Smith Incorporated. The Capped Call Transactions initial conversion rate and number of options substantially corresponds to each $1,000 principal amount of </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. The Company used approximately </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the net proceeds from the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes offering to pay for the cost of the Capped Call Transactions. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Capped Call Transactions are separate transactions entered into by the Company with Bank of America, N.A., are not part of the terms of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes and will not change the holders&#8217; rights under the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. The Capped Call Transactions have anti-dilution adjustments substantially similar to those applicable to the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. The Capped Call Transactions are derivative instruments that are recorded within stockholders&#8217; equity because they meet an exemption from mark-to-market derivative accounting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Capped Call Transactions are expected generally to reduce the potential dilution and/or offset potential cash payments that the Company is required to make in excess of the principal amount upon conversion of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes in the event that the market price per share of the Company&#8217;s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions, which initially corresponds to the </font><font style="font-family:inherit;font-size:10pt;">$24.04</font><font style="font-family:inherit;font-size:10pt;"> conversion price of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. If, however, the market price per share of the Company&#8217;s common stock, as measured under the terms of the Capped Call Transactions, exceeds the initial cap price of </font><font style="font-family:inherit;font-size:10pt;">$29.02</font><font style="font-family:inherit;font-size:10pt;">, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the Capped Call Transactions. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company will not be required to make any cash payments to Bank of America, N.A. or any of its affiliates upon the exercise of the options that are a part of the Capped Call Transactions, but will be entitled to receive from Bank of America, N.A. (or an affiliate thereof) a number of shares of the Company&#8217;s common stock and/or an amount of cash generally based on the amount by which the market price per share of the Company&#8217;s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions during the relevant valuation period under the Capped Call Transactions. However, if the market price of the Company&#8217;s common stock, as measured under the terms of the Capped Call Transactions, exceeds the cap price of the Capped Call Transactions during such valuation period under the Capped Call Transactions, the number of shares of common stock and/or the amount of cash the Company expects to receive upon exercise of the Capped Call Transactions will be capped based on the amount by which the cap price exceeds the strike price of the Capped Call Transactions.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For any conversions of </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes prior to the close of business on the 55th scheduled trading day immediately preceding the stated maturity date of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, including without limitation upon an acquisition of the Company or similar business combination, a corresponding portion of the Capped Call Transactions will be terminated. Upon such termination, the portion of the Capped Call Transactions being terminated will be settled at fair value (subject to certain limitations), as determined by Bank of America, N.A., in its capacity as calculation agent under the Capped Call Transactions, which the Company expects to receive from Bank of America, N.A., and no payments will be due Bank of America, N.A. The capped call expires on December 13, 2018.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Company&#8217;s repurchase of approximately </font><font style="font-family:inherit;font-size:10pt;">$68 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of outstanding </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes in April 2017, the Company and Bank of America, N.A. unwound a portion of the Capped Call Transactions relating to the repurchased </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. These Capped Call Transactions were originally classified in stockholders&#8217; equity and continued to meet the criteria for classification thereof while outstanding, and therefore were not subsequently measured at fair value. The Company did not pay or receive any amount related to the unwind of the Capped Call Transactions. Therefore, the Company accounted for the unwind of the Capped Call Transactions by removing these options at their carrying value in additional paid-in capital and recording an offsetting entry to additional paid-in capital. As a result, the Company did not recognize any gain or loss, and the unwind had no net impact on additional paid-in capital. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">3.25%</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> Convertible Senior Notes due 2020 </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 2, 2015, the Company issued </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Convertible Notes due 2020 (the &#8220;</font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes&#8221;). The </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes are governed by the Base Indenture, as amended and supplemented by the second supplemental indenture relating to the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes (the &#8220;Second Supplemental Indenture,&#8221; and together with the Base Indenture, the &#8220;</font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes Indenture&#8221;), dated as of November 2, 2015, by and between the Company and the Trustee. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes are senior unsecured obligations and are: senior in right of payment to the Company&#8217;s future indebtedness that is expressly subordinated in right of payment to the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes; equal in right of payment to the Company&#8217;s existing and future unsecured indebtedness that is not so subordinated, including the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes; effectively junior to any of the Company&#8217;s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company&#8217;s subsidiaries. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> per year, payable semi-annually in arrears on May 1 and November 1 of each year, commencing May 1, 2016. The </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes mature on November 1, 2020, unless earlier purchased, redeemed or converted into shares of common stock in accordance with the terms of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes Indenture. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may not redeem the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes prior to November 1, 2018. On or after November 1, 2018, the Company may redeem for cash all or any portion of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, at its option, but only if the closing sale price of the Company&#8217;s common stock for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during any </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price on each applicable trading day. The redemption date can be no sooner than </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> trading days from the date on which notice of redemption is provided to the holders, during which time, up until </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> trading days prior to the redemption, the holders may elect to convert all or a portion of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes into shares of the Company&#8217;s common stock. The redemption price will equal </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes are convertible at the option of the holders: (1) in the calendar quarter following any quarter in which, for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> out of the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days (whether or not consecutive) ending on the last day of the quarter, the closing price of the Company&#8217;s common stock is more than </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the then-current conversion price of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes; (2) in the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> business days following any </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> day period in which the trading price per $1,000 note was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the product of the closing sale price of the Company&#8217;s common stock and the current conversion rate; (3) in the event that the Company has provided notice of redemption, but no later than </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> trading days prior to Company&#8217;s proposed redemption date; or (4) upon the occurrence of specified corporate events. On or after August 1, 2020 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes for conversion at any time, regardless of the foregoing circumstances. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial conversion rate of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes is </font><font style="font-family:inherit;font-size:10pt;">89.4314</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock per </font><font style="font-family:inherit;font-size:10pt;">1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, which is equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$11.18</font><font style="font-family:inherit;font-size:10pt;"> per share. The conversion rate is subject to adjustment upon the occurrence of certain specified events. Upon conversion, the Company will at its election pay or deliver, as the case may be, cash, shares of the Company&#8217;s common stock or a combination of cash and shares of the Company&#8217;s common stock. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a fundamental change (as defined in the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes at a fundamental change purchase price equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes to be purchased, plus accrued and unpaid interest. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes Indenture contains customary terms and covenants and events of default with respect to the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. If an event of default (as defined in the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes Indenture) occurs and is continuing, either the Trustee or the holders of at least </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of the outstanding </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes may declare the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes Indenture) occurs with respect to us, the principal amount of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon issuance and through December 31, 2015, the Company was not required to separate the conversion option from the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes under ASC 815, "Derivatives and Hedging". However, because the Company has the ability to settle the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes in cash, common stock or a combination of cash and common stock, the Company applied the cash conversion guidance contained in ASC 470-20, "Debt With Conversion and other Options", and accounted for the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes by allocating the issuance proceeds between the liability-classified debt component and a separate equity component attributable to the conversion option. The equity component is classified in stockholders&#8217; equity and the resulting discount on the liability component is accreted such that interest expense equals the Company&#8217;s borrowing rate for nonconvertible loan products of similar duration. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was </font><font style="font-family:inherit;font-size:10pt;">$97.8 million</font><font style="font-family:inherit;font-size:10pt;"> resulting in a </font><font style="font-family:inherit;font-size:10pt;">$27.2 million</font><font style="font-family:inherit;font-size:10pt;"> allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders&#8217; equity and as a debt discount, to be subsequently accreted to interest expense over the term of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. Underwriting discounts and commissions and offering expenses totaled </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to the indebtedness was recorded as deferred financing costs &#160;in other assets, to be subsequently amortized as interest expense over the term of the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, and&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#160;attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders&#8217; equity. The company adopted ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" during the first quarter of 2016, utilizing retrospective application as permitted. As a result, the Company reclassified </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> of debt issuance costs from other assets to reduce the convertible notes as of December 31, 2015. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding borrowings of </font><font style="font-family:inherit;font-size:10pt;">$105.5 million</font><font style="font-family:inherit;font-size:10pt;">, and deferred financing costs of </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, related to the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes. There are </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> principal payments due during the term. Annual interest expense on these </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes will range from </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;"> through maturity. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with its merger with TriVascular in February 2016, the Company issued </font><font style="font-family:inherit;font-size:10pt;">13.6 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock as consideration to the former stockholders of TriVascular. As a result of the Company's issuance of such shares in the merger, the quantity of authorized common shares available for future issuance was reduced to a level insufficient to honor all of the potential common shares underlying instruments then outstanding. Such instruments include the conversion options related to the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes and </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes, employee stock options, restricted stock units, contingently issuable common stock relating to the prior Nellix acquisition, and stock warrants. The creation of this authorized share deficiency in February 2016 required the Company, during the first quarter of 2016, to separate as a stand-alone derivative the </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes conversion option and a portion of the </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Senior Notes conversion option for which no authorized shares are available to effect share settlement in the event of a conversion. Accordingly, in February 2016 the Company re-classed </font><font style="font-family:inherit;font-size:10pt;">$24.8 million</font><font style="font-family:inherit;font-size:10pt;"> of the conversion features originally recorded in stockholder&#8217;s equity of the Senior Notes to derivative liabilities which will be marked to market each period until the Company authorizes sufficient new common shares to alleviate the deficiency. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 2, 2016, the Company amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">135,000,000</font><font style="font-family:inherit;font-size:10pt;">, which is currently at a level sufficient to alleviate the share deficiency. Accordingly, on June 2, 2016, the Company re-classed </font><font style="font-family:inherit;font-size:10pt;">$68.6 million</font><font style="font-family:inherit;font-size:10pt;"> of the conversion features of the Senior Notes from derivative liabilities to additional paid-in capital.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$38.7 million</font><font style="font-family:inherit;font-size:10pt;"> as a fair value adjustment of derivative liabilities. The primary factor causing the change in the fair value of the derivative liability was during the period February 3, 2016 through June 2, 2016 when the Company's stock price increased. Adjustments to the fair value of the derivative liabilities are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The value of the derivative liabilities were estimated using a &#8220;with&#8221; and &#8220;without&#8221; approach utilizing observable and unobservable inputs causing this to be a Level 3 measurement. In the &#8220;with&#8221; scenario, the value of the Senior Notes were estimated in a binomial lattice model that considers all terms of the Senior Notes, including the conversion features, with a range of probabilities and assumptions related to the timing and likelihood of the conversion features being exercised by either the Company or the holders of the Senior Notes. In the &#8220;without&#8221; scenario the value of the Senior Notes absent the conversion options were estimated.&#160;The difference between the values estimated in the &#8220;with&#8221; and &#8220;without&#8221; scenarios represents the value of the derivative liabilities. Changes in the value of the derivative liabilities were driven by changes in the Company&#8217;s stock price, expected volatility, credit spreads, and market yields.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Bank of America line of credit</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">July&#160;21, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a revolving credit facility with Bank of America, N.A. (&#8220;BOA&#8221;), whereby the Company could borrow up to </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> (the &#8220;BOA Credit Facility&#8221;). All amounts owing under the BOA Credit Facility would become due and payable upon its expiration on </font><font style="font-family:inherit;font-size:10pt;">July&#160;21, 2017</font><font style="font-family:inherit;font-size:10pt;">. A sub-feature in the line of credit allowed for the issuance of up to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in letters of credit. The BOA Credit Facility was collateralized by all of the Company's assets, except its intellectual property. The BOA Credit Facility could be terminated at any time during the </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> year term by the Company upon </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> business days</font><font style="font-family:inherit;font-size:10pt;color:#0000ff;">&#8217;</font><font style="font-family:inherit;font-size:10pt;"> notice. The BOA Credit Facility usage was priced at a spread over the one, two, three and six month LIBOR rates, and was subject to a covenant related to timely providing publicly reported information and a liquidity covenant tied to &#8220;Unencumbered Liquid Assets&#8221; ("ULA") of not less than </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;">. If not in default, the Company had the ability to reduce the ULA covenant requirement by reducing the BOA Credit Facility, with the ULA maintained at </font><font style="font-family:inherit;font-size:10pt;">1.5</font><font style="font-family:inherit;font-size:10pt;"> times the BOA Credit Facility. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company terminated the BOA Credit Facility on July 29, 2016 concurrent with its entry into a credit and security agreement with MidCap. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">MidCap Credit Facility</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 29, 2016, the Company entered into a credit and security agreement with MidCap Financial Trust ("MidCap"), as agent for the lenders party thereto and as a lender, whereby the Company could borrow up to the lesser of </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> or its applicable borrowing base of asset-based revolving loans (the &#8220;MidCap Credit Facility&#8221;). All amounts owing under the MidCap Credit Facility accrued interest at a rate equal to the LIBOR Rate plus four and one tenth percent (</font><font style="font-family:inherit;font-size:10pt;">4.10%</font><font style="font-family:inherit;font-size:10pt;">). For purposes of the MidCap Credit Facility, LIBOR Rate meant a per annum rate of interest equal to the greater of (a) one half of one percent (</font><font style="font-family:inherit;font-size:10pt;">0.50%</font><font style="font-family:inherit;font-size:10pt;">) and (b) the rate determined by MidCap by dividing (i) the Base LIBOR Rate, meaning the base London interbank offer rate for the applicable interest period, by (ii) the sum of one minus the daily average during such interest period of the aggregate maximum reserve requirement then imposed under Regulation D of the Board of Governors of the Federal Reserve System for &#8220;Eurocurrency Liabilities&#8221; (as defined therein). </font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The MidCap Credit Facility was secured by substantially all of the Company's assets, excluding its intellectual property (&#8220;Collateral&#8221;), and placed customary limitations on indebtedness, liens, distributions, acquisitions, investments, and other activities of the Company in a manner designed to protect the Collateral. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred financing costs directly related to the MidCap Credit Facility such as legal, origination, and professional services fees totaled </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">. In conjunction with the Company&#8217;s adoption of ASU 2015-03 &#8220;Simplifying the Presentation of Debt Issuance Costs&#8221; during the first quarter of 2016, the Company also adopted an update thereof or ASU 2015-15 &#8220;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of Credit Arrangements.&#8221; As a result, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> attributable to the MidCap Credit Facility was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the MidCap Credit Facility. The MidCap Credit Facility also contains a lockbox arrangement clause requiring the Company to maintain a lockbox bank account in favor of the MidCap Credit Facility; Company cash receipts remitted to the lockbox bank account are swept on a regular basis to reduce outstanding borrowings related to the MidCap Credit Facility.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the Company&#8217;s termination of the BOA Credit Facility and concurrent entry into a credit and security agreement with MidCap in July 2016, the Company entered into a corporate credit card agreement whereby the Company is required to maintain a </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> deposit in favor of the credit card issuer. The deposit account related to these credit cards will be presented as restricted cash on the Company&#8217;s Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 3, 2017, the Company replaced the MidCap Credit Facility with a new revolving line of credit with Deerfield ELGX Revolver, LLC. As a result, and as of June&#160;30, 2017, the Company wrote off approximately </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred financing costs and was required to pay a </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> termination fee to Midcap; the foregoing were charged to loss on debt extinguishment on the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Deerfield Facility Agreement</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;3, 2017, the Company entered into a Facility Agreement (the &#8220;Deerfield Facility Agreement&#8221; or &#8220;Facility Agreement&#8221;) with affiliates of Deerfield Management Company, L.P. (collectively, &#8220;Deerfield&#8221;), pursuant to which Deerfield agreed to loan to the Company up to </font><font style="font-family:inherit;font-size:10pt;">$120.0 million</font><font style="font-family:inherit;font-size:10pt;">, subject to the terms and conditions set forth in the Facility Agreement (the &#8220;Term Loan&#8221;). The Company drew the entire principal amount of the Term Loan on the Agreement Date. The Company agreed to pay Deerfield a yield enhancement fee equal to </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the funds disbursed on the Agreement Date. The Company also agreed to reimburse Deerfield for all reasonable out-of-pocket expenses incurred by Deerfield in connection with the negotiation and documentation of the Facility Agreement up to a capped amount. Accordingly, deferred financing costs of </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded on the Company&#8217;s Condensed Consolidated Balance Sheet as a direct reduction of the Term Loan, to be subsequently amortized as interest expense over the effective period of the Term Loan. Concurrently with entering into the Facility Agreement, the Company entered into a Guaranty and Security Agreement with Deerfield (the &#8220;Security Agreement&#8221;), pursuant to which, as security for the repayment of the Company&#8217;s obligations under the Facility Agreement, the Company granted to Deerfield a first priority security interest in substantially all of the Company&#8217;s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted pursuant to the Facility Agreement.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any amounts drawn under the Facility Agreement accrue interest at a rate of </font><font style="font-family:inherit;font-size:10pt;">6.87%</font><font style="font-family:inherit;font-size:10pt;">&#160;per annum, payable quarterly in arrears beginning on July&#160;1, 2017 and on the first business day of each calendar quarter thereafter and on the Maturity Date, unless repaid earlier. The Company will be required to pay Deerfield on each of April&#160;2, 2021,&#160;April&#160;2, 2022 and April&#160;2, 2023 (the &#8220;Maturity Date&#8221;), an amortization payment equal to </font><font style="font-family:inherit;font-size:10pt;">$40 million</font><font style="font-family:inherit;font-size:10pt;"> (or, if on the Maturity Date, the remaining outstanding principal amount of the Term Loan).</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon a change of control of the Company, if the acquirer satisfies certain conditions set forth in the Facility Agreement, such acquirer may assume the outstanding principal amount under the Facility Agreement without penalty. If such acquirer does not satisfy the conditions set forth in the Facility Agreement, Deerfield may, at its option, require the Company to repay the outstanding principal balance under the Facility Agreement plus, depending on the timing of the change of control transaction, the Company may be required to pay a make-whole premium and will be required to pay a change of control fee.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time on or after the fourth anniversary of the Agreement Date, the Company has the right to prepay any amounts owed under the Facility Agreement without premium or penalty, unless such prepayment occurs in connection with a change of control of the Company, in which case the Company must pay Deerfield a change of control fee unless such change of control occurs beyond a certain period after the Maturity Date. At any time prior to the fourth anniversary of the Agreement Date, any prepayment made by the Company will be subject to a make-whole premium and, if such prepayment occurs in connection with a change of control of the Company, a change of control fee.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any amounts drawn under the Facility Agreement may become immediately due and payable upon customary events of default, as defined in the Facility Agreement, or the consummation of certain change of control transactions, as described above.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Facility Agreement contains various representations and warranties, events of default, and affirmative and negative covenants, customary for financings of this type, including reporting requirements, requirements that the Company maintain timely reporting with the SEC and restrictions on the ability of the Company and its subsidiaries to incur additional liens on their assets, incur additional indebtedness and acquire and dispose of assets outside the ordinary course of business.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of June&#160;30, 2017, the Company had outstanding borrowings of </font><font style="font-family:inherit;font-size:10pt;">$105.3 million</font><font style="font-family:inherit;font-size:10pt;">, and deferred financing costs of </font><font style="font-family:inherit;font-size:10pt;">$4.9 million</font><font style="font-family:inherit;font-size:10pt;">, related to the Term Loan. Annual interest expense on these notes will range from </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;"> through maturity.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the execution of the Facility Agreement, the Company issued to Deerfield warrants to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">6,470,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of the Company at an exercise price of </font><font style="font-family:inherit;font-size:10pt;">$9.23</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Deerfield Warrants&#8221;). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Warrants expire on the </font><font style="font-family:inherit;font-size:10pt;">seven</font><font style="font-family:inherit;font-size:10pt;">th anniversary of the Agreement Date. Subject to certain exceptions, the Warrants contain limitations such that the Company may not issue shares of common stock of the Company to Deerfield upon the exercise of the Warrants if such issuance would result in Deerfield beneficially owning in excess of </font><font style="font-family:inherit;font-size:10pt;">4.985%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of common stock of the Company then issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of the Warrants may exercise the Warrants for cash, on a cashless basis or through a reduction of an amount of principal outstanding under the Term Loan. In connection with certain major transactions, the holders may have the option to convert the Warrants, in whole or in part, into the right to receive the transaction consideration payable upon consummation of such major transaction in respect of a number of shares of common stock of the Company equal to the Black-Scholes value of the Warrants, as defined therein, and in the case of other major transactions, the holders may have the right to exercise the Warrants, in whole or in part, for a number of shares of common stock of the Company equal to the Black-Scholes value of the Warrants.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measured the initial fair value of the </font><font style="font-family:inherit;font-size:10pt;">6,470,000</font><font style="font-family:inherit;font-size:10pt;"> shares underlying the Deerfield Warrants at </font><font style="font-family:inherit;font-size:10pt;">$14.3 million</font><font style="font-family:inherit;font-size:10pt;">, net of issuance costs of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">, and recorded the amount in additional paid-in-capital and as a direct reduction of the Term Loan, to be subsequently amortized as interest expense over the effective period of the Term Loan.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Registration Rights Agreement</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Term Loan and the issuance of the Warrants, the Company entered into a Registration Rights Agreement with Deerfield (the &#8220;Registration Rights Agreement&#8221;). Pursuant to the terms of the Registration Rights Agreement, the Company has agreed to file a registration statement on Form S-3 (or if Form S-3 is not then available, such other form of registration statement as is then available) with the Commission on or prior to the 30th day following the Agreement Date, to register for resale the shares of common stock of the Company issuable upon the exercise of the Warrants. The aforementioned registration statement was filed on Form S-3 on May 2, 2017.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Credit and Security Agreement</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the Agreement Date, the Company entered into a Credit and Security Agreement (the &#8220;Credit Agreement&#8221;) with Deerfield ELGX Revolver, LLC (&#8220;Deerfield Revolver&#8221;), pursuant to which the Company may borrow up to the lesser of </font><font style="font-family:inherit;font-size:10pt;">$50 million</font><font style="font-family:inherit;font-size:10pt;"> or its applicable borrowing base from time to time prior to March&#160;31, 2020 (the &#8220;Revolver&#8221;). Any outstanding principal under the Revolver will accrue interest at a rate equal to 3-month LIBOR (with a </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> floor) plus </font><font style="font-family:inherit;font-size:10pt;">4.60%</font><font style="font-family:inherit;font-size:10pt;">, payable monthly in arrears on the first business day of the immediately succeeding calendar month and on the maturity date. The Company is subject to other fees in addition to interest on the outstanding principal amount under the Revolver, including in connection with an early termination of the Revolver.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Revolver replaces the Company&#8217;s </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> asset-based revolving line of credit with MidCap Financial Trust. In conjunction with the Company&#8217;s adoption of ASU 2015-03 &#8220;Simplifying the Presentation of Debt Issuance Costs&#8221; during the first quarter of 2016, the Company also adopted an update thereof or ASU 2015-15 &#8220;Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of Credit Arrangements.&#8221; As a result, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in deferred financing costs related to the Revolver and presents these costs as a deferred asset, to be subsequently amortized as interest expense over the term of the Revolver, on the Company&#8217;s Condensed Consolidated Balance Sheets. The Company&#8217;s obligations under the Credit Agreement are secured by a first priority security interest in substantially all of the Company&#8217;s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted pursuant to the Term Loan. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding borrowings of </font><font style="font-family:inherit;font-size:10pt;">$24.3 million</font><font style="font-family:inherit;font-size:10pt;">, and deferred financing costs of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> related to the revolver. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the Company&#8217;s entry into the Credit Agreement, the Company entered into a corporate credit card agreement whereby the Company is required to maintain a </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> deposit in favor of the credit card issuer. The deposit account related to these credit cards will be presented as restricted cash on the Company&#8217;s Condensed Consolidated Balance Sheet.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For a complete summary of the Company's significant accounting policies, please refer to Note 2, "Use of Estimates and Summary of Significant Accounting Policies", in Part II, Item 8, of the Company's </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, filed with the SEC on March 1, 2017. There have been no material changes to the Company's significant accounting policies during the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Account Detail</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(a) Property and Equipment</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment consisted of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production equipment, molds, and office furniture</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,746</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,162</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress (software and related implementation, production equipment, and leasehold improvements)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, at cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,210</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,945</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,300</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for property and equipment for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the&#160;</font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> depreciation expense for property and equipment was&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;and&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(b) Inventories</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,291</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work-in-process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Finished goods</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,497</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,888</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,555</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,160</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(c) Goodwill and Intangible Assets</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Intangible assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Indefinite lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Trademarks and trade names</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In-process research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Finite lived intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Developed technology</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,375</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,810</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Developed technology, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63,790</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Customer relationships</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,063</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(687</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;Customer relationships, net</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,437</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,813</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Intangible assets (excluding goodwill), net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82,570</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,511</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in the carrying amount of goodwill for the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows (in thousands): </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance at January 1, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency translation adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Balance at June 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">120,845</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense for intangible assets for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. For the&#160;</font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> amortization expense for intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> and&#160;</font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization expense for the five succeeding years and thereafter is as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Remainder of 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022 &amp; Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,213</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68,662</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(d) Marketable securities</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in held-to-maturity marketable securities consist of the following at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June 30, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Agency bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,001</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,999</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortized<br clear="none"/>Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Gain</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross<br clear="none"/>Unrealized<br clear="none"/>Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Agency bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,488</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,492</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Commercial paper</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,987</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company&#8217;s investments included </font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;"> held-to-maturity debt securities in unrealized loss positions with a total unrealized loss of approximately </font><font style="font-family:inherit;font-size:10pt;">$3 thousand</font><font style="font-family:inherit;font-size:10pt;"> and a total fair market value of approximately </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">. All investments with gross unrealized losses have been in unrealized loss positions for less than </font><font style="font-family:inherit;font-size:10pt;">11</font><font style="font-family:inherit;font-size:10pt;"> months. The unrealized losses were caused by interest rate fluctuations. There was no change in the credit risk of the securities. The Company does not intend to sell the securities and it is not likely that the Company will be required to sell the securities before the expected recovery of their amortized cost bases. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> realized gains or losses on the investments for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. All of the Company's investments of held-to-maturity securities will mature within less than 12 months with an average maturity of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;"> month. </font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(e) Fair Value Measurements</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s assets and liabilities measured at fair value on a recurring basis as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;Fair value measurement at reporting date using:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Quoted prices in<br clear="none"/>active markets for<br clear="none"/>identical assets<br clear="none"/>(Level 1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant other<br clear="none"/>observable<br clear="none"/>inputs<br clear="none"/>(Level 2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Significant<br clear="none"/>unobservable<br clear="none"/>inputs<br clear="none"/>(Level 3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">At June 30, 2017</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,641</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingently issuable common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">At December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,120</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Restricted cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contingently issuable common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were no re-measurements to fair value during the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers between Level 1, Level 2 or Level 3 securities during the </font><font style="font-family:inherit;font-size:10pt;">six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(f) Financial Instruments Not Recorded at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures the fair value of its </font><font style="font-family:inherit;font-size:10pt;">2.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2018 and </font><font style="font-family:inherit;font-size:10pt;">3.25%</font><font style="font-family:inherit;font-size:10pt;"> Convertible Senior Notes due 2020 (collectively, the &#8220;Senior Notes&#8221;) carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Senior Notes is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar securities. Based on the market prices, the fair value of our long-term debt was </font><font style="font-family:inherit;font-size:10pt;">$123.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$187.6 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures the fair value of its Term Loan carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Term Loan is determined by Level 3 inputs and is based primarily on unobservable inputs that are not corroborated by market data. The fair value of our Term Loan was </font><font style="font-family:inherit;font-size:10pt;">$100.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to short-term nature, the Company believes that the carrying value of its revolving line of credit approximated its fair value at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company measures the fair value of its held-to-maturity marketable securities carried at amortized cost quarterly for disclosure purposes. The fair value of marketable securities is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar instruments.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.</font></div></div> EX-101.SCH 8 elgx-20170630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2103100 - Disclosure - Balance Sheet Account Detail link:presentationLink link:calculationLink link:definitionLink 2403406 - Disclosure - Balance Sheet Account Detail (Amortization) (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Balance Sheet Account Detail (Change in Carrying Amount of Goodwill) (Details) link:presentationLink link:calculationLink link:definitionLink 2403408 - Disclosure - Balance Sheet Account Detail (Fair Value Measurements) (Details) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Balance Sheet Account Detail (Goodwill and Intangible Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 2403407 - Disclosure - Balance Sheet Account Detail (Held to Maturity Marketable Securities) (Details) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Balance Sheet Account Detail (Inventories) (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Balance Sheet Account Detail (Property and Equipment) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Balance Sheet Account Detail (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Commitments and Contingencies (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Lease Payments, Fiscal Year Maturity) (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Contingently Issuable Common Stock link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Contingently Issuable Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Contingently Issuable Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Credit Facilities link:presentationLink link:calculationLink link:definitionLink 2406401 - Disclosure - Credit Facilities (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Policies) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Income Tax Expense link:presentationLink link:calculationLink link:definitionLink 2410401 - Disclosure - Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Restructuring Charges link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Restructuring Charges (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Revenue by Geographic Region link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Revenue by Geographic Region (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Revenue by Geographic Region (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - TriVascular Merger link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - TriVascular Merger (Assets and Liabilities Acquired) (Details) link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - TriVascular Merger (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - TriVascular Merger (Price Consideration) (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - TriVascular Merger (Pro-Forma Information) (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - TriVascular Merger (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Use of Estimates and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 elgx-20170630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 elgx-20170630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 elgx-20170630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Restructuring and Related Activities [Abstract] Schedule of Restructuring Reserve Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Business Combinations [Abstract] TriVascular Merger Mergers, Acquisitions and Dispositions Disclosures [Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] TriVascular Technologies, Inc. TriVascular Technologies, Inc. [Member] TriVascular Technologies, Inc. [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Short-term investments Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Prepaid expenses and other current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Property and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Accounts payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Accrued liabilities and other Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Notes payable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Goodwill Goodwill Total purchase consideration Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business, Basis of Presentation, and Operating Segment Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Geographic Areas, Revenues from External Customers [Abstract] Schedule of Revenue by Geographic Region Schedule of Revenue from External Customers, by Geographical Areas [Table Text Block] Schedule of Revenue from External Customers, by Geographical Areas [Table Text Block] Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Operating Segment Segment Reporting, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Balance Sheet Related Disclosures [Abstract] Goodwill, Finite-lived, and Indefinite-lived Intangible Assets Goodwill and Finite and Indefnite Lived Intangible Asset [Table] Goodwill and Finite and Indefnite Lived Intangible Asset [Table] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Trademarks and trade names Trademarks and Trade Names [Member] In-process research and development In Process Research and Development [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed technology Developed technology [Member] Developed technology [Member] Customer relationships Customer Relationships [Member] Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items] Goodwill, Finite, and Indefnite Intangible Assets [Line Items] Goodwill, Finite, and Indefnite Intangible Assets [Line Items] Indefinite lived intangibles Indefinite-Lived Intangible Assets (Excluding Goodwill) Finite lived intangibles Finite-Lived Intangible Assets, Gross Accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Total Finite-Lived Intangible Assets, Net Intangible assets (excluding goodwill), net Intangible Assets, Net (Excluding Goodwill) Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of goods sold Cost of Sales [Member] Research and development Research and Development Expense [Member] Clinical and regulatory affairs Clinical and regulatory affairs [Member] Clinical and regulatory affairs [Member] Marketing and sales Selling and Marketing Expense [Member] General and administrative General and Administrative Expense [Member] Total operating expenses Operating Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Allocated stock-based compensation expense Allocated Share-based Compensation Expense Summary of Purchase Consideration Given in Acquisition Schedule of Business Acquisitions, by Acquisition [Table Text Block] Summary of Allocation of Purchase Consideration Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Summary of Pro Forma Financial Information of Acquisition Business Acquisition, Pro Forma Information [Table Text Block] Balance Sheet Account Detail Supplemental Balance Sheet Disclosures [Text Block] Schedule of Revenue by Geographic Region Schedule of Revenues by Geographic Region [Table] Schedule of Revenues by Geographic Region [Table] Geographical [Axis] Geographical [Axis] Segment, Geographical [Domain] Geographical [Domain] United States UNITED STATES Total International Non-US [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Geographic Concentration Risk Geographic Concentration Risk [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Sales [Member] Schedule of Revenue by Geographic Region [Line Items] Schedule of Revenue by Geographic Region [Line Items] Schedule of Revenue by Geographic Region [Line Items] Revenue Sales Revenue, Goods, Net Concentration risk percentage Concentration Risk, Percentage Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Total Inventories Inventory, Net Schedule of Calculation of Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Combined net loss from continuing operations Business Acquisition, Pro Forma Revenue Combined net loss from continuing operations Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax Pro forma basic net loss per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Basic Pro forma diluted net loss per share (in dollars per share) Business Acquisition, Pro Forma Earnings Per Share, Diluted Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Current Reporting Status Entity Current Reporting Status Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Non-Cancelable Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] Remainder of 2017 Operating Leases, Future Minimum Payments, Remainder of Fiscal Year 2018 Operating Leases, Future Minimum Payments, Due in Two Years 2019 Operating Leases, Future Minimum Payments, Due in Three Years 2020 Operating Leases, Future Minimum Payments, Due in Four Years 2021 Operating Leases, Future Minimum Payments, Due in Five Years 2022 and thereafter Operating Leases, Future Minimum Payments, Due Thereafter Total future minimum lease payments Operating Leases, Future Minimum Payments Due Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Convertible Preferred Stock Convertible Preferred Stock [Member] Statement [Line Items] Statement [Line Items] Allowance for doubtful accounts Allowance for Doubtful Accounts Receivable Convertible preferred stock par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Convertible preferred stock authorized (in shares) Preferred Stock, Shares Authorized Convertible preferred stock issued (in shares) Preferred Stock, Shares Issued Convertible preferred stock outstanding (in shares) Preferred Stock, Shares Outstanding Common stock par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock authorized (in shares) Common Stock, Shares Authorized Common stock issued (in shares) Common Stock, Shares, Issued Common stock outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock (in shares) Treasury Stock, Shares Line of Credit Facility [Abstract] Credit Facilities Short-term Debt [Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Quoted prices in active markets for identical assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant other observable inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant unobservable inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Nonrecurring Fair Value, Measurements, Nonrecurring [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] 2.25% Convertible Senior Notes Convertible Senior Notes due 2018 [Member] Convertible Senior Notes due 2018 [Member] 3.25% Convertible Senior Notes Convertible Senior Notes Due 2020 [Member] Convertible Senior Notes Due 2020 [Member] Facility Agreement Facility Agreement, Due 2023 [Member] Facility Agreement, Due 2023 [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Convertible Debt Convertible Debt [Member] Secured Debt Secured Debt [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Restricted cash Restricted Cash and Cash Equivalents, Current Contingently issuable common stock Business Acquisition, Contingently Issuable Common Stock, Noncurrent Business Acquisition, Contingently Issuable Common Stock, Noncurrent Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Fair value of long-term debt Long-term Debt, Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill, beginning balance Foreign currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Goodwill, ending balance Amortization expense Amortization of Intangible Assets Remainder of 2017 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2018 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2019 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Five 2022 & Thereafter Finite-Lived Intangible Assets, Amortization Expense, after Year Five Restructuring, expected cost Restructuring and Related Cost, Expected Cost Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Accrual, beginning balance Restructuring Reserve Restructuring costs Restructuring Charges Utilization Restructuring Reserve, Settled without Cash Accrual, ending balance Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Income Tax Expense Income Tax Disclosure [Text Block] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Production equipment, molds, and office furniture Production Equipment, Molds, and Office Furniture [Member] Production Equipment, Molds, and Office Furniture [Member] Computer hardware and software Computer Equipment [Member] Leasehold improvements Leasehold Improvements [Member] Construction in progress (software and related implementation, production equipment, and leasehold improvements) Construction in Progress [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property and equipment, at cost Property, Plant and Equipment, Gross Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Property, Plant and Equipment, Net Depreciation expense Depreciation Equity consideration issued in merger (in shares) Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Equity consideration issued in merger Business Acquisition, Equity Interest Issued or Issuable, Value Assigned Share price (in dollars per share) Share Price Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Common stock options Employee Stock Option [Member] Restricted stock awards Restricted Stock [Member] Restricted stock units Restricted Stock Units (RSUs) [Member] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Deerfield Warrants Facility Agreement, Due 2023, Deerfield Warrants [Member] Facility Agreement, Due 2023, Deerfield Warrants [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock Common Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Earnings Per Share, Basic and Diluted [Abstract] Earnings Per Share, Basic and Diluted [Abstract] Net loss Net Income (Loss) Attributable to Parent Shares used in computing basic and diluted net loss per share (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Basic and diluted net loss per share (in dollars per share) Earnings Per Share, Basic and Diluted Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract] Earnings Per Share, Diluted, Other Disclosures [Abstract] Outstanding securities used in calculations (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Convertible notes Convertible Notes Payable Debt instrument face amount Debt Instrument, Face Amount Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price of warrants issued (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Potential Dilutive Effect of Securities [Abstract] Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Conversion of the Notes (in shares) Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities Conversion of Deerfield Warrants (in shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Schedule of Held-to-maturity Securities [Table] Schedule of Held-to-maturity Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Agency bonds Bonds [Member] Corporate bonds Corporate Bond Securities [Member] Commercial paper Commercial Paper [Member] Schedule of Held-to-maturity Securities [Line Items] Schedule of Held-to-maturity Securities [Line Items] Amortized Cost Held-to-maturity Securities, Amortized Cost before Other than Temporary Impairment Gross Unrealized Gain Held-to-maturity Securities, Accumulated Unrecognized Holding Gain Gross Unrealized Loss Held-to-maturity Securities, Accumulated Unrecognized Holding Loss Fair Value Held-to-maturity Securities, Fair Value Held-to-maturity debt securities held Held to Maturity Securities, Number of Securities Held Held to Maturity Securities, Number of Securities Held Time held in unrealized loss position (less than) Held-to-maturity, Securities in Unrealized Loss Positions, Qualitative Disclosure, Duration of Loss Held-to-maturity, Securities in Unrealized Loss Positions, Qualitative Disclosure, Duration of Loss Unrealized gains (losses) on investments Held-to-maturity Securities, Sold Security, Realized Gain (Loss) Average maturity Held-to-maturity, Average Maturity Held-to-maturity, Average Maturity ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Marketable Securities Accounts receivable, net allowance for doubtful accounts of $994 and $1,037, respectively. Accounts Receivable, Net, Current Other receivables Other Receivables, Net, Current Inventories Prepaid expenses and other current assets Other Assets, Current Total current assets Assets, Current Property and equipment, net Intangibles, net Deposits and other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued payroll Employee-related Liabilities, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Revolving line of credit Line of Credit, Current Total current liabilities Liabilities, Current Deferred income taxes Deferred Tax Liabilities, Net, Noncurrent Deferred rent Deferred Rent Credit, Noncurrent Other liabilities Other Liabilities, Noncurrent Contingently issuable common stock Business Combination, Contingent Consideration, Liability, Noncurrent Debt Long-term Debt, Excluding Current Maturities Total liabilities Liabilities Commitments and contingencies Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding. Preferred Stock, Value, Issued Common stock, $0.001 par value; 135,000,000 shares authorized. 83,638,895 and 82,986,244 shares issued, respectively. 83,426,656 and 82,774,005 shares outstanding, respectively. Common Stock, Value, Issued Treasury stock, at cost, 212,239 shares. Treasury Stock, Value Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Bad debt expense Provision for Doubtful Accounts Depreciation and amortization Depreciation, Depletion and Amortization Stock-based compensation Share-based Compensation Change in fair value of derivative liabilities Gain (Loss) on Derivative Instruments, Net, Pretax Change in fair value of contingent consideration related to acquisition Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Accretion of interest & amortization of deferred financing costs on debt Accretion Expense Non-cash foreign exchange loss (gain) Foreign Currency Transaction Gain (Loss), before Tax Non-cash loss on debt extinguishment Noncash Gain (Loss) On Extinguishment Of Debt Noncash Gain (Loss) On Extinguishment Of Debt Changes in operating assets and liabilities: Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract] Restricted cash Increase (Decrease) in Restricted Cash for Operating Activities Accounts receivable and other receivables Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued payroll Increase (Decrease) in Employee Related Liabilities Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of marketable securities Payments to Acquire Marketable Securities Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Acquisition of business, net of cash acquired of $0 and $24,012, respectively Payments to Acquire Businesses, Net of Cash Acquired Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from revolving line of credit Proceeds from (Repayments of) Lines of Credit Deferred financing costs Payments of Financing Costs Proceeds from sale of common stock under employee stock purchase plan Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt Repayment of debt Repayments of Long-term Debt Minimum tax withholding paid on behalf of employees for restricted stock units Payments Related to Tax Withholding for Share-based Compensation Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Cash paid for income taxes Income Taxes Paid Non-cash investing and financing activities: Other Noncash Investing and Financing Items [Abstract] Acquisition of property and equipment included in accounts payable Noncash or Part Noncash Acquisition, Other Assets Acquired Fair value of common stock issued for business acquisition Stock Issued Fair value of warrants issued for business acquisition Warrants Issued, Business Acquisition Warrants Issued, Business Acquisition Fair value of warrants issued in connection with the Facility Agreement Warrants Issued, Debt Facility Agreement Warrants Issued, Debt Facility Agreement Number of operating segments Number of Operating Segments Number of reportable segments Number of Reportable Segments Accounting Policies [Abstract] Use of Estimates and Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Restructuring Charges Restructuring and Related Activities Disclosure [Text Block] Cash acquired in acquisition of business Cash Acquired from Acquisition Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Cash consideration Payments to Acquire Businesses, Gross Common stock consideration Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair value of assumed TriVascular stock warrants Business Combination, Consideration Transferred, Liabilities Incurred Total purchase consideration Business Combination, Consideration Transferred Property and Equipment Property, Plant and Equipment [Table Text Block] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Schedule of Goodwill and Intangible Assets Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Schedule of Investments in Marketable Securities Marketable Securities [Table Text Block] Schedule of Assets and Liabilities Measured at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Revenue by Geographic Region Segment Reporting Disclosure [Text Block] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Manufacturing Facility Manufacturing Facility [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Contract Termination Contract Termination [Member] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Aggregate square feet Operating Leases, Facility, Area Operating Leases, Facility, Area Renewal term Lessee, Operating Lease, Renewal Term Rent expense Operating Leases, Rent Expense Severance payment, prior to change in control Severance Payment, Period, Prior To Change in Control Severance Payment, Period, Prior To Change in Control Severance payment, period following change in control Severance Payment, Period, Following Change in Control Severance Payment, Period, Following Change in Control Settlement costs from litigation Gain (Loss) Related to Litigation Settlement Termination costs Operating Income (Loss) Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Redemption, Period One Debt Instrument, Redemption, Period One [Member] Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other Assets Other Assets [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Long-term Debt Long-term Debt [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2015-03 Accounting Standards Update 2015-03 [Member] Debt Instrument, Convertible, Convertible Conditions [Axis] Debt Instrument, Convertible, Convertible Conditions [Axis] Debt Instrument, Convertible, Convertible Conditions [Axis] Debt Instrument, Convertible, Convertible Conditions [Domain] Debt Instrument, Convertible, Convertible Conditions [Domain] [Domain] for Debt Instrument, Convertible, Convertible Conditions [Axis] Convertible Condition One Convertible Condition One [Member] Convertible Condition One [Member] Convertible Condition Two Convertible Condition Two [Member] Convertible Condition Two [Member] Convertible Condition Three Convertible Condition Three [Member] Convertible Condition Three [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility Revolving Credit Facility [Member] Letter of Credit Letter of Credit [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] Bank of America Bank of America [Member] Bank of America [Member] MidCap MidCap Financial Trust [Member] MidCap Financial Trust [Member] Deerfield Revolver Deerfield ELGX Revolver, LLC [Member] Deerfield ELGX Revolver, LLC [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] LIBOR London Interbank Offered Rate (LIBOR) [Member] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Proceeds from convertible debt Proceeds from Convertible Debt Threshold trading days Debt Instrument, Convertible, Threshold Trading Days Threshold consecutive trading days Debt Instrument, Convertible, Threshold Consecutive Trading Days Threshold percentage of stock price trigger Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Redemption price percentage Debt Instrument, Redemption Price, Percentage Threshold consecutive business days Debt Instrument, Convertible, Threshold Consecutive Business Days Debt Instrument, Convertible, Threshold Consecutive Business Days Threshold business days Debt Instrument, Convertible, Threshold Business Days Debt Instrument, Convertible, Threshold Business Days Conversion of convertible securities Debt Instrument, Convertible, Conversion Ratio Convertible conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Price Violation or event of default, declaration by note holders, percentage Debt Instrument, Debt Default, Violation Or Event Of Default, Declaration By Note Holders, Percentage Debt Instrument, Debt Default, Violation Or Event Of Default, Declaration By Note Holders, Percentage Fair value disclosure Debt Instrument, Fair Value Disclosure Beneficial conversion feature Debt Instrument, Convertible, Beneficial Conversion Feature Unamortized discount Debt Instrument, Unamortized Discount Debt issuance costs, net Debt Issuance Costs, Net Repurchased debt amount Debt Instrument, Repurchase Amount Non-cash loss on debt extinguishment Gain (Loss) on Extinguishment of Debt Deferred finance costs, noncurrent, net Debt Issuance Costs, Noncurrent, Net Periodic principal payment Debt Instrument, Periodic Payment, Principal Periodic interest payment Debt Instrument, Periodic Payment, Interest Payments of derivative issuance costs Payments of Derivative Issuance Costs Cap price (in dollars per security) Derivative, Cap Price Holding threshold required to declare debt due Debt Instrument, Holding Threshold To Declare Debt Due Debt Instrument, Holding Threshold To Declare Debt Due Debt issuance costs Debt Issuance Costs, Gross Reclassification of conversion features to derivative liabilities Stockholders' Equity, Reclassification, Equity Component of Convertible Debt Stockholders' Equity, Reclassification, Equity Component of Convertible Debt Adjustments to additional paid-in capital, conversion features of Senior Notes Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature Change in fair value of derivative liabilities Aggregate maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Term of line of credit Debt Instrument, Term Termination notice period Debt Instrument, Termination Notice Period Debt Instrument, Termination Notice Period Liquidation proceeds, monetary amount Credit Derivative, Liquidation Proceeds, Monetary Amount Minimum current ratio Debt Covenant, Minimum Current Ratio Debt Covenant, Minimum Current Ratio Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Variable rate, maximum Debt Instrument, Variable Rate, Maximum Debt Instrument, Variable Rate, Maximum Deferred financing costs - professional fees Debt Issuance Costs, Line of Credit Arrangements, Gross Restricted cash Restricted Cash and Cash Equivalents, Required Deposit Restricted Cash and Cash Equivalents, Required Deposit Write off of deferred financing costs Write off of Deferred Debt Issuance Cost Debt termination fees Payment for Debt Extinguishment or Debt Prepayment Cost Yield enhancement fee Debt Instrument, Yield Enhancement Fee Debt Instrument, Yield Enhancement Fee Periodic amortization payment Debt Instrument, Periodic Payment Amount outstanding Long-term Debt, Gross Shares in which warrants can be converted (in shares) Expiration date of warrants issued Class Of Warrant Or Right, Expiration Date Class Of Warrant Or Right, Expiration Date Warrant exercise limitation threshold Class Of Warrant Or Right, Exercise Limitation Threshold Class Of Warrant Or Right, Exercise Limitation Threshold Fair value of warrants Warrants and Rights Outstanding Variable rate, floor Debt Instrument, Variable Rate, Floor Debt Instrument, Variable Rate, Floor Amount outstanding Long-term Line of Credit Income Statement [Abstract] Cost of goods sold Cost of Goods Sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense Clinical and regulatory affairs Clinical And Regulatory Affairs Clinical And Regulatory Affairs Marketing and sales Selling and Marketing Expense General and administrative General and Administrative Expense Settlement costs Contract termination and business acquisition expenses Contract Termination And Business Acquisition Expense Contract Termination And Business Acquisition Expense Total operating expenses Operating Expenses Loss from operations Other income (expense): Nonoperating Income (Expense) [Abstract] Interest income Investment Income, Interest Interest expense Interest Expense Other income (expense), net Other Nonoperating Income (Expense) Change in fair value of contingent consideration related to acquisition Loss on debt extinguishment Total other income (expense) Nonoperating Income (Expense) Net loss before income tax expense Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Income tax expense Income Tax Expense (Benefit) Net loss Other comprehensive income (loss) foreign currency translation Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of Fair Value of Contingent Payment Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Contingently Issuable Common Stock Business Combination Disclosure [Text Block] Income tax expense (benefit) Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Nellix Nellix [Member] Nellix [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Nelix Milestones Nelix Milestones [Member] Nelix Milestones [Member] PMA Milestone PMA Milestone [Member] PMA Milestone [Member] Purchase price common shares (in shares) Common shares value Number of shares contingently issuable (in shares) Weighted Average Number of Shares, Contingently Issuable Estimated fair value of contingent payment Contingent Consideration Classified as Equity, Fair Value Disclosure Share price (in dollars per share) Business Acquisition, Share Price Closing stock price (in dollars per share) Business Acquisition, Contingent Consideration, Closing Stock Price Per Share Business Acquisition, Contingent Consideration, Closing Stock Price Per Share Average daily closing stock price Weighted Average Number Of Shares, Daily Average Closing Stock Price Weighted Average Number Of Shares, Daily Average Closing Stock Price Days prior to milestone achievement announcement Business Acquisition, Contingent Consideration, Days Prior To Milestone Achievement Announcement Business Acquisition, Contingent Consideration, Days Prior To Milestone Achievement Announcement Contingent consideration, at fair value hypothetical value Business Acquisition, Contingent Consideration, at Fair Value Hypothetical Value Business Acquisition, Contingent Consideration, at Fair Value Hypothetical Value Fair Value of Contingently Issuable Common Stock Fair Value of Contingently Issuable Common Stock [Roll Forward] Fair Value of Contingently Issuable Common Stock [Roll Forward] Beginning balance Business Combination, Contingent Consideration, Liability, Current Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017 Ending balance Schedule of Share-based Compensation Expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Future Minimum Lease Payments by Year Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] EX-101.PRE 12 elgx-20170630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 elgxnewlogoa04.jpg begin 644 elgxnewlogoa04.jpg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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.7.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2017
Aug. 01, 2017
Document and Entity Information [Abstract]    
Entity Registrant Name ENDOLOGIX INC /DE/  
Entity Central Index Key 0001013606  
Document Type 10-Q  
Document Period End Date Jun. 30, 2017  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Current Reporting Status Yes  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   83,434,656
Document Fiscal Year Focus 2017  
Document Fiscal Period Focus Q2  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 81,641 $ 26,120
Restricted cash 2,877 2,001
Marketable securities 10,000 20,988
Accounts receivable, net allowance for doubtful accounts of $994 and $1,037, respectively. 33,118 34,430
Other receivables 390 1,787
Inventories 43,555 41,160
Prepaid expenses and other current assets 4,235 3,359
Total current assets 175,816 129,845
Property and equipment, net 21,300 23,265
Goodwill 120,845 120,711
Intangibles, net 82,570 84,511
Deposits and other assets 1,536 1,352
Total assets 402,067 359,684
Current liabilities:    
Accounts payable 11,030 13,237
Accrued payroll 16,933 19,997
Accrued expenses and other current liabilities 10,001 11,668
Revolving line of credit 24,297 0
Total current liabilities 62,261 44,902
Deferred income taxes 879 879
Deferred rent 7,859 7,949
Other liabilities 4,194 3,783
Contingently issuable common stock 9,600 12,200
Debt 220,520 177,178
Total liabilities 305,313 246,891
Commitments and contingencies
Stockholders’ equity:    
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding. 0 0
Common stock, $0.001 par value; 135,000,000 shares authorized. 83,638,895 and 82,986,244 shares issued, respectively. 83,426,656 and 82,774,005 shares outstanding, respectively. 84 83
Treasury stock, at cost, 212,239 shares. (2,942) (2,942)
Additional paid-in capital 588,194 567,765
Accumulated deficit (491,207) (453,601)
Accumulated other comprehensive income 2,625 1,488
Total stockholders’ equity 96,754 112,793
Total liabilities and stockholders’ equity $ 402,067 $ 359,684
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Allowance for doubtful accounts $ 994 $ 1,037
Common stock par value (in dollars per share) $ 0.001 $ 0.001
Common stock authorized (in shares) 135,000,000 135,000,000
Common stock issued (in shares) 83,638,895 82,986,244
Common stock outstanding (in shares) 83,426,656 82,774,005
Treasury stock (in shares) 212,239 212,239
Convertible Preferred Stock    
Convertible preferred stock par value (in dollars per share) $ 0.001 $ 0.001
Convertible preferred stock authorized (in shares) 5,000,000 5,000,000
Convertible preferred stock issued (in shares) 0 0
Convertible preferred stock outstanding (in shares) 0 0
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Income Statement [Abstract]        
Revenue $ 48,556 $ 50,974 $ 91,168 $ 93,340
Cost of goods sold 16,332 21,515 30,302 35,940
Gross profit 32,224 29,459 60,866 57,400
Operating expenses:        
Research and development 5,734 7,714 11,264 15,559
Clinical and regulatory affairs 2,740 4,022 6,575 7,905
Marketing and sales 23,781 28,824 49,681 56,742
General and administrative 7,904 10,210 16,777 20,156
Restructuring costs (29) 790 137 8,114
Settlement costs 0 0 0 4,650
Contract termination and business acquisition expenses 0 1,127 0 5,905
Total operating expenses 40,130 52,687 84,434 119,031
Loss from operations (7,906) (23,228) (23,568) (61,631)
Other income (expense):        
Interest income 28 48 72 110
Interest expense (5,803) (3,815) (10,098) (7,597)
Other income (expense), net 223 (556) 176 (912)
Change in fair value of contingent consideration related to acquisition 3,800 (100) 2,600 (100)
Loss on debt extinguishment (6,512) 0 (6,512) 0
Change in fair value of derivative liabilities 0 (38,743) 0 (43,831)
Total other income (expense) (8,264) (43,166) (13,762) (52,330)
Net loss before income tax expense (16,170) (66,394) (37,330) (113,961)
Income tax expense (122) (443) (276) (546)
Net loss (16,292) (66,837) (37,606) (114,507)
Other comprehensive income (loss) foreign currency translation 781 1,019 1,137 914
Comprehensive loss $ (15,511) $ (65,818) $ (36,469) $ (113,593)
Basic and diluted net loss per share (in dollars per share) $ (0.20) $ (0.81) $ (0.45) $ (1.44)
Shares used in computing basic and diluted net loss per share (in shares) 83,247 82,072 83,087 79,368
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Cash flows from operating activities:    
Net loss $ (37,606) $ (114,507)
Adjustments to reconcile net loss to net cash used in operating activities:    
Bad debt expense (89) 0
Depreciation and amortization 4,645 4,229
Stock-based compensation 6,188 6,768
Change in fair value of derivative liabilities 0 43,831
Change in fair value of contingent consideration related to acquisition (2,600) 100
Accretion of interest & amortization of deferred financing costs on debt 5,004 4,603
Non-cash foreign exchange loss (gain) (206) 810
Non-cash loss on debt extinguishment 3,997 0
Changes in operating assets and liabilities:    
Restricted cash (876) 0
Accounts receivable and other receivables 3,470 (2,445)
Inventories (2,174) 3,557
Prepaid expenses and other current assets (762) 1,100
Accounts payable (3,486) (5,812)
Accrued payroll (3,220) 6,922
Accrued expenses and other liabilities (1,092) 1,889
Net cash used in operating activities (28,807) (48,955)
Cash flows from investing activities:    
Purchases of marketable securities 0 (5,017)
Maturities of marketable securities 11,000 19,350
Purchases of property and equipment (833) (1,304)
Acquisition of business, net of cash acquired of $0 and $24,012, respectively 0 (60,622)
Net cash (used in) provided by investing activities 10,167 (47,593)
Cash flows from financing activities:    
Net proceeds from revolving line of credit 24,297 0
Deferred financing costs (6,285) 0
Proceeds from sale of common stock under employee stock purchase plan 1,681 1,826
Proceeds from exercise of stock options 449 1,777
Proceeds from issuance of debt 120,000 0
Repayment of debt (66,613) 0
Minimum tax withholding paid on behalf of employees for restricted stock units 0 (134)
Net cash provided by financing activities 73,529 3,469
Effect of exchange rate changes on cash and cash equivalents 632 (26)
Net (decrease) in cash and cash equivalents 55,521 (93,105)
Cash and cash equivalents, beginning of period 26,120 124,553
Cash and cash equivalents, end of period 81,641 31,448
Supplemental disclosure of cash flow information:    
Cash paid for interest 2,956 2,994
Cash paid for income taxes 565 167
Non-cash investing and financing activities:    
Acquisition of property and equipment included in accounts payable 26 0
Fair value of common stock issued for business acquisition 0 100,812
Fair value of warrants issued for business acquisition 0 44
Fair value of warrants issued in connection with the Facility Agreement $ 14,704 $ 0
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows (Parenthetical) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Statement of Cash Flows [Abstract]    
Cash acquired in acquisition of business $ 0 $ 24,012
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business, Basis of Presentation, and Operating Segment
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business, Basis of Presentation, and Operating Segment
Description of Business, Basis of Presentation, and Operating Segment
(a) Description of Business
Endologix, Inc. (the "Company") is a Delaware corporation with corporate headquarters in Irvine, California and production facilities located in Irvine, California and Santa Rosa, California. The Company develops, manufactures, markets, and sells innovative medical devices for the treatment of aortic disorders. The Company's products are intended for the minimally invasive endovascular treatment of abdominal aortic aneurysms ("AAA"). The Company's AAA products include innovations for minimally-invasive endovascular aneurysm repair ("EVAR") or endovascular aneurysm sealing (“EVAS”), the Company's innovative solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The Company's current EVAR products include the Ovation® Abdominal Stent Graft System (the “Ovation” System), and the AFX® Endovascular AAA System (the “AFX” System) which features the VELA™ Proximal Endograft System, and the AFX2 Bifurcated Endograft System (the “AFX2” System). The Company's current EVAS product is the Nellix® EndoVascular Aneurysm Sealing System (the “Nellix EVAS System”). Sales of the Company's EVAR and EVAS platforms (including extensions and accessories) to hospitals in the U.S. and Europe, and to third-party international distributors worldwide, provide the sole source of the Company's reported revenue.
On February 3, 2016, the Company completed its previously announced merger with TriVascular Technologies, Inc. (“TriVascular”). The merger with TriVascular expanded the Company's product offering and intellectual property, increased the Company's sales force, and enhanced our product development capabilities.
The Company’s Ovation System consist of a radiopaque nitinol stent for suprarenal fixation and a low-permeability polytetrafluoroethylene (PTFE) graft. The stent is designed with integral anchors to enable fixation to the aortic wall. To seal the graft and to provide support for the aortic body legs into which the iliac limbs are deployed, the graft contains a network of inflatable rings that are filled with a liquid polymer that solidifies during the deployment procedure.
The Company's AFX System consist of (i) a cobalt chromium alloy stent covered by polytetrafluoroethylene (commonly referred to as "ePTFE") graft material and (ii) accompanying delivery systems. Once fixed in its proper position within the abdominal aortic bifurcation, the Company's AFX System provides a conduit for blood flow, thereby relieving pressure within the weakened or “aneurysmal” section of the vessel wall, which greatly reduces the potential for the AAA to rupture.
The Company's Nellix EVAS System consists of (i) bilateral covered stents with endobags, (ii) a biocompatible polymer injected into the endobags to seal the aneurysm and (iii) a delivery system and polymer dispenser. The Company's Nellix EVAS System seals the entire aneurysm sac effectively excluding the aneurysm reducing the likelihood of future aneurysm rupture. Additionally, the Nellix EVAS System has the potential to reduce post procedural re-interventions.
(b) Basis of Presentation
The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2017 and 2016, there were no related party transactions.
The interim financial data as of June 30, 2017 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three and six months ended June 30, 2017. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The interim financial data includes the results of TriVascular, beginning on February 3, 2016, the effective date of the merger.
The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 1, 2017.
(c) Operating Segment
The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three and six months ended June 30, 2017, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.7.0.1
Use of Estimates and Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2017
Accounting Policies [Abstract]  
Use of Estimates and Summary of Significant Accounting Policies
Use of Estimates and Summary of Significant Accounting Policies
The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.
For a complete summary of the Company's significant accounting policies, please refer to Note 2, "Use of Estimates and Summary of Significant Accounting Policies", in Part II, Item 8, of the Company's 2016 Annual Report on Form 10-K for the year ended December 31, 2016, filed with the SEC on March 1, 2017. There have been no material changes to the Company's significant accounting policies during the three and six months ended June 30, 2017.
XML 22 R9.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail
 6 Months Ended
Jun. 30, 2017
Balance Sheet Related Disclosures [Abstract]  
Balance Sheet Account Detail
Balance Sheet Account Detail
(a) Property and Equipment
Property and equipment consisted of the following:
 
June 30,
2017
 
December 31,
2016
Production equipment, molds, and office furniture
$
11,908

 
$
11,714

Computer hardware and software
8,746

 
8,162

Leasehold improvements
15,495

 
15,495

Construction in progress (software and related implementation, production equipment, and leasehold improvements)
842

 
839

Property and equipment, at cost
$
36,991

 
$
36,210

Accumulated depreciation
(15,691
)
 
(12,945
)
Property and equipment, net
$
21,300

 
$
23,265


Depreciation expense for property and equipment for the three months ended June 30, 2017 and 2016 was $1.3 million and $1.3 million, respectively. For the six months ended June 30, 2017 and 2016 depreciation expense for property and equipment was $2.7 million and $2.6 million, respectively.
(b) Inventories
Inventories consisted of the following:
 
June 30,
2017
 
December 31,
2016
Raw materials
$
11,291

 
$
13,133

Work-in-process
11,767

 
10,139

Finished goods
20,497

 
17,888

Total Inventories
$
43,555

 
$
41,160


(c) Goodwill and Intangible Assets
The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization: 

June 30,
2017

December 31,
2016
Goodwill
$
120,845


$
120,711







Intangible assets:





Indefinite lived intangibles





Trademarks and trade names
$
2,708


$
2,708

In-process research and development
11,200

 
11,200

 
 
 
 
Finite lived intangibles





Developed technology
$
67,600


$
67,600

Accumulated amortization
(5,375
)

(3,810
)
Developed technology, net
$
62,225


$
63,790







Customer relationships
$
7,500


$
7,500

Accumulated amortization
(1,063
)

(687
)
 Customer relationships, net
$
6,437


$
6,813







Intangible assets (excluding goodwill), net
$
82,570


$
84,511


The change in the carrying amount of goodwill for the six months ended June 30, 2017 is as follows (in thousands):
Balance at January 1, 2017
120,711

Foreign currency translation adjustment
134

Balance at June 30, 2017
$
120,845


Amortization expense for intangible assets for the three months ended June 30, 2017 and 2016 was $1.0 million and $0.7 million, respectively. For the six months ended June 30, 2017 and 2016 amortization expense for intangible assets was $1.9 million and $1.6 million, respectively.
Estimated amortization expense for the five succeeding years and thereafter is as follows:
Remainder of 2017
$
1,940

2018
3,978

2019
3,978

2020
4,996

2021
6,557

2022 & Thereafter
47,213

Total
$
68,662



(d) Marketable securities
Investments in held-to-maturity marketable securities consist of the following at June 30, 2017 and December 31, 2016:

June 30, 2017

Amortized
Cost

Gross
Unrealized
Gain
 
Gross
Unrealized
Loss
 
Fair Value
Agency bonds
$
3,999


$
—


$
(1
)

$
3,998

Corporate bonds
6,001


—


(2
)

5,999

Total
$
10,000


$
—


$
(3
)

$
9,997










December 31, 2016

Amortized
Cost

Gross
Unrealized
Gain
 
Gross
Unrealized
Loss
 
Fair Value
Agency bonds
$
6,488


$
2


$
—


$
6,490

Corporate bonds
10,513


—


(21
)

10,492

Commercial paper
3,987


—


—


3,987

Total
$
20,988


$
2


$
(21
)

$
20,969



At June 30, 2017, the Company’s investments included 4 held-to-maturity debt securities in unrealized loss positions with a total unrealized loss of approximately $3 thousand and a total fair market value of approximately $10.0 million. All investments with gross unrealized losses have been in unrealized loss positions for less than 11 months. The unrealized losses were caused by interest rate fluctuations. There was no change in the credit risk of the securities. The Company does not intend to sell the securities and it is not likely that the Company will be required to sell the securities before the expected recovery of their amortized cost bases. There were no realized gains or losses on the investments for the three and six months ended June 30, 2017. All of the Company's investments of held-to-maturity securities will mature within less than 12 months with an average maturity of 1 month.
(e) Fair Value Measurements
The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016:

 Fair value measurement at reporting date using:
 
Quoted prices in
active markets for
identical assets
(Level 1)

Significant other
observable
inputs
(Level 2)

Significant
unobservable
inputs
(Level 3)

Total
At June 30, 2017











Cash and cash equivalents
$
81,641


$
—


$
—


$
81,641

Restricted cash
$
2,877


$
—


$
—


$
2,877

Contingently issuable common stock
$
—


$
—


$
9,600


$
9,600

At December 31, 2016











Cash and cash equivalents
$
26,120


$
—


$
—


$
26,120

Restricted cash
$
2,001


$
—


$
—


$
2,001

Contingently issuable common stock
$
—


$
—


$
12,200


$
12,200



There were no re-measurements to fair value during the six months ended June 30, 2017 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers between Level 1, Level 2 or Level 3 securities during the six months ended June 30, 2017.
(f) Financial Instruments Not Recorded at Fair Value on a Recurring Basis
The Company measures the fair value of its 2.25% Convertible Senior Notes due 2018 and 3.25% Convertible Senior Notes due 2020 (collectively, the “Senior Notes”) carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Senior Notes is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar securities. Based on the market prices, the fair value of our long-term debt was $123.2 million as of June 30, 2017 and $187.6 million as of December 31, 2016.
The Company measures the fair value of its Term Loan carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Term Loan is determined by Level 3 inputs and is based primarily on unobservable inputs that are not corroborated by market data. The fair value of our Term Loan was $100.2 million as of June 30, 2017.
Due to short-term nature, the Company believes that the carrying value of its revolving line of credit approximated its fair value at June 30, 2017.
The Company measures the fair value of its held-to-maturity marketable securities carried at amortized cost quarterly for disclosure purposes. The fair value of marketable securities is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar instruments.
XML 23 R10.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation

The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss, based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the three and six months ended June 30, 2017 and 2016, was as follows:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Cost of goods sold
$
304


$
259

 
$
473


$
532

Operating expenses:





 





Research and development
323


434

 
583


797

Clinical and regulatory affairs
160


593

 
420


493

Marketing and sales
1,283


1,261

 
2,341


2,391

General and administrative
1,164


1,339

 
2,371


2,555

Total operating expenses
$
2,930


$
3,627

 
$
5,715


$
6,236

Total
$
3,234


$
3,886

 
$
6,188


$
6,768
XML 24 R11.htm IDEA: XBRL DOCUMENT v3.7.0.1
Net Loss Per Share
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Net Loss Per Share
Net Loss Per Share
Net loss per share was calculated by dividing net loss by the weighted average number of common shares outstanding for the three and six months ended June 30, 2017 and 2016.

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016
Net loss
$
(16,292
)

$
(66,837
)

$
(37,606
)

$
(114,507
)
Shares used in computing basic and diluted net loss per share
83,247


82,072


83,087


79,368

Basic and diluted net loss per share
$
(0.20
)

$
(0.81
)

$
(0.45
)

$
(1.44
)


The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Common stock options
574


1,620

 
636


1,193

Restricted stock awards
121


135

 
120


131

Restricted stock units
207


438

 
248


299

  Total
902


2,193

 
1,004


1,623



Conversion of Senior Notes
As discussed in Note 6, in December 2013, the Company issued $86.3 million in aggregate principal amount of 2.25% Convertible Senior Notes due 2018 (the “2.25% Senior Notes”) in an underwritten public offering. In November 2015, the Company also issued $125.0 million aggregate principal amount of 3.25% Convertible Senior Notes due 2020 (the “3.25% Senior Notes”) in an underwritten public offering. Upon any conversion, the 2.25% Senior Notes and/or 3.25% Senior Notes, (collectively the "Senior Notes") may be settled, at the Company’s election, in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. For purposes of calculating the maximum dilutive impact, the Company presumed that the Senior Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Senior Notes is excluded from the calculation of diluted loss per share because the impact of these securities would be anti-dilutive.

Deerfield Warrants
On April 3, 2017, the Company entered into a Facility Agreement (the “Facility Agreement”) with affiliates of Deerfield Management Company, L.P. (collectively, “Deerfield”), pursuant to which Deerfield agreed to loan to the Company up to $120.0 million, subject to the terms and conditions set forth in the Facility Agreement (the “Term Loan”). As part of the Facility Agreement, the Company also issued warrants to Deerfield to purchase an aggregate of 6,470,000 shares of common stock of the Company at an exercise price of $9.23 per share (the “Deerfield Warrants”). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company. Refer to Note 6 of the Notes to the Condensed Consolidated Financial Statements for further discussion.
The potential dilutive effect of these securities is shown in the chart below:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Conversion of the Notes
11,939


14,767

 
11,939


14,767

Deerfield Warrants
6,470


—

 
6,470


—


The effect of the contingently issuable common stock is excluded from the calculation of basic net loss per share until all necessary conditions for issuance have been satisfied. Refer to Note 9 of the Notes to the Condensed Consolidated Financial Statements for further discussion.
XML 25 R12.htm IDEA: XBRL DOCUMENT v3.7.0.1
Credit Facilities
 6 Months Ended
Jun. 30, 2017
Line of Credit Facility [Abstract]  
Credit Facilities
Credit Facilities
2.25% Convertible Senior Notes
On December 10, 2013, the Company issued $86.3 million in aggregate principal amount of 2.25% Convertible Senior Notes (the “2.25% Senior Notes”). The 2.25% Senior Notes mature on December 15, 2018 unless earlier repurchased by the Company or converted. The Company received net proceeds of approximately $82.6 million from the sale of the 2.25% Senior Notes, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Interest is payable on the 2.25% Senior Notes on June 15 and December 15 of each year, beginning June 15, 2016.
The 2.25% Senior Notes are governed by the terms of a base indenture (the “Base Indenture”), as supplemented by the first supplemental indenture relating to the 2.25% Senior Notes (the “First Supplemental Indenture,” and together with the Base Indenture, the “Indenture”), between the Company and Wells Fargo Bank, National Association (the “Trustee”), each of which were entered into on December 10, 2013.
The 2.25% Senior Notes are senior unsecured obligations and are: (a) senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the 2.25% Senior Notes; (b) equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; (c) effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and (d) and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries.
The Company could not redeem the 2.25% Senior Notes prior to December 15, 2016. On or after December 15, 2016, the Company may redeem for cash all or any portion of the 2.25% Senior Notes, at its option, but only if the closing sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds 130% of the conversion price on each applicable trading day. The redemption price will equal 100% of the principal amount of the 2.25% Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2.25% Senior Notes.
Holders may convert their 2.25% Senior Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014, if the closing sale price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the 2.25% Senior Notes in effect on each applicable trading day; (2) during the five consecutive business-day period following any five consecutive trading-day period in which the trading price for the 2.25% Senior Notes for each such trading day was less than 98% of the closing sale price of the Company’s common stock on such date multiplied by the then-current conversion rate; (3) if the Company calls all or any portion of the notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2018 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their 2.25% Senior Notes for conversion at any time, regardless of the foregoing circumstances.
Upon conversion, the Company will, at its election, pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
The initial conversion rate of the 2.25% Senior Notes will be 41.6051 shares of the Company’s common stock for each $1,000 principal amount of 2.25% Senior Notes, which represents an initial conversion price of approximately $24.04 per share. Following certain corporate transactions that occur on or prior to the stated maturity date or the Company’s delivery of a notice of redemption, the Company will increase the conversion rate for a holder that elects to convert its 2.25% Senior Notes in connection with such a corporate transaction.
If a fundamental change (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their 2.25% Senior Notes at a fundamental change purchase price equal to 100% of the principal amount of the 2.25% Senior Notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.
The 2.25% Senior Notes Indenture contains customary terms and covenants and events of default with respect to the 2.25% Senior Notes. If an event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding 2.25% Senior Notes may declare the principal amount of the 2.25% Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to us, the principal amount of the 2.25% Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable.
The Company was not required to separate the conversion option in the 2.25% Senior Notes under ASC 815, "Derivatives and Hedging", and has the ability to settle the 2.25% Senior Notes in cash, common stock or a combination of cash and common stock, at its option. In accordance with cash conversion guidance contained in ASC 470-20, "Debt with Conversion and Other Options", the Company accounted for the 2.25% Senior Notes by allocating the issuance proceeds between the liability and the equity component. The equity component is classified in stockholders’ equity and the resulting discount on the liability component is accreted such that interest expense equals the Company’s nonconvertible debt borrowing rate. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the 2.25% Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was $66.9 million resulting in a $19.3 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders’ equity and as debt discount, to be subsequently accreted to interest expense over the term of the 2.25% Senior Notes. Underwriting discounts and commissions and offering expenses totaled $3.7 million and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, $2.9 million attributable to the indebtedness was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the 2.25% Senior Notes, and $0.8 million attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders’ equity. During the three months ended March 31, 2016, the Company adopted ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" utilizing retrospective application as permitted. As a result, the Company reclassified $1.9 million of debt issuance costs from current and non-current other assets to reduce the 2.25% Senior Notes as of December 31, 2015.
On April 3, 2017, the Company entered into a Facility with affiliates of Deerfield Management Company, L.P., pursuant to which Deerfield agreed to loan to the Company up to $120 million, subject to the terms and conditions set forth in the Facility Agreement. The Company used a portion of the proceeds from the Term Loan to repurchase $68 million aggregate principal amount of outstanding 2.25% Senior Notes, plus the accrued but unpaid interest thereon, from the holders thereof in privately negotiated transactions. Refer to section Deerfield Facility Agreement below for further discussion. The embedded conversion option of the 2.25% Senior Notes, which was originally recorded in additional paid-in capital, was reduced by $2.2 million. Additionally, $3.2 million related to the reduction of outstanding principal related to the 2.25% Senior Notes was charged to loss on debt extinguishment on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss.
As of June 30, 2017, the Company had outstanding borrowings of $18.3 million, and deferred financing costs of $0.2 million, related to the 2.25% Senior Notes. There are no principal payments due during the term. Annual interest expense on these notes will range from $1.1 million to $1.5 million through maturity.
Capped Call Transactions
On December 10, 2013, in connection with the pricing of the 2.25% Senior Notes and the exercise in full of their overallotment option by the underwriters, the Company entered into privately-negotiated capped call transactions (the “Capped Call Transactions”) with Bank of America, N.A., an affiliate of Merrill Lynch, Pierce, Fenner & Smith Incorporated. The Capped Call Transactions initial conversion rate and number of options substantially corresponds to each $1,000 principal amount of 2.25% Senior Notes. The Company used approximately $7.4 million of the net proceeds from the 2.25% Senior Notes offering to pay for the cost of the Capped Call Transactions.
The Capped Call Transactions are separate transactions entered into by the Company with Bank of America, N.A., are not part of the terms of the 2.25% Senior Notes and will not change the holders’ rights under the 2.25% Senior Notes. The Capped Call Transactions have anti-dilution adjustments substantially similar to those applicable to the 2.25% Senior Notes. The Capped Call Transactions are derivative instruments that are recorded within stockholders’ equity because they meet an exemption from mark-to-market derivative accounting.
The Capped Call Transactions are expected generally to reduce the potential dilution and/or offset potential cash payments that the Company is required to make in excess of the principal amount upon conversion of the 2.25% Senior Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions, which initially corresponds to the $24.04 conversion price of the 2.25% Senior Notes. If, however, the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the initial cap price of $29.02, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the Capped Call Transactions.
The Company will not be required to make any cash payments to Bank of America, N.A. or any of its affiliates upon the exercise of the options that are a part of the Capped Call Transactions, but will be entitled to receive from Bank of America, N.A. (or an affiliate thereof) a number of shares of the Company’s common stock and/or an amount of cash generally based on the amount by which the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions during the relevant valuation period under the Capped Call Transactions. However, if the market price of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the cap price of the Capped Call Transactions during such valuation period under the Capped Call Transactions, the number of shares of common stock and/or the amount of cash the Company expects to receive upon exercise of the Capped Call Transactions will be capped based on the amount by which the cap price exceeds the strike price of the Capped Call Transactions.
For any conversions of 2.25% Senior Notes prior to the close of business on the 55th scheduled trading day immediately preceding the stated maturity date of the 2.25% Senior Notes, including without limitation upon an acquisition of the Company or similar business combination, a corresponding portion of the Capped Call Transactions will be terminated. Upon such termination, the portion of the Capped Call Transactions being terminated will be settled at fair value (subject to certain limitations), as determined by Bank of America, N.A., in its capacity as calculation agent under the Capped Call Transactions, which the Company expects to receive from Bank of America, N.A., and no payments will be due Bank of America, N.A. The capped call expires on December 13, 2018.
In connection with the Company’s repurchase of approximately $68 million aggregate principal amount of outstanding 2.25% Senior Notes in April 2017, the Company and Bank of America, N.A. unwound a portion of the Capped Call Transactions relating to the repurchased 2.25% Senior Notes. These Capped Call Transactions were originally classified in stockholders’ equity and continued to meet the criteria for classification thereof while outstanding, and therefore were not subsequently measured at fair value. The Company did not pay or receive any amount related to the unwind of the Capped Call Transactions. Therefore, the Company accounted for the unwind of the Capped Call Transactions by removing these options at their carrying value in additional paid-in capital and recording an offsetting entry to additional paid-in capital. As a result, the Company did not recognize any gain or loss, and the unwind had no net impact on additional paid-in capital.
3.25% Convertible Senior Notes due 2020
On November 2, 2015, the Company issued $125.0 million aggregate principal amount of 3.25% Senior Convertible Notes due 2020 (the “3.25% Senior Notes”). The 3.25% Senior Notes are governed by the Base Indenture, as amended and supplemented by the second supplemental indenture relating to the 3.25% Senior Notes (the “Second Supplemental Indenture,” and together with the Base Indenture, the “3.25% Senior Notes Indenture”), dated as of November 2, 2015, by and between the Company and the Trustee.
The 3.25% Senior Notes are senior unsecured obligations and are: senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the 3.25% Senior Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, including the 2.25% Senior Notes; effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries.
The 3.25% Senior Notes accrue interest at a rate of 3.25% per year, payable semi-annually in arrears on May 1 and November 1 of each year, commencing May 1, 2016. The 3.25% Senior Notes mature on November 1, 2020, unless earlier purchased, redeemed or converted into shares of common stock in accordance with the terms of the 3.25% Senior Notes Indenture.
The Company may not redeem the 3.25% Senior Notes prior to November 1, 2018. On or after November 1, 2018, the Company may redeem for cash all or any portion of the 3.25% Senior Notes, at its option, but only if the closing sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds 130% of the conversion price on each applicable trading day. The redemption date can be no sooner than 30 trading days from the date on which notice of redemption is provided to the holders, during which time, up until two trading days prior to the redemption, the holders may elect to convert all or a portion of the 3.25% Senior Notes into shares of the Company’s common stock. The redemption price will equal 100% of the principal amount of the 3.25% Senior Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 3.25% Senior Notes.
The 3.25% Senior Notes are convertible at the option of the holders: (1) in the calendar quarter following any quarter in which, for at least 20 out of the 30 consecutive trading days (whether or not consecutive) ending on the last day of the quarter, the closing price of the Company’s common stock is more than 130% of the then-current conversion price of the 3.25% Senior Notes; (2) in the five business days following any five day period in which the trading price per $1,000 note was less than 98% of the product of the closing sale price of the Company’s common stock and the current conversion rate; (3) in the event that the Company has provided notice of redemption, but no later than two trading days prior to Company’s proposed redemption date; or (4) upon the occurrence of specified corporate events. On or after August 1, 2020 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their 3.25% Senior Notes for conversion at any time, regardless of the foregoing circumstances.
The initial conversion rate of the 3.25% Senior Notes is 89.4314 shares of the Company’s common stock per 1,000 principal amount of the 3.25% Senior Notes, which is equivalent to an initial conversion price of approximately $11.18 per share. The conversion rate is subject to adjustment upon the occurrence of certain specified events. Upon conversion, the Company will at its election pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
If a fundamental change (as defined in the 3.25% Senior Notes Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their 3.25% Senior Notes at a fundamental change purchase price equal to 100% of the principal amount of the 3.25% Senior Notes to be purchased, plus accrued and unpaid interest.
The 3.25% Senior Notes Indenture contains customary terms and covenants and events of default with respect to the 3.25% Senior Notes. If an event of default (as defined in the 3.25% Senior Notes Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding 3.25% Senior Notes may declare the principal amount of the 3.25% Senior Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the 3.25% Senior Notes Indenture) occurs with respect to us, the principal amount of the 3.25% Senior Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable.
Upon issuance and through December 31, 2015, the Company was not required to separate the conversion option from the 3.25% Senior Notes under ASC 815, "Derivatives and Hedging". However, because the Company has the ability to settle the 3.25% Senior Notes in cash, common stock or a combination of cash and common stock, the Company applied the cash conversion guidance contained in ASC 470-20, "Debt With Conversion and other Options", and accounted for the 3.25% Senior Notes by allocating the issuance proceeds between the liability-classified debt component and a separate equity component attributable to the conversion option. The equity component is classified in stockholders’ equity and the resulting discount on the liability component is accreted such that interest expense equals the Company’s borrowing rate for nonconvertible loan products of similar duration. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the 3.25% Senior Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was $97.8 million resulting in a $27.2 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders’ equity and as a debt discount, to be subsequently accreted to interest expense over the term of the 3.25% Senior Notes. Underwriting discounts and commissions and offering expenses totaled $3.7 million and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, $2.9 million attributable to the indebtedness was recorded as deferred financing costs  in other assets, to be subsequently amortized as interest expense over the term of the 3.25% Senior Notes, and $0.8 million attributable to the equity component was recorded as a reduction to additional paid-in-capital in stockholders’ equity. The company adopted ASU 2015-03, "Simplifying the Presentation of Debt Issuance Costs" during the first quarter of 2016, utilizing retrospective application as permitted. As a result, the Company reclassified $2.9 million of debt issuance costs from other assets to reduce the convertible notes as of December 31, 2015.
As of June 30, 2017, the Company had outstanding borrowings of $105.5 million, and deferred financing costs of $2.1 million, related to the 3.25% Senior Notes. There are no principal payments due during the term. Annual interest expense on these 3.25% Senior Notes will range from $9.1 million to $10.7 million through maturity.
In connection with its merger with TriVascular in February 2016, the Company issued 13.6 million shares of common stock as consideration to the former stockholders of TriVascular. As a result of the Company's issuance of such shares in the merger, the quantity of authorized common shares available for future issuance was reduced to a level insufficient to honor all of the potential common shares underlying instruments then outstanding. Such instruments include the conversion options related to the 3.25% Senior Notes and 2.25% Senior Notes, employee stock options, restricted stock units, contingently issuable common stock relating to the prior Nellix acquisition, and stock warrants. The creation of this authorized share deficiency in February 2016 required the Company, during the first quarter of 2016, to separate as a stand-alone derivative the 3.25% Senior Notes conversion option and a portion of the 2.25% Senior Notes conversion option for which no authorized shares are available to effect share settlement in the event of a conversion. Accordingly, in February 2016 the Company re-classed $24.8 million of the conversion features originally recorded in stockholder’s equity of the Senior Notes to derivative liabilities which will be marked to market each period until the Company authorizes sufficient new common shares to alleviate the deficiency.
On June 2, 2016, the Company amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 135,000,000, which is currently at a level sufficient to alleviate the share deficiency. Accordingly, on June 2, 2016, the Company re-classed $68.6 million of the conversion features of the Senior Notes from derivative liabilities to additional paid-in capital.
For the three and six months ended June 30, 2016, the Company recorded $38.7 million as a fair value adjustment of derivative liabilities. The primary factor causing the change in the fair value of the derivative liability was during the period February 3, 2016 through June 2, 2016 when the Company's stock price increased. Adjustments to the fair value of the derivative liabilities are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
The value of the derivative liabilities were estimated using a “with” and “without” approach utilizing observable and unobservable inputs causing this to be a Level 3 measurement. In the “with” scenario, the value of the Senior Notes were estimated in a binomial lattice model that considers all terms of the Senior Notes, including the conversion features, with a range of probabilities and assumptions related to the timing and likelihood of the conversion features being exercised by either the Company or the holders of the Senior Notes. In the “without” scenario the value of the Senior Notes absent the conversion options were estimated. The difference between the values estimated in the “with” and “without” scenarios represents the value of the derivative liabilities. Changes in the value of the derivative liabilities were driven by changes in the Company’s stock price, expected volatility, credit spreads, and market yields.
Bank of America line of credit
On July 21, 2015, the Company entered into a revolving credit facility with Bank of America, N.A. (“BOA”), whereby the Company could borrow up to $20.0 million (the “BOA Credit Facility”). All amounts owing under the BOA Credit Facility would become due and payable upon its expiration on July 21, 2017. A sub-feature in the line of credit allowed for the issuance of up to $10.0 million in letters of credit. The BOA Credit Facility was collateralized by all of the Company's assets, except its intellectual property. The BOA Credit Facility could be terminated at any time during the two year term by the Company upon three business days’ notice. The BOA Credit Facility usage was priced at a spread over the one, two, three and six month LIBOR rates, and was subject to a covenant related to timely providing publicly reported information and a liquidity covenant tied to “Unencumbered Liquid Assets” ("ULA") of not less than $30.0 million. If not in default, the Company had the ability to reduce the ULA covenant requirement by reducing the BOA Credit Facility, with the ULA maintained at 1.5 times the BOA Credit Facility.
The Company terminated the BOA Credit Facility on July 29, 2016 concurrent with its entry into a credit and security agreement with MidCap.
MidCap Credit Facility
On July 29, 2016, the Company entered into a credit and security agreement with MidCap Financial Trust ("MidCap"), as agent for the lenders party thereto and as a lender, whereby the Company could borrow up to the lesser of $50.0 million or its applicable borrowing base of asset-based revolving loans (the “MidCap Credit Facility”). All amounts owing under the MidCap Credit Facility accrued interest at a rate equal to the LIBOR Rate plus four and one tenth percent (4.10%). For purposes of the MidCap Credit Facility, LIBOR Rate meant a per annum rate of interest equal to the greater of (a) one half of one percent (0.50%) and (b) the rate determined by MidCap by dividing (i) the Base LIBOR Rate, meaning the base London interbank offer rate for the applicable interest period, by (ii) the sum of one minus the daily average during such interest period of the aggregate maximum reserve requirement then imposed under Regulation D of the Board of Governors of the Federal Reserve System for “Eurocurrency Liabilities” (as defined therein).
The MidCap Credit Facility was secured by substantially all of the Company's assets, excluding its intellectual property (“Collateral”), and placed customary limitations on indebtedness, liens, distributions, acquisitions, investments, and other activities of the Company in a manner designed to protect the Collateral.
Deferred financing costs directly related to the MidCap Credit Facility such as legal, origination, and professional services fees totaled $0.9 million. In conjunction with the Company’s adoption of ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs” during the first quarter of 2016, the Company also adopted an update thereof or ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of Credit Arrangements.” As a result, $0.9 million attributable to the MidCap Credit Facility was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the MidCap Credit Facility. The MidCap Credit Facility also contains a lockbox arrangement clause requiring the Company to maintain a lockbox bank account in favor of the MidCap Credit Facility; Company cash receipts remitted to the lockbox bank account are swept on a regular basis to reduce outstanding borrowings related to the MidCap Credit Facility.
In conjunction with the Company’s termination of the BOA Credit Facility and concurrent entry into a credit and security agreement with MidCap in July 2016, the Company entered into a corporate credit card agreement whereby the Company is required to maintain a $2.0 million deposit in favor of the credit card issuer. The deposit account related to these credit cards will be presented as restricted cash on the Company’s Condensed Consolidated Balance Sheet.
On April 3, 2017, the Company replaced the MidCap Credit Facility with a new revolving line of credit with Deerfield ELGX Revolver, LLC. As a result, and as of June 30, 2017, the Company wrote off approximately $0.8 million in deferred financing costs and was required to pay a $2.5 million termination fee to Midcap; the foregoing were charged to loss on debt extinguishment on the Company’s Condensed Consolidated Statements of Operations and Comprehensive Loss.

Deerfield Facility Agreement
On April 3, 2017, the Company entered into a Facility Agreement (the “Deerfield Facility Agreement” or “Facility Agreement”) with affiliates of Deerfield Management Company, L.P. (collectively, “Deerfield”), pursuant to which Deerfield agreed to loan to the Company up to $120.0 million, subject to the terms and conditions set forth in the Facility Agreement (the “Term Loan”). The Company drew the entire principal amount of the Term Loan on the Agreement Date. The Company agreed to pay Deerfield a yield enhancement fee equal to 2.25% of the principal amount of the funds disbursed on the Agreement Date. The Company also agreed to reimburse Deerfield for all reasonable out-of-pocket expenses incurred by Deerfield in connection with the negotiation and documentation of the Facility Agreement up to a capped amount. Accordingly, deferred financing costs of $5.1 million was recorded on the Company’s Condensed Consolidated Balance Sheet as a direct reduction of the Term Loan, to be subsequently amortized as interest expense over the effective period of the Term Loan. Concurrently with entering into the Facility Agreement, the Company entered into a Guaranty and Security Agreement with Deerfield (the “Security Agreement”), pursuant to which, as security for the repayment of the Company’s obligations under the Facility Agreement, the Company granted to Deerfield a first priority security interest in substantially all of the Company’s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted pursuant to the Facility Agreement.
Any amounts drawn under the Facility Agreement accrue interest at a rate of 6.87% per annum, payable quarterly in arrears beginning on July 1, 2017 and on the first business day of each calendar quarter thereafter and on the Maturity Date, unless repaid earlier. The Company will be required to pay Deerfield on each of April 2, 2021, April 2, 2022 and April 2, 2023 (the “Maturity Date”), an amortization payment equal to $40 million (or, if on the Maturity Date, the remaining outstanding principal amount of the Term Loan).
Upon a change of control of the Company, if the acquirer satisfies certain conditions set forth in the Facility Agreement, such acquirer may assume the outstanding principal amount under the Facility Agreement without penalty. If such acquirer does not satisfy the conditions set forth in the Facility Agreement, Deerfield may, at its option, require the Company to repay the outstanding principal balance under the Facility Agreement plus, depending on the timing of the change of control transaction, the Company may be required to pay a make-whole premium and will be required to pay a change of control fee.
At any time on or after the fourth anniversary of the Agreement Date, the Company has the right to prepay any amounts owed under the Facility Agreement without premium or penalty, unless such prepayment occurs in connection with a change of control of the Company, in which case the Company must pay Deerfield a change of control fee unless such change of control occurs beyond a certain period after the Maturity Date. At any time prior to the fourth anniversary of the Agreement Date, any prepayment made by the Company will be subject to a make-whole premium and, if such prepayment occurs in connection with a change of control of the Company, a change of control fee.
Any amounts drawn under the Facility Agreement may become immediately due and payable upon customary events of default, as defined in the Facility Agreement, or the consummation of certain change of control transactions, as described above.
The Facility Agreement contains various representations and warranties, events of default, and affirmative and negative covenants, customary for financings of this type, including reporting requirements, requirements that the Company maintain timely reporting with the SEC and restrictions on the ability of the Company and its subsidiaries to incur additional liens on their assets, incur additional indebtedness and acquire and dispose of assets outside the ordinary course of business.
As of June 30, 2017, the Company had outstanding borrowings of $105.3 million, and deferred financing costs of $4.9 million, related to the Term Loan. Annual interest expense on these notes will range from $1.4 million to $8.4 million through maturity.
Warrants
In connection with the execution of the Facility Agreement, the Company issued to Deerfield warrants to purchase an aggregate of 6,470,000 shares of common stock of the Company at an exercise price of $9.23 per share (the “Deerfield Warrants”). The number of shares of common stock of the Company into which the Warrants are exercisable and the exercise price of the Warrants will be adjusted to reflect any stock splits, recapitalizations or similar adjustments in the number of outstanding shares of common stock of the Company.
The Warrants expire on the seventh anniversary of the Agreement Date. Subject to certain exceptions, the Warrants contain limitations such that the Company may not issue shares of common stock of the Company to Deerfield upon the exercise of the Warrants if such issuance would result in Deerfield beneficially owning in excess of 4.985% of the total number of shares of common stock of the Company then issued and outstanding.
The holders of the Warrants may exercise the Warrants for cash, on a cashless basis or through a reduction of an amount of principal outstanding under the Term Loan. In connection with certain major transactions, the holders may have the option to convert the Warrants, in whole or in part, into the right to receive the transaction consideration payable upon consummation of such major transaction in respect of a number of shares of common stock of the Company equal to the Black-Scholes value of the Warrants, as defined therein, and in the case of other major transactions, the holders may have the right to exercise the Warrants, in whole or in part, for a number of shares of common stock of the Company equal to the Black-Scholes value of the Warrants.
The Company measured the initial fair value of the 6,470,000 shares underlying the Deerfield Warrants at $14.3 million, net of issuance costs of $0.4 million, and recorded the amount in additional paid-in-capital and as a direct reduction of the Term Loan, to be subsequently amortized as interest expense over the effective period of the Term Loan.
Registration Rights Agreement
In connection with the Term Loan and the issuance of the Warrants, the Company entered into a Registration Rights Agreement with Deerfield (the “Registration Rights Agreement”). Pursuant to the terms of the Registration Rights Agreement, the Company has agreed to file a registration statement on Form S-3 (or if Form S-3 is not then available, such other form of registration statement as is then available) with the Commission on or prior to the 30th day following the Agreement Date, to register for resale the shares of common stock of the Company issuable upon the exercise of the Warrants. The aforementioned registration statement was filed on Form S-3 on May 2, 2017.
Credit and Security Agreement
On the Agreement Date, the Company entered into a Credit and Security Agreement (the “Credit Agreement”) with Deerfield ELGX Revolver, LLC (“Deerfield Revolver”), pursuant to which the Company may borrow up to the lesser of $50 million or its applicable borrowing base from time to time prior to March 31, 2020 (the “Revolver”). Any outstanding principal under the Revolver will accrue interest at a rate equal to 3-month LIBOR (with a 1% floor) plus 4.60%, payable monthly in arrears on the first business day of the immediately succeeding calendar month and on the maturity date. The Company is subject to other fees in addition to interest on the outstanding principal amount under the Revolver, including in connection with an early termination of the Revolver.
The Revolver replaces the Company’s $50.0 million asset-based revolving line of credit with MidCap Financial Trust. In conjunction with the Company’s adoption of ASU 2015-03 “Simplifying the Presentation of Debt Issuance Costs” during the first quarter of 2016, the Company also adopted an update thereof or ASU 2015-15 “Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of Credit Arrangements.” As a result, the Company recorded $1.2 million in deferred financing costs related to the Revolver and presents these costs as a deferred asset, to be subsequently amortized as interest expense over the term of the Revolver, on the Company’s Condensed Consolidated Balance Sheets. The Company’s obligations under the Credit Agreement are secured by a first priority security interest in substantially all of the Company’s assets including intellectual property, with the priority of such security interest being pari passu with the security interest granted pursuant to the Term Loan. As of June 30, 2017, the Company had outstanding borrowings of $24.3 million, and deferred financing costs of $1.1 million related to the revolver.
In conjunction with the Company’s entry into the Credit Agreement, the Company entered into a corporate credit card agreement whereby the Company is required to maintain a $2.0 million deposit in favor of the credit card issuer. The deposit account related to these credit cards will be presented as restricted cash on the Company’s Condensed Consolidated Balance Sheet.
XML 26 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Revenue by Geographic Region
 6 Months Ended
Jun. 30, 2017
Geographic Areas, Revenues from External Customers [Abstract]  
Revenue by Geographic Region
Revenue by Geographic Region
The Company's revenue by geographic region, was as follows:

Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017

2016
 
2017

2016
United States
$
31,906


65.7%

$
36,283


71.2%
 
$
62,795


68.9%

$
66,151


70.9%
Total International
$
16,650


34.3%

$
14,691


28.8%
 
$
28,373


31.1%

$
27,189


29.1%
Revenue
$
48,556


100.0%

$
50,974


100.0%
 
$
91,168

 
100.0%
 
$
93,340

 
100.0%
XML 27 R14.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
(a) Leases
The Company leases its administrative, research, and manufacturing facilities located in Irvine, California, Santa Rosa, California and an administrative office located in Rosmalen, The Netherlands. These facility lease agreements require the Company to pay operating costs, including property taxes, insurance and maintenance. In addition, the Company has certain equipment under long-term agreements that are accounted for as operating leases.
In conjunction with the TriVascular merger, the Company assumed the lease for TriVascular's facility in Santa Rosa, California. The Company uses the Santa Rosa facility for manufacturing, research & development, and administrative purposes and the facility consists of 110,000 square feet under an operating lease scheduled to expire in February 2018. In July 2017, the Company renewed the lease for an additional 5 years.
Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of June 30, 2017:
Remainder of 2017
$
1,856

2018
3,317

2019
3,435

2020
3,659

2021
3,692

2022 and thereafter
21,821

Total
$
37,780



Facilities rent expense for the three months ended June 30, 2017 and 2016 was $1.0 million and $0.9 million, respectively. For the six months ended June 30, 2017 and 2016 facilities rent expense was $1.9 million and $1.6 million, respectively.
(b) Employment Agreements and Retention Plan
The Company has employment agreements with certain of its executive officers under which payment and benefits would become payable in the event of termination by the Company for any reason other than cause, death or disability or termination by the employee for good reason (collectively, an “Involuntary Termination”) prior to, upon or following a change in control of the Company. The severance payment will generally be in a range of six to eighteen months of the employee’s then current salary for an Involuntary Termination prior to a change in control of the Company, and will generally be in a range of eighteen to twenty-four months of the employee’s then current salary for an Involuntary Termination upon or following a change in control of the Company.
(c) Legal Matters
We are from time to time involved in various claims and legal proceedings of a nature we believe are normal and incidental to a medical device business. These matters may include product liability, intellectual property, employment, and other general claims. Such cases and claims may raise complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. We accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.
LifePort Sciences LLC v. Endologix, Inc.
On December 28, 2012, LifePort Sciences, LLC ("LifePort") filed a complaint against the Company in the U.S. District Court, District of Delaware, alleging that certain of the Company's products infringe U.S. Patent Nos. 5,489,295, 5,676,696, 5,993,481, 6,117,167, 6,302,906, and 8,192,482, which were alleged to be owned by LifePort. On March 17, 2016, the Company entered into a Settlement and Patent License Agreement with LifePort (the “Settlement Agreement”) whereby LifePort granted the Company license rights to patents in exchange for a settlement of $4.7 million. The Settlement Agreement resolves this litigation and fully and finally releases the Company and LifePort from any claims arising out of or in connection with the litigation or the subject patents. The Settlement Agreement also contained a covenant not to sue for other patents owned by LifePort. However, since the subject patents were all expired and the Company was not currently using and has no plans to use the other patents owned by LifePort in products that could reach technological feasibility during the covenant not to sue period, there is no alternative future use and the full amount was recorded as settlement costs in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss.
Shareholder Securities Litigation
In January 2017, two stockholders purporting to represent a class of persons who purchased the Company’s securities between August 2, 2016 and November 16, 2016, filed lawsuits against the Company and certain of its officers in the United States District Court for the Central District of California. The lawsuits allege that the Company made materially false and misleading statements and failed to disclose material adverse facts about its business, operational and financial performance, in violation of federal securities laws, relating to U.S. Food and Drug Administration Premarket Approval for the Company’s Nellix EVAS System. On May 26, 2017, the plaintiffs filed an amended complaint extending the class period to include persons who purchased the Company’s securities between May 5, 2016 and May 18, 2017 and adding certain factual assertions and allegations regarding the Nellix EVAS System. The Company believes the lawsuits are without merit and intends to defend itself vigorously.

Shareholder Derivative Litigation

On May 22, 2017, a purported stockholder of the Company filed a shareholder derivative complaint in the Superior Court for the State of California, County of Los Angeles, naming certain executive officers and the directors of the Company as defendants and alleging, among other things, breach of fiduciary duty by such executive officers and director. The Company believes this lawsuit is without merit and intends to defend itself vigorously.

SEC Investigation

In July 2017, the Company learned that the United States Securities and Exchange Commission (SEC) has issued a Formal Order of Investigation to investigate, among other things, events surrounding  the Nellix EVAS System and the prospect of its FDA pre-market approval.  The Company intends to fully cooperate with the investigation, but cannot predict its outcome or the timing of the investigation’s conclusion.

(d) Contract Termination
In the three and six months ended June 30, 2016, the Company sent notices of termination to certain of its distributors providing for the termination of the respective distribution agreements. In accordance with ASC No. 420 “Exit or Disposal Cost Obligations”, the Company expensed distributor termination costs in the period in which the written notification of termination occurred. As a result, the Company incurred termination costs of $1.1 million and $2.7 million for the three and six months ended June 30, 2016. Such termination costs are included in contract termination and business acquisition expenses for the three and six months ended June 30, 2016.
XML 28 R15.htm IDEA: XBRL DOCUMENT v3.7.0.1
Contingently Issuable Common Stock
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Contingently Issuable Common Stock
Contingently Issuable Common Stock
On October 27, 2010, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Nepal Acquisition Corporation, a wholly-owned subsidiary of the Company (“Merger Sub”), Nellix, Inc. ("Nellix"), certain of Nellix’s stockholders named therein and Essex Woodlands Health Ventures, Inc., as representative of the former Nellix stockholders. On December 10, 2010 (the “Nellix Closing Date”), the Company completed the merger (the “Merger”) of Merger Sub with and into Nellix pursuant to the terms of the Merger Agreement. The purchase price consisted of 3.2 million shares of the Company's common stock, issuable to the former Nellix stockholders as of the Nellix Closing Date, then representing a value of $19.4 million. Under the agreement, additional payments, solely in the form of shares of the Company's common stock (the “Contingent Payment”), could be made upon the achievement of a revenue milestone and a regulatory approval milestone (collectively, the “Nellix Milestones”).
Under the merger agreement, the ultimate value of each Contingent Payment would be determined on the date that each Nellix Milestone is achieved. The number of issuable shares would be established using an applicable per share price, which is subject to a ceiling and/or floor, resulting at the closing of the merger in a potential maximum of 10.2 million shares issuable upon the achievement of the Nellix Milestones. As of the Closing Date, the aggregate fair value of the cash Contingent Payment was estimated to be $28.2 million.

The Merger Agreement provides that, in addition to the shares of common stock of the Company (the “Common Stock”) issued to the former Nellix stockholders at the closing of the Merger, if the Company receives approval from the FDA to sell the Nellix Product in the United States (the “PMA Milestone”), the Company will issue additional shares of the Common Stock to the former stockholders of Nellix. The dollar value of the shares of the Common Stock to be issued upon achievement of the PMA Milestone will be equal to $15.0 million (less the dollar value of certain cash payments and other deductions). The price per share of the shares of the Common Stock to be issued upon achievement of the PMA Milestone is subject to a stock price floor of $4.50 per share, but not subject to a stock price ceiling.
As of June 30, 2017 the Company's stock price last closed at $4.86 per share. Thus, had the PMA Milestone been achieved on June 30, 2017 the Contingent Payment would have comprised 3.0 million shares (based on the 30-day average closing stock price ending 5 days prior to the announcement), representing a value of $14.5 million.
The value of the Contingent Payment is derived using a discounted income approach model, with a range of probabilities and assumptions related to the timing and likelihood of achievement of the PMA Milestone (which include Level 3 inputs - see Note 3(e) and the Company's stock price (Level 1 input) as of the balance sheet date). These varying probabilities and assumptions and changes in the Company's stock price have required fair value adjustments of the Contingent Payment in periods subsequent to the Nellix Closing Date.
The Contingent Payment fair value will continue to be evaluated on a quarterly basis until milestone achievement occurs, or until the expiration of the "earn-out period," as defined within the Nellix purchase agreement. Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
 
Fair Value of Contingently Issuable Common Stock
December 31, 2016
$
12,200

Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017
(2,600
)
June 30, 2017
$
9,600
XML 29 R16.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Tax Expense
 6 Months Ended
Jun. 30, 2017
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]  
Income Tax Expense
Income Tax Expense
The Company applied an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods. The Company recorded a provision for income taxes of $0.1 million and $0.3 million for the three and six months ended June 30, 2017, respectively. The Company's ETR was (0.7)% for the three and six months ended June 30, 2017. The Company's ETR for the three and six months ended June 30, 2017 differs from the U.S. federal statutory tax rate of 34% primarily as a result of nondeductible expenses (including the Nellix Contingent Payment), state income taxes, foreign income taxes, and the impact of a full valuation allowance on its deferred tax assets.
The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made.
XML 30 R17.htm IDEA: XBRL DOCUMENT v3.7.0.1
Restructuring Charges
 6 Months Ended
Jun. 30, 2017
Restructuring and Related Activities [Abstract]  
Restructuring Charges
Restructuring Charges
In the six months ended June 30, 2017, the Company recorded $0.1 million in restructuring costs within operating expenses related to focused reductions of its workforce. The Company began substantially formulating plans around this workforce reduction during the first quarter of 2016 in conjunction with its merger of TriVascular. The targeted reductions and other restructuring activities were initiated to provide efficiencies and realign resources as well as to allow for continued investment in strategic areas and drive growth. The Company expects to incur a total of $11.2 million in restructuring charges upon the completion of the plan, which represents the Company’s best estimate as of June 30, 2017. In the year ended December 31, 2016, the Company recorded $11.1 million in restructuring costs. The recognition of restructuring charges requires that the Company make certain judgments and estimates regarding the nature, timing and amount of costs associated with the planned reductions of workforce. At the end of each reporting period, the Company will evaluate the remaining accrued balance to ensure that no excess accruals are retained and the utilization of the provisions are for their intended purpose in accordance with developed plans. The following table reflects the movement of activity of the restructuring reserve for the six months ended June 30, 2017:

One-time Termination Benefits
Accrual balance as of December 31, 2016
$
2,754

Restructuring charges
137

Utilization
(2,656
)
Accrual balance as of June 30, 2017
$
235


The accrual balance as of June 30, 2017 is classified within accrued expenses and other current liabilities in the Company’s Condensed Consolidated Balance Sheet.
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
TriVascular Merger
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
TriVascular Merger
TriVascular Merger
On February 3, 2016, the Company completed its merger with TriVascular pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated October 26, 2015, by and among Endologix, TriVascular and Teton Merger Sub, Inc., a Delaware corporation and direct wholly-owned subsidiary of Endologix (“Merger Sub”). Pursuant to the terms of the Merger Agreement, Endologix acquired all of TriVascular’s outstanding capital stock through the merger of Merger Sub with and into TriVascular (the “Merger”), with TriVascular surviving the Merger as a wholly-owned subsidiary of Endologix. The Company completed the merger in order to become the innovation leader with broad clinical indications for the treatment of AAA, leverage the combined company’s commercial capabilities, and provide an accelerated path to profitability. The total purchase consideration given related to the acquisition follows:
Cash consideration
$
84,634

Common stock consideration
100,812
Fair value of assumed TriVascular stock warrants
44
Total purchase consideration
$
185,490


Common stock consideration consisted of 13,586,503 shares of Endologix common stock, worth $100.8 million based on the market value of $7.42 per share as of the effective date of the Merger on February 3, 2016.
In connection with the Merger, the Company assumed stock warrants, originally issued by TriVascular, and converted them to Endologix stock warrants. The fair value of the stock warrants represents a component of the total consideration for the Merger. Stock warrants assumed were valued using the Black-Scholes option pricing model as of the effective date of the Merger.
The acquisition was recorded by allocating the costs of the net assets acquired based on their estimated fair values at the acquisition date. The excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. The fair values were based on management’s analysis, including work performed by third-party valuation specialists. The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 3, 2016 (in thousands):
  Cash and cash equivalents
$
24,012

  Short-term investments
3,008

  Accounts receivable
5,780

  Inventories
17,765

  Prepaid expenses and other current assets
1,895

  Property and equipment
3,152

  Intangible assets
46,200

  Other assets
317

  Accounts payable
(2,214
)
  Accrued liabilities and other
(6,450
)
  Notes payable
(61
)
  Net assets acquired
$
93,404

Goodwill
$
92,086

Total purchase consideration
$
185,490


The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of TriVascular, such as broadening the product portfolio for the treatment of AAA and leveraging the combined company’s technology and commercial capabilities. The goodwill is not deductible for tax purposes.
Pro Forma Condensed Combined Financial Information (Unaudited)
The following unaudited pro forma combined financial information summarizes the results of operations for the period indicated as if the TriVascular merger had been completed as of January 1, 2015. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect, among other things, the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of January 1, 2015 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

Three Months Ended
 
Six Months Ended

June 30, 2016
 
June 30, 2016
Combined net sales
$
50,974

 
$
96,011

Combined net loss from continuing operations
(62,507
)
 
(110,730
)
Combined basic and diluted net loss per share
$
(0.76
)
 
$
(1.35
)
XML 32 R19.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business, Basis of Presentation, and Operating Segment (Policies)
 6 Months Ended
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission (the "SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three and six months ended June 30, 2017 and 2016, there were no related party transactions.
The interim financial data as of June 30, 2017 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three and six months ended June 30, 2017. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements. The interim financial data includes the results of TriVascular, beginning on February 3, 2016, the effective date of the merger.
The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 1, 2017.
Operating Segment
Operating Segment
The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three and six months ended June 30, 2017, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.
XML 33 R20.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Tables)
 6 Months Ended
Jun. 30, 2017
Balance Sheet Related Disclosures [Abstract]  
Property and Equipment
Property and equipment consisted of the following:
 
June 30,
2017
 
December 31,
2016
Production equipment, molds, and office furniture
$
11,908

 
$
11,714

Computer hardware and software
8,746

 
8,162

Leasehold improvements
15,495

 
15,495

Construction in progress (software and related implementation, production equipment, and leasehold improvements)
842

 
839

Property and equipment, at cost
$
36,991

 
$
36,210

Accumulated depreciation
(15,691
)
 
(12,945
)
Property and equipment, net
$
21,300

 
$
23,265
Schedule of Inventories
Inventories consisted of the following:
 
June 30,
2017
 
December 31,
2016
Raw materials
$
11,291

 
$
13,133

Work-in-process
11,767

 
10,139

Finished goods
20,497

 
17,888

Total Inventories
$
43,555

 
$
41,160
Schedule of Goodwill and Intangible Assets
The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets and related accumulated amortization: 

June 30,
2017

December 31,
2016
Goodwill
$
120,845


$
120,711







Intangible assets:





Indefinite lived intangibles





Trademarks and trade names
$
2,708


$
2,708

In-process research and development
11,200

 
11,200

 
 
 
 
Finite lived intangibles





Developed technology
$
67,600


$
67,600

Accumulated amortization
(5,375
)

(3,810
)
Developed technology, net
$
62,225


$
63,790







Customer relationships
$
7,500


$
7,500

Accumulated amortization
(1,063
)

(687
)
 Customer relationships, net
$
6,437


$
6,813







Intangible assets (excluding goodwill), net
$
82,570


$
84,511
Schedule of Carrying Amount of Goodwill
The change in the carrying amount of goodwill for the six months ended June 30, 2017 is as follows (in thousands):
Balance at January 1, 2017
120,711

Foreign currency translation adjustment
134

Balance at June 30, 2017
$
120,845
Schedule of Estimated Amortization Expense
Estimated amortization expense for the five succeeding years and thereafter is as follows:
Remainder of 2017
$
1,940

2018
3,978

2019
3,978

2020
4,996

2021
6,557

2022 & Thereafter
47,213

Total
$
68,662
Schedule of Investments in Marketable Securities
Investments in held-to-maturity marketable securities consist of the following at June 30, 2017 and December 31, 2016:

June 30, 2017

Amortized
Cost

Gross
Unrealized
Gain
 
Gross
Unrealized
Loss
 
Fair Value
Agency bonds
$
3,999


$
—


$
(1
)

$
3,998

Corporate bonds
6,001


—


(2
)

5,999

Total
$
10,000


$
—


$
(3
)

$
9,997










December 31, 2016

Amortized
Cost

Gross
Unrealized
Gain
 
Gross
Unrealized
Loss
 
Fair Value
Agency bonds
$
6,488


$
2


$
—


$
6,490

Corporate bonds
10,513


—


(21
)

10,492

Commercial paper
3,987


—


—


3,987

Total
$
20,988


$
2


$
(21
)

$
20,969
Schedule of Assets and Liabilities Measured at Fair Value
The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of June 30, 2017 and December 31, 2016:

 Fair value measurement at reporting date using:
 
Quoted prices in
active markets for
identical assets
(Level 1)

Significant other
observable
inputs
(Level 2)

Significant
unobservable
inputs
(Level 3)

Total
At June 30, 2017











Cash and cash equivalents
$
81,641


$
—


$
—


$
81,641

Restricted cash
$
2,877


$
—


$
—


$
2,877

Contingently issuable common stock
$
—


$
—


$
9,600


$
9,600

At December 31, 2016











Cash and cash equivalents
$
26,120


$
—


$
—


$
26,120

Restricted cash
$
2,001


$
—


$
—


$
2,001

Contingently issuable common stock
$
—


$
—


$
12,200


$
12,200
XML 34 R21.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Share-based Compensation Expense
Stock-based compensation expense included in cost of goods sold and operating expenses during the three and six months ended June 30, 2017 and 2016, was as follows:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Cost of goods sold
$
304


$
259

 
$
473


$
532

Operating expenses:





 





Research and development
323


434

 
583


797

Clinical and regulatory affairs
160


593

 
420


493

Marketing and sales
1,283


1,261

 
2,341


2,391

General and administrative
1,164


1,339

 
2,371


2,555

Total operating expenses
$
2,930


$
3,627

 
$
5,715


$
6,236

Total
$
3,234


$
3,886

 
$
6,188


$
6,768
XML 35 R22.htm IDEA: XBRL DOCUMENT v3.7.0.1
Net Loss Per Share (Tables)
 6 Months Ended
Jun. 30, 2017
Earnings Per Share [Abstract]  
Schedule of Calculation of Net Loss Per Share
Net loss per share was calculated by dividing net loss by the weighted average number of common shares outstanding for the three and six months ended June 30, 2017 and 2016.

Three Months Ended

Six Months Ended

June 30,

June 30,

2017

2016

2017

2016
Net loss
$
(16,292
)

$
(66,837
)

$
(37,606
)

$
(114,507
)
Shares used in computing basic and diluted net loss per share
83,247


82,072


83,087


79,368

Basic and diluted net loss per share
$
(0.20
)

$
(0.81
)

$
(0.45
)

$
(1.44
)
Schedule of Antidilutive Securities Excluded from Computation of Loss Per Share
The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net loss per share because their impact would have been anti-dilutive:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Common stock options
574


1,620

 
636


1,193

Restricted stock awards
121


135

 
120


131

Restricted stock units
207


438

 
248


299

  Total
902


2,193

 
1,004


1,623

The potential dilutive effect of these securities is shown in the chart below:

Three Months Ended
 
Six Months Ended

June 30,
 
June 30,

2017

2016
 
2017

2016
Conversion of the Notes
11,939


14,767

 
11,939


14,767

Deerfield Warrants
6,470


—

 
6,470


—
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.7.0.1
Revenue by Geographic Region (Tables)
 6 Months Ended
Jun. 30, 2017
Geographic Areas, Revenues from External Customers [Abstract]  
Schedule of Revenue by Geographic Region
The Company's revenue by geographic region, was as follows:

Three Months Ended
 
Six Months Ended
 
June 30,
 
June 30,
 
2017

2016
 
2017

2016
United States
$
31,906


65.7%

$
36,283


71.2%
 
$
62,795


68.9%

$
66,151


70.9%
Total International
$
16,650


34.3%

$
14,691


28.8%
 
$
28,373


31.1%

$
27,189


29.1%
Revenue
$
48,556


100.0%

$
50,974


100.0%
 
$
91,168

 
100.0%
 
$
93,340

 
100.0%
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Tables)
 6 Months Ended
Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]  
Future Minimum Lease Payments by Year
Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of June 30, 2017:
Remainder of 2017
$
1,856

2018
3,317

2019
3,435

2020
3,659

2021
3,692

2022 and thereafter
21,821

Total
$
37,780
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.7.0.1
Contingently Issuable Common Stock (Tables)
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Schedule of Fair Value of Contingent Payment
 
Fair Value of Contingently Issuable Common Stock
December 31, 2016
$
12,200

Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017
(2,600
)
June 30, 2017
$
9,600
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.7.0.1
Restructuring Charges (Tables)
 6 Months Ended
Jun. 30, 2017
Restructuring and Related Activities [Abstract]  
Schedule of Restructuring Reserve
The following table reflects the movement of activity of the restructuring reserve for the six months ended June 30, 2017:

One-time Termination Benefits
Accrual balance as of December 31, 2016
$
2,754

Restructuring charges
137

Utilization
(2,656
)
Accrual balance as of June 30, 2017
$
235
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.7.0.1
TriVascular Merger (Tables)
 6 Months Ended
Jun. 30, 2017
Business Combinations [Abstract]  
Summary of Purchase Consideration Given in Acquisition
The total purchase consideration given related to the acquisition follows:
Cash consideration
$
84,634

Common stock consideration
100,812
Fair value of assumed TriVascular stock warrants
44
Total purchase consideration
$
185,490
Summary of Allocation of Purchase Consideration
The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on February 3, 2016 (in thousands):
  Cash and cash equivalents
$
24,012

  Short-term investments
3,008

  Accounts receivable
5,780

  Inventories
17,765

  Prepaid expenses and other current assets
1,895

  Property and equipment
3,152

  Intangible assets
46,200

  Other assets
317

  Accounts payable
(2,214
)
  Accrued liabilities and other
(6,450
)
  Notes payable
(61
)
  Net assets acquired
$
93,404

Goodwill
$
92,086

Total purchase consideration
$
185,490
Summary of Pro Forma Financial Information of Acquisition
The following unaudited pro forma combined financial information summarizes the results of operations for the period indicated as if the TriVascular merger had been completed as of January 1, 2015. Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are directly attributable to the merger. The unaudited pro forma results include adjustments to reflect, among other things, the amortization of the inventory step-up, direct transaction costs relating to the acquisition, the incremental intangible asset amortization to be incurred based on the preliminary values of each identifiable intangible asset, and to eliminate interest expense related to legacy TriVascular's former loans, which was repaid upon completion of the TriVascular merger. The pro forma amounts do not purport to be indicative of the results that would have actually been obtained if the merger had occurred as of January 1, 2015 or that may be obtained in the future, and do not reflect future synergies, integration costs, or other such costs or savings.

Three Months Ended
 
Six Months Ended

June 30, 2016
 
June 30, 2016
Combined net sales
$
50,974

 
$
96,011

Combined net loss from continuing operations
(62,507
)
 
(110,730
)
Combined basic and diluted net loss per share
$
(0.76
)
 
$
(1.35
)
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.7.0.1
Description of Business, Basis of Presentation, and Operating Segment (Details)
 6 Months Ended
Jun. 30, 2017
segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of operating segments 1
Number of reportable segments 1
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Property and Equipment) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost $ 36,991   $ 36,991   $ 36,210
Accumulated depreciation (15,691)   (15,691)   (12,945)
Property and equipment, net 21,300   21,300   23,265
Depreciation expense 1,300 $ 1,300 2,700 $ 2,600  
Production equipment, molds, and office furniture          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost 11,908   11,908   11,714
Computer hardware and software          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost 8,746   8,746   8,162
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost 15,495   15,495   15,495
Construction in progress (software and related implementation, production equipment, and leasehold improvements)          
Property, Plant and Equipment [Line Items]          
Property and equipment, at cost $ 842   $ 842   $ 839
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Inventories) (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Balance Sheet Related Disclosures [Abstract]    
Raw materials $ 11,291 $ 13,133
Work-in-process 11,767 10,139
Finished goods 20,497 17,888
Total Inventories $ 43,555 $ 41,160
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Goodwill and Intangible Assets) (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]    
Goodwill $ 120,845 $ 120,711
Total 68,662  
Intangible assets (excluding goodwill), net 82,570 84,511
Developed technology    
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]    
Finite lived intangibles 67,600 67,600
Accumulated amortization (5,375) (3,810)
Total 62,225 63,790
Customer relationships    
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]    
Finite lived intangibles 7,500 7,500
Accumulated amortization (1,063) (687)
Total 6,437 6,813
Trademarks and trade names    
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]    
Indefinite lived intangibles 2,708 2,708
In-process research and development    
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]    
Indefinite lived intangibles $ 11,200 $ 11,200
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Change in Carrying Amount of Goodwill) (Details)
$ in Thousands
 6 Months Ended
Jun. 30, 2017
USD ($)
Goodwill [Roll Forward]  
Goodwill, beginning balance $ 120,711
Foreign currency translation adjustment 134
Goodwill, ending balance $ 120,845
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Amortization) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Balance Sheet Related Disclosures [Abstract]        
Amortization expense $ 1,000 $ 700 $ 1,900 $ 1,600
Remainder of 2017 1,940   1,940  
2018 3,978   3,978  
2019 3,978   3,978  
2020 4,996   4,996  
2021 6,557   6,557  
2022 & Thereafter 47,213   47,213  
Total $ 68,662   $ 68,662  
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Held to Maturity Marketable Securities) (Details)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
USD ($)
security
Jun. 30, 2017
USD ($)
security
Dec. 31, 2016
USD ($)
Schedule of Held-to-maturity Securities [Line Items]      
Amortized Cost $ 10,000,000 $ 10,000,000 $ 20,988,000
Gross Unrealized Gain 0 0 2,000
Gross Unrealized Loss (3,000) (3,000) (21,000)
Fair Value $ 9,997,000 $ 9,997,000 20,969,000
Held-to-maturity debt securities held | security 4 4  
Time held in unrealized loss position (less than)   11 months  
Unrealized gains (losses) on investments $ 0 $ 0  
Average maturity   1 month  
Agency bonds      
Schedule of Held-to-maturity Securities [Line Items]      
Amortized Cost 3,999,000 $ 3,999,000 6,488,000
Gross Unrealized Gain 0 0 2,000
Gross Unrealized Loss (1,000) (1,000) 0
Fair Value 3,998,000 3,998,000 6,490,000
Corporate bonds      
Schedule of Held-to-maturity Securities [Line Items]      
Amortized Cost 6,001,000 6,001,000 10,513,000
Gross Unrealized Gain 0 0 0
Gross Unrealized Loss (2,000) (2,000) (21,000)
Fair Value $ 5,999,000 $ 5,999,000 10,492,000
Commercial paper      
Schedule of Held-to-maturity Securities [Line Items]      
Amortized Cost     3,987,000
Gross Unrealized Gain     0
Gross Unrealized Loss     0
Fair Value     $ 3,987,000
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.7.0.1
Balance Sheet Account Detail (Fair Value Measurements) (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Nov. 02, 2015
Dec. 10, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and cash equivalents $ 81,641 $ 26,120    
Restricted cash 2,877 2,001    
Contingently issuable common stock $ 9,600 12,200    
2.25% Convertible Senior Notes | Convertible Debt        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Stated interest rate 2.25%     2.25%
3.25% Convertible Senior Notes | Convertible Debt        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Stated interest rate     3.25%  
Facility Agreement | Secured Debt        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Stated interest rate 6.87%      
Quoted prices in active markets for identical assets (Level 1) | Fair Value, Measurements, Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and cash equivalents $ 81,641 26,120    
Restricted cash 2,877 2,001    
Contingently issuable common stock 0 0    
Significant other observable inputs (Level 2) | Fair Value, Measurements, Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and cash equivalents 0 0    
Restricted cash 0 0    
Contingently issuable common stock 0 0    
Significant other observable inputs (Level 2) | Fair Value, Measurements, Nonrecurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of long-term debt 123,200 187,600    
Significant unobservable inputs (Level 3) | Fair Value, Measurements, Recurring        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Cash and cash equivalents 0 0    
Restricted cash 0 0    
Contingently issuable common stock 9,600 $ 12,200    
Significant unobservable inputs (Level 3) | Fair Value, Measurements, Nonrecurring | Facility Agreement | Secured Debt        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Fair value of long-term debt $ 100,200      
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense $ 3,234 $ 3,886 $ 6,188 $ 6,768
Cost of goods sold        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense 304 259 473 532
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense 323 434 583 797
Clinical and regulatory affairs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense 160 593 420 493
Marketing and sales        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense 1,283 1,261 2,341 2,391
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense 1,164 1,339 2,371 2,555
Total operating expenses        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Allocated stock-based compensation expense $ 2,930 $ 3,627 $ 5,715 $ 6,236
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.7.0.1
Net Loss Per Share (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Apr. 03, 2017
Nov. 30, 2015
Nov. 02, 2015
Dec. 10, 2013
Earnings Per Share, Basic and Diluted [Abstract]                
Net loss $ (16,292,000) $ (66,837,000) $ (37,606,000) $ (114,507,000)        
Shares used in computing basic and diluted net loss per share (in shares) 83,247,000 82,072,000 83,087,000 79,368,000        
Basic and diluted net loss per share (in dollars per share) $ (0.20) $ (0.81) $ (0.45) $ (1.44)        
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Outstanding securities used in calculations (in shares) 902,000 2,193,000 1,004,000 1,623,000        
Potential Dilutive Effect of Securities [Abstract]                
Conversion of the Notes (in shares) 11,939,000 14,767,000 11,939,000 14,767,000        
Conversion of Deerfield Warrants (in shares) 6,470,000 0 6,470,000 0        
Facility Agreement | Deerfield Warrants | Common Stock                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Warrants issued (in shares)         6,470,000      
Exercise price of warrants issued (in dollars per share)         $ 9.23      
Convertible Debt | 2.25% Convertible Senior Notes                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Convertible notes $ 18,300,000   $ 18,300,000         $ 86,300,000
Stated interest rate 2.25%   2.25%         2.25%
Debt instrument face amount               $ 86,250,000
Convertible Debt | 3.25% Convertible Senior Notes                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Convertible notes $ 105,500,000   $ 105,500,000     $ 125,000,000    
Stated interest rate             3.25%  
Debt instrument face amount             $ 125,000,000.0  
Secured Debt | Facility Agreement                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Stated interest rate 6.87%   6.87%          
Debt instrument face amount         $ 120,000,000.0      
Common stock options                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Outstanding securities used in calculations (in shares) 574,000 1,620,000 636,000 1,193,000        
Restricted stock awards                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Outstanding securities used in calculations (in shares) 121,000 135,000 120,000 131,000        
Restricted stock units                
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]                
Outstanding securities used in calculations (in shares) 207,000 438,000 248,000 299,000        
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.7.0.1
Credit Facilities (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Apr. 03, 2017
USD ($)
$ / shares
shares
Jul. 29, 2016
USD ($)
Jun. 02, 2016
USD ($)
shares
Feb. 03, 2016
shares
Nov. 02, 2015
USD ($)
$ / shares
Jul. 21, 2015
USD ($)
Dec. 10, 2013
USD ($)
$ / shares
$ / security
Feb. 29, 2016
USD ($)
Jun. 30, 2017
USD ($)
$ / shares
shares
Jun. 30, 2017
USD ($)
$ / shares
shares
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
d
$ / shares
shares
Jun. 30, 2016
USD ($)
Dec. 31, 2016
shares
Jun. 01, 2016
shares
Dec. 31, 2015
USD ($)
Nov. 30, 2015
USD ($)
Line of Credit Facility [Line Items]                                  
Non-cash loss on debt extinguishment                 $ 6,512,000   $ 0 $ 6,512,000 $ 0        
Payments of derivative issuance costs             $ 7,400,000                    
Common stock authorized (in shares) | shares     135,000,000           135,000,000 135,000,000   135,000,000   135,000,000 100,000,000    
Adjustments to additional paid-in capital, conversion features of Senior Notes     $ 68,600,000                            
Change in fair value of derivative liabilities                 $ 0   $ (38,743,000) $ 0 $ (43,831,000)        
Revolving Credit Facility | Bank of America                                  
Line of Credit Facility [Line Items]                                  
Aggregate maximum borrowing capacity           $ 20,000,000                      
Minimum current ratio                       1.5          
Revolving Credit Facility | MidCap                                  
Line of Credit Facility [Line Items]                                  
Aggregate maximum borrowing capacity   $ 50,000,000.0                              
Deferred financing costs - professional fees                 900,000 $ 900,000   $ 900,000          
Restricted cash                 2,000,000 2,000,000   2,000,000          
Write off of deferred financing costs                   800,000              
Debt termination fees                   2,500,000              
Revolving Credit Facility | MidCap | LIBOR                                  
Line of Credit Facility [Line Items]                                  
Basis spread on variable rate   4.10%                              
Variable rate, maximum   0.50%                              
Revolving Credit Facility | Deerfield Revolver                                  
Line of Credit Facility [Line Items]                                  
Deferred finance costs, noncurrent, net                 1,100,000 1,100,000   1,100,000          
Debt issuance costs $ 1,200,000                                
Aggregate maximum borrowing capacity $ 50,000,000                                
Restricted cash                 2,000,000 2,000,000   2,000,000          
Amount outstanding                 24,300,000 24,300,000   $ 24,300,000          
Revolving Credit Facility | Deerfield Revolver | LIBOR                                  
Line of Credit Facility [Line Items]                                  
Basis spread on variable rate 4.60%                                
Variable rate, floor 1.00%                                
Letter of Credit | Bank of America                                  
Line of Credit Facility [Line Items]                                  
Aggregate maximum borrowing capacity           $ 10,000,000                      
Term of line of credit           2 years                      
Termination notice period                       3 days          
TriVascular Technologies, Inc.                                  
Line of Credit Facility [Line Items]                                  
Equity consideration issued in merger (in shares) | shares       13,586,503                          
Minimum | Revolving Credit Facility | Bank of America                                  
Line of Credit Facility [Line Items]                                  
Liquidation proceeds, monetary amount                       $ 30,000,000          
Other Assets | Accounting Standards Update 2015-03 | Revolving Credit Facility | MidCap                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs, net                 900,000 900,000   900,000          
Long-term Debt | Accounting Standards Update 2015-03 | Revolving Credit Facility | MidCap                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs, net                 $ (900,000) $ (900,000)   $ (900,000)          
Facility Agreement | Deerfield Warrants                                  
Line of Credit Facility [Line Items]                                  
Expiration date of warrants issued                       7 years          
Warrant exercise limitation threshold                       4.985%          
Facility Agreement | Common Stock | Deerfield Warrants                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs $ 400,000                                
Shares in which warrants can be converted (in shares) | shares 6,470,000                                
Exercise price of warrants issued (in dollars per share) | $ / shares $ 9.23                                
Fair value of warrants $ 14,300,000                                
3.25% Convertible Senior Notes | Other Assets | Accounting Standards Update 2015-03                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs, net                               $ 2,900,000  
Convertible Debt                                  
Line of Credit Facility [Line Items]                                  
Reclassification of conversion features to derivative liabilities               $ 24,800,000                  
Convertible Debt | 2.25% Convertible Senior Notes                                  
Line of Credit Facility [Line Items]                                  
Debt instrument face amount             $ 86,250,000                    
Stated interest rate             2.25%   2.25% 2.25%   2.25%          
Proceeds from convertible debt             $ 82,600,000                    
Redemption price percentage                       100.00%          
Conversion of convertible securities                       41.6051          
Convertible conversion price (in dollars per share) | $ / shares             $ 24.04   $ 24.04 $ 24.04   $ 24.04          
Violation or event of default, declaration by note holders, percentage                       25.00%          
Fair value disclosure             $ 66,900,000                    
Beneficial conversion feature (2,200,000)           19,300,000                    
Unamortized discount             3,700,000                    
Repurchased debt amount 68,000,000                                
Non-cash loss on debt extinguishment 3,200,000                                
Convertible notes             $ 86,300,000   $ 18,300,000 $ 18,300,000   $ 18,300,000          
Deferred finance costs, noncurrent, net                 200,000 200,000   200,000          
Periodic principal payment                       0          
Cap price (in dollars per security) | $ / security             29.02                    
Convertible Debt | 2.25% Convertible Senior Notes | Minimum                                  
Line of Credit Facility [Line Items]                                  
Periodic interest payment                       1,100,000          
Convertible Debt | 2.25% Convertible Senior Notes | Maximum                                  
Line of Credit Facility [Line Items]                                  
Periodic interest payment                       $ 1,500,000          
Convertible Debt | 2.25% Convertible Senior Notes | Other Assets                                  
Line of Credit Facility [Line Items]                                  
Unamortized discount             $ 2,900,000                    
Convertible Debt | 2.25% Convertible Senior Notes | Other Assets | Accounting Standards Update 2015-03                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs, net                               1,900,000  
Convertible Debt | 2.25% Convertible Senior Notes | Additional Paid-in Capital                                  
Line of Credit Facility [Line Items]                                  
Unamortized discount             $ 800,000                    
Convertible Debt | 2.25% Convertible Senior Notes | Long-term Debt | Accounting Standards Update 2015-03                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs, net                               (1,900,000)  
Convertible Debt | 2.25% Convertible Senior Notes | Redemption, Period One                                  
Line of Credit Facility [Line Items]                                  
Threshold trading days | d                       20          
Threshold consecutive trading days | d                       30          
Threshold percentage of stock price trigger                       130.00%          
Redemption price percentage                       100.00%          
Convertible Debt | 2.25% Convertible Senior Notes | Redemption, Period Two                                  
Line of Credit Facility [Line Items]                                  
Threshold trading days | d                       20          
Threshold consecutive trading days | d                       5          
Threshold percentage of stock price trigger                       98.00%          
Threshold consecutive business days                       30 days          
Threshold business days | d                       5          
Convertible Debt | 3.25% Convertible Senior Notes                                  
Line of Credit Facility [Line Items]                                  
Debt instrument face amount         $ 125,000,000.0                        
Stated interest rate         3.25%                        
Threshold consecutive trading days | d                       30          
Redemption price percentage                       100.00%          
Conversion of convertible securities         89.4314                        
Convertible conversion price (in dollars per share) | $ / shares         $ 11.18                        
Fair value disclosure         $ 97,800,000                        
Beneficial conversion feature         27,200,000                        
Unamortized discount         2,900,000                        
Convertible notes                 105,500,000 105,500,000   $ 105,500,000         $ 125,000,000
Periodic principal payment                       $ 0          
Holding threshold required to declare debt due                       25.00%          
Debt issuance costs                 $ 2,100,000 $ 2,100,000   $ 2,100,000          
Convertible Debt | 3.25% Convertible Senior Notes | Convertible Condition One                                  
Line of Credit Facility [Line Items]                                  
Threshold trading days | d                       20          
Threshold consecutive trading days | d                       30          
Threshold percentage of stock price trigger                       130.00%          
Convertible Debt | 3.25% Convertible Senior Notes | Convertible Condition Two                                  
Line of Credit Facility [Line Items]                                  
Threshold percentage of stock price trigger                       98.00%          
Threshold consecutive business days                       5 days          
Threshold business days | d                       5          
Convertible Debt | 3.25% Convertible Senior Notes | Convertible Condition Three                                  
Line of Credit Facility [Line Items]                                  
Threshold trading days | d                       2          
Convertible Debt | 3.25% Convertible Senior Notes | Minimum                                  
Line of Credit Facility [Line Items]                                  
Periodic interest payment                       $ 9,100,000          
Convertible Debt | 3.25% Convertible Senior Notes | Maximum                                  
Line of Credit Facility [Line Items]                                  
Periodic interest payment                       $ 10,700,000          
Convertible Debt | 3.25% Convertible Senior Notes | Other Assets                                  
Line of Credit Facility [Line Items]                                  
Unamortized discount         3,700,000                        
Convertible Debt | 3.25% Convertible Senior Notes | Additional Paid-in Capital                                  
Line of Credit Facility [Line Items]                                  
Unamortized discount         $ 800,000                        
Convertible Debt | 3.25% Convertible Senior Notes | Long-term Debt | Accounting Standards Update 2015-03                                  
Line of Credit Facility [Line Items]                                  
Debt issuance costs, net                               $ (2,900,000)  
Convertible Debt | 3.25% Convertible Senior Notes | Redemption, Period One                                  
Line of Credit Facility [Line Items]                                  
Threshold trading days | d                       30          
Convertible Debt | 3.25% Convertible Senior Notes | Redemption, Period Two                                  
Line of Credit Facility [Line Items]                                  
Threshold trading days | d                       2          
Secured Debt | Facility Agreement                                  
Line of Credit Facility [Line Items]                                  
Debt instrument face amount 120,000,000.0                                
Stated interest rate                 6.87% 6.87%   6.87%          
Deferred finance costs, noncurrent, net $ 5,100,000               $ 4,900,000 $ 4,900,000   $ 4,900,000          
Yield enhancement fee 2.25%                                
Periodic amortization payment $ 40,000,000                                
Amount outstanding                 $ 105,300,000 $ 105,300,000   105,300,000          
Secured Debt | Facility Agreement | Minimum                                  
Line of Credit Facility [Line Items]                                  
Periodic interest payment                       1,400,000          
Secured Debt | Facility Agreement | Maximum                                  
Line of Credit Facility [Line Items]                                  
Periodic interest payment                       $ 8,400,000          
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.7.0.1
Revenue by Geographic Region (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Schedule of Revenue by Geographic Region [Line Items]        
Revenue $ 48,556 $ 50,974 $ 91,168 $ 93,340
Geographic Concentration Risk | Sales        
Schedule of Revenue by Geographic Region [Line Items]        
Concentration risk percentage 100.00% 100.00% 100.00% 100.00%
United States        
Schedule of Revenue by Geographic Region [Line Items]        
Revenue $ 31,906 $ 36,283 $ 62,795 $ 66,151
United States | Geographic Concentration Risk | Sales        
Schedule of Revenue by Geographic Region [Line Items]        
Concentration risk percentage 65.70% 71.20% 68.90% 70.90%
Total International        
Schedule of Revenue by Geographic Region [Line Items]        
Revenue $ 16,650 $ 14,691 $ 28,373 $ 27,189
Total International | Geographic Concentration Risk | Sales        
Schedule of Revenue by Geographic Region [Line Items]        
Concentration risk percentage 34.30% 28.80% 31.10% 29.10%
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Narrative) (Details)
ft² in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Jul. 31, 2017
Jun. 30, 2017
USD ($)
ft²
Jun. 30, 2016
USD ($)
Jun. 30, 2017
USD ($)
ft²
Jun. 30, 2016
USD ($)
Operating Leased Assets [Line Items]          
Rent expense   $ 1,000 $ 900 $ 1,900 $ 1,600
Settlement costs from litigation   0 0 0 4,650
Termination costs   $ 7,906 23,228 $ 23,568 61,631
Contract Termination          
Operating Leased Assets [Line Items]          
Termination costs     $ 1,100   $ 2,700
Minimum          
Operating Leased Assets [Line Items]          
Severance payment, prior to change in control       6 months  
Severance payment, period following change in control       18 months  
Maximum          
Operating Leased Assets [Line Items]          
Severance payment, prior to change in control       18 months  
Severance payment, period following change in control       24 months  
TriVascular Technologies, Inc. | Manufacturing Facility          
Operating Leased Assets [Line Items]          
Aggregate square feet | ft²   110   110  
Subsequent Event | TriVascular Technologies, Inc.          
Operating Leased Assets [Line Items]          
Renewal term 5 years        
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.7.0.1
Commitments and Contingencies (Schedule of Future Minimum Lease Payments, Fiscal Year Maturity) (Details)
$ in Thousands
Jun. 30, 2017
USD ($)
Non-Cancelable Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]  
Remainder of 2017 $ 1,856
2018 3,317
2019 3,435
2020 3,659
2021 3,692
2022 and thereafter 21,821
Total future minimum lease payments $ 37,780
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.7.0.1
Contingently Issuable Common Stock (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
 3 Months Ended 6 Months Ended
Dec. 10, 2010
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Fair Value of Contingently Issuable Common Stock          
Beginning balance       $ 12,200  
Fair Value Adjustment of Contingent Payment for the six months ended June 30, 2017   $ (3,800) $ 100 (2,600) $ 100
Ending balance   9,600   9,600  
Nelix Milestones          
Business Acquisition [Line Items]          
Number of shares contingently issuable (in shares) 10.2        
Estimated fair value of contingent payment $ 28,200        
PMA Milestone          
Business Acquisition [Line Items]          
Common shares value   $ 15,000   $ 15,000  
Number of shares contingently issuable (in shares)       3.0  
Share price (in dollars per share)   $ 4.5   $ 4.5  
Closing stock price (in dollars per share)   $ 4.86   $ 4.86  
Average daily closing stock price       30 days  
Days prior to milestone achievement announcement       5 days  
Contingent consideration, at fair value hypothetical value   $ 14,500   $ 14,500  
Nellix          
Business Acquisition [Line Items]          
Purchase price common shares (in shares) 3.2        
Common shares value $ 19,400        
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.7.0.1
Income Tax Expense (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]        
Income tax expense (benefit) $ 122 $ 443 $ 276 $ 546
Effective income tax rate (0.70%)   (0.70%)  
Federal statutory income tax rate 34.00%   34.00%  
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.7.0.1
Restructuring Charges (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Dec. 31, 2016
Restructuring and Related Activities [Abstract]          
Restructuring, expected cost $ 11,200   $ 11,200    
Restructuring Reserve [Roll Forward]          
Accrual, beginning balance     2,754    
Restructuring costs (29) $ 790 137 $ 8,114 $ 11,100
Utilization     (2,656)    
Accrual, ending balance $ 235   $ 235   $ 2,754
XML 58 R45.htm IDEA: XBRL DOCUMENT v3.7.0.1
TriVascular Merger (Price Consideration) (Details) - TriVascular Technologies, Inc.
$ in Thousands
Feb. 03, 2016
USD ($)
Business Acquisition [Line Items]  
Cash consideration $ 84,634
Common stock consideration 100,812
Fair value of assumed TriVascular stock warrants 44
Total purchase consideration $ 185,490
XML 59 R46.htm IDEA: XBRL DOCUMENT v3.7.0.1
TriVascular Merger (Narrative) (Details)
$ / shares in Units, $ in Millions
Feb. 03, 2016
USD ($)
$ / shares
shares
Business Acquisition [Line Items]  
Share price (in dollars per share) | $ / shares $ 7.42
TriVascular Technologies, Inc.  
Business Acquisition [Line Items]  
Equity consideration issued in merger (in shares) | shares 13,586,503
Equity consideration issued in merger | $ $ 100.8
XML 60 R47.htm IDEA: XBRL DOCUMENT v3.7.0.1
TriVascular Merger (Assets and Liabilities Acquired) (Details) - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Feb. 03, 2016
Business Acquisition [Line Items]      
Goodwill $ 120,845 $ 120,711  
TriVascular Technologies, Inc.      
Business Acquisition [Line Items]      
Cash and cash equivalents     $ 24,012
Short-term investments     3,008
Accounts receivable     5,780
Inventories     17,765
Prepaid expenses and other current assets     1,895
Property and equipment     3,152
Intangible assets     46,200
Other assets     317
Accounts payable     (2,214)
Accrued liabilities and other     (6,450)
Notes payable     (61)
Net assets acquired     93,404
Goodwill     92,086
Total purchase consideration     $ 185,490
XML 61 R48.htm IDEA: XBRL DOCUMENT v3.7.0.1
TriVascular Merger (Pro-Forma Information) (Details) - TriVascular Technologies, Inc. - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2016
Business Acquisition [Line Items]      
Combined net loss from continuing operations   $ 50,974 $ 96,011
Combined net loss from continuing operations   $ (62,507) $ (110,730)
Pro forma basic net loss per share (in dollars per share)   $ (0.76) $ (1.35)
Pro forma diluted net loss per share (in dollars per share) $ (0.76)    
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 63 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 174 281 1 false 61 0 false 9 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.endologix.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.endologix.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.endologix.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.endologix.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.endologix.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 5 false false R6.htm 1003501 - Statement - Condensed Consolidated Statements of Cash Flows (Parenthetical) Sheet http://www.endologix.com/role/CondensedConsolidatedStatementsOfCashFlowsParenthetical Condensed Consolidated Statements of Cash Flows (Parenthetical) Statements 6 false false R7.htm 2101100 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment Sheet http://www.endologix.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegment Description of Business, Basis of Presentation, and Operating Segment Notes 7 false false R8.htm 2102100 - Disclosure - Use of Estimates and Summary of Significant Accounting Policies Sheet http://www.endologix.com/role/UseOfEstimatesAndSummaryOfSignificantAccountingPolicies Use of Estimates and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Balance Sheet Account Detail Sheet http://www.endologix.com/role/BalanceSheetAccountDetail Balance Sheet Account Detail Notes 9 false false R10.htm 2104100 - Disclosure - Stock-Based Compensation Sheet http://www.endologix.com/role/StockBasedCompensation Stock-Based Compensation Notes 10 false false R11.htm 2105100 - Disclosure - Net Loss Per Share Sheet http://www.endologix.com/role/NetLossPerShare Net Loss Per Share Notes 11 false false R12.htm 2106100 - Disclosure - Credit Facilities Sheet http://www.endologix.com/role/CreditFacilities Credit Facilities Notes 12 false false R13.htm 2107100 - Disclosure - Revenue by Geographic Region Sheet http://www.endologix.com/role/RevenueByGeographicRegion Revenue by Geographic Region Notes 13 false false R14.htm 2108100 - Disclosure - Commitments and Contingencies Sheet http://www.endologix.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 2109100 - Disclosure - Contingently Issuable Common Stock Sheet http://www.endologix.com/role/ContingentlyIssuableCommonStock Contingently Issuable Common Stock Notes 15 false false R16.htm 2110100 - Disclosure - Income Tax Expense Sheet http://www.endologix.com/role/IncomeTaxExpense Income Tax Expense Notes 16 false false R17.htm 2111100 - Disclosure - Restructuring Charges Sheet http://www.endologix.com/role/RestructuringCharges Restructuring Charges Notes 17 false false R18.htm 2112100 - Disclosure - TriVascular Merger Sheet http://www.endologix.com/role/TrivascularMerger TriVascular Merger Notes 18 false false R19.htm 2201201 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Policies) Sheet http://www.endologix.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegmentPolicies Description of Business, Basis of Presentation, and Operating Segment (Policies) Policies http://www.endologix.com/role/UseOfEstimatesAndSummaryOfSignificantAccountingPolicies 19 false false R20.htm 2303301 - Disclosure - Balance Sheet Account Detail (Tables) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailTables Balance Sheet Account Detail (Tables) Tables http://www.endologix.com/role/BalanceSheetAccountDetail 20 false false R21.htm 2304301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.endologix.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.endologix.com/role/StockBasedCompensation 21 false false R22.htm 2305301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.endologix.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.endologix.com/role/NetLossPerShare 22 false false R23.htm 2307301 - Disclosure - Revenue by Geographic Region (Tables) Sheet http://www.endologix.com/role/RevenueByGeographicRegionTables Revenue by Geographic Region (Tables) Tables http://www.endologix.com/role/RevenueByGeographicRegion 23 false false R24.htm 2308301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.endologix.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.endologix.com/role/CommitmentsAndContingencies 24 false false R25.htm 2309301 - Disclosure - Contingently Issuable Common Stock (Tables) Sheet http://www.endologix.com/role/ContingentlyIssuableCommonStockTables Contingently Issuable Common Stock (Tables) Tables http://www.endologix.com/role/ContingentlyIssuableCommonStock 25 false false R26.htm 2311301 - Disclosure - Restructuring Charges (Tables) Sheet http://www.endologix.com/role/RestructuringChargesTables Restructuring Charges (Tables) Tables http://www.endologix.com/role/RestructuringCharges 26 false false R27.htm 2312301 - Disclosure - TriVascular Merger (Tables) Sheet http://www.endologix.com/role/TrivascularMergerTables TriVascular Merger (Tables) Tables http://www.endologix.com/role/TrivascularMerger 27 false false R28.htm 2401402 - Disclosure - Description of Business, Basis of Presentation, and Operating Segment (Details) Sheet http://www.endologix.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegmentDetails Description of Business, Basis of Presentation, and Operating Segment (Details) Details http://www.endologix.com/role/DescriptionOfBusinessBasisOfPresentationAndOperatingSegmentPolicies 28 false false R29.htm 2403402 - Disclosure - Balance Sheet Account Detail (Property and Equipment) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailPropertyAndEquipmentDetails Balance Sheet Account Detail (Property and Equipment) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 29 false false R30.htm 2403403 - Disclosure - Balance Sheet Account Detail (Inventories) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailInventoriesDetails Balance Sheet Account Detail (Inventories) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 30 false false R31.htm 2403404 - Disclosure - Balance Sheet Account Detail (Goodwill and Intangible Assets) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailGoodwillAndIntangibleAssetsDetails Balance Sheet Account Detail (Goodwill and Intangible Assets) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 31 false false R32.htm 2403405 - Disclosure - Balance Sheet Account Detail (Change in Carrying Amount of Goodwill) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailChangeInCarryingAmountOfGoodwillDetails Balance Sheet Account Detail (Change in Carrying Amount of Goodwill) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 32 false false R33.htm 2403406 - Disclosure - Balance Sheet Account Detail (Amortization) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailAmortizationDetails Balance Sheet Account Detail (Amortization) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 33 false false R34.htm 2403407 - Disclosure - Balance Sheet Account Detail (Held to Maturity Marketable Securities) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailHeldToMaturityMarketableSecuritiesDetails Balance Sheet Account Detail (Held to Maturity Marketable Securities) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 34 false false R35.htm 2403408 - Disclosure - Balance Sheet Account Detail (Fair Value Measurements) (Details) Sheet http://www.endologix.com/role/BalanceSheetAccountDetailFairValueMeasurementsDetails Balance Sheet Account Detail (Fair Value Measurements) (Details) Details http://www.endologix.com/role/BalanceSheetAccountDetailTables 35 false false R36.htm 2404402 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.endologix.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.endologix.com/role/StockBasedCompensationTables 36 false false R37.htm 2405402 - Disclosure - Net Loss Per Share (Details) Sheet http://www.endologix.com/role/NetLossPerShareDetails Net Loss Per Share (Details) Details http://www.endologix.com/role/NetLossPerShareTables 37 false false R38.htm 2406401 - Disclosure - Credit Facilities (Details) Sheet http://www.endologix.com/role/CreditFacilitiesDetails Credit Facilities (Details) Details http://www.endologix.com/role/CreditFacilities 38 false false R39.htm 2407402 - Disclosure - Revenue by Geographic Region (Details) Sheet http://www.endologix.com/role/RevenueByGeographicRegionDetails Revenue by Geographic Region (Details) Details http://www.endologix.com/role/RevenueByGeographicRegionTables 39 false false R40.htm 2408402 - Disclosure - Commitments and Contingencies (Narrative) (Details) Sheet http://www.endologix.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies (Narrative) (Details) Details http://www.endologix.com/role/CommitmentsAndContingenciesTables 40 false false R41.htm 2408403 - Disclosure - Commitments and Contingencies (Schedule of Future Minimum Lease Payments, Fiscal Year Maturity) (Details) Sheet http://www.endologix.com/role/CommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsFiscalYearMaturityDetails Commitments and Contingencies (Schedule of Future Minimum Lease Payments, Fiscal Year Maturity) (Details) Details http://www.endologix.com/role/CommitmentsAndContingenciesTables 41 false false R42.htm 2409402 - Disclosure - Contingently Issuable Common Stock (Details) Sheet http://www.endologix.com/role/ContingentlyIssuableCommonStockDetails Contingently Issuable Common Stock (Details) Details http://www.endologix.com/role/ContingentlyIssuableCommonStockTables 42 false false R43.htm 2410401 - Disclosure - Income Tax Expense (Details) Sheet http://www.endologix.com/role/IncomeTaxExpenseDetails Income Tax Expense (Details) Details http://www.endologix.com/role/IncomeTaxExpense 43 false false R44.htm 2411402 - Disclosure - Restructuring Charges (Details) Sheet http://www.endologix.com/role/RestructuringChargesDetails Restructuring Charges (Details) Details http://www.endologix.com/role/RestructuringChargesTables 44 false false R45.htm 2412402 - Disclosure - TriVascular Merger (Price Consideration) (Details) Sheet http://www.endologix.com/role/TrivascularMergerPriceConsiderationDetails TriVascular Merger (Price Consideration) (Details) Details http://www.endologix.com/role/TrivascularMergerTables 45 false false R46.htm 2412403 - Disclosure - TriVascular Merger (Narrative) (Details) Sheet http://www.endologix.com/role/TrivascularMergerNarrativeDetails TriVascular Merger (Narrative) (Details) Details http://www.endologix.com/role/TrivascularMergerTables 46 false false R47.htm 2412404 - Disclosure - TriVascular Merger (Assets and Liabilities Acquired) (Details) Sheet http://www.endologix.com/role/TrivascularMergerAssetsAndLiabilitiesAcquiredDetails TriVascular Merger (Assets and Liabilities Acquired) (Details) Details http://www.endologix.com/role/TrivascularMergerTables 47 false false R48.htm 2412405 - Disclosure - TriVascular Merger (Pro-Forma Information) (Details) Sheet http://www.endologix.com/role/TrivascularMergerProFormaInformationDetails TriVascular Merger (Pro-Forma Information) (Details) Details http://www.endologix.com/role/TrivascularMergerTables 48 false false All Reports Book All Reports elgx-20170630.xml elgx-20170630.xsd elgx-20170630_cal.xml elgx-20170630_def.xml elgx-20170630_lab.xml elgx-20170630_pre.xml true true ZIP 68 0001013606-17-000121-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001013606-17-000121-xbrl.zip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